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Abstract
Purpose of project
The purposeofthe project was to set up a system to diagnose and categorise
lymphoproliferative disorders in Ghana using modern diagnostic techniques, not
currently available locally in a clinically meaningful way. Results would be used to
inform treatment decisions, as well as provide epidemiological data regarding
lymphoproliferative disorders in West Africa. This system would be robust and
sustainable so that local clinicians could continueto useit once the initial project had
finished and, as resources becameavailable locally, transfer of skills and techniques was
envisaged so that they could be performedlocally.
Methods and Results
Biopsy samples from patients with a suspected lymphoproliferative disorder, from two
teaching hospitals in Ghana, were sent by post to the Haematological Malignant
Diagnostic Service, Leeds and results were e-mailed back to clinicians in Ghana. This
system wasfeasible, sample quality was preserved and adequate for processing and
turnaround times were rapid enoughforresults to be used to guide patient management.
Using this model, 61 patients with lymphoproliferative disorders were diagnosed and
classified according to the World Health Organisation classification of
lymphoproliferative disorders. Preliminary epidemiological data regarding
lymphoproliferative disorders in West Africa wasalso collected with a view to expanding
on this in future studies. The system was robustandis potentially sustainable.
There weresignificant differences between the spectrum of lymphoproliferative disorders
diagnosed in Ghanaand those diagnosed at HMDS.In the project there were significantly
morecasesofsplenic marginal zone lymphoma, peripheral T-cell lymphoma and T-cell
acute lymphoblastic leukaemia, butless cases ofdiffuse large B-cell lymphoma than seen
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at the Haematological Malignant Diagnostic Service. Amongst the patients with splenic
marginal zone lymphomathere wasa striking excess of female patients. We envisaged
that the excess numbers ofcases of splenic marginal zone lymphomaseen in Ghana
compared to Yorkshire would be due to chronic infection causing antigenic stimulation.
Wedid not see an excess of cases with mutated immunoglobulin heavy chain genes and
in those cases that were mutated, the mutation load wasrelatively low.
This project suggests that there are fascinating differences between the spectrum of
lymphoproliferative disorders in temperate and tropical climates and has highlighted
potential areas of further research that could provide importantinsights into the biology
of lymphoproliferative disorders.
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Introduction
Purpose and overview of the project
The purposeofthe project was to set up a system to diagnose and categorise
lymphoproliferative disorders (LPDs) in Ghana using modern diagnostic techniques, not
currently availablelocally, in a clinically meaningful way. Results would be used to
inform treatment decisions, as well as provide epidemiological data regarding LPDsin
West Africa. This system would be robust and sustainable so that local clinicians could
continue to use it oncethe initial project had finished and, as resources becameavailable
locally, transfer of skills and techniques was envisaged so that they could be performed
locally.
Biopsy samples from patients with a suspected LPD, from two teaching hospitals in
Ghana, weresent by post to the Haematological Malignant Diagnostic Service (HMDS),
Leeds and results were e-mailed back to clinicians in Ghana. This system wasfeasible,
sample quality was preserved and adequate for processing and turnaround times were
rapid enough for results to be used to guide patient management. Using this model, 61
patients with LPDs were diagnosedclassified according to the World Health Organisation
(WHO)classification of LPDs (Jaffe et al, 2001).
Brief Background
LPDs,cancers of the lymphoid system, occur throughout the world (Parkin et al, 1999).
Muchis known about LPDsin developed countries, for example incidence,
immunophenotype and genotype, but in comparison there is little published information
about LPDsin developing countries (Jaffe et al, 2001). There is marked variation in the
incidence and sub-types of LPDs worldwide (Jaffe et al, 2001). As will be discussed in
Chapter1, there is strong evidence for a link between LPDsandinfection andthis, along
with variations in race and socioeconomic status may account for muchofthe global
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variation, however the influence of other factors such as poverty and nutrition is not
known.
The increasing incidence, morbidity, mortality and socioeconomic impact ofchronic
illnesses, such as hypertension, diabetes, stroke and cancer, in developing countries has
become a major concern (Jones, 1999; Jones ef al, 2006; Kanavos, 2006; Mellstedt, 2006;
Ngoma, 2006; Abegundeetal, 2007). Accessto, and availability of, healthcare in many
developing countries has improved with a resultant increase in availability of both
chemotherapy and radiotherapy.It is therefore crucial that diagnostic techniques
necessary to diagnosecancers, such as LPDs, in developing countries, improve so that the
correct treatmentis given.
Workto investigate patients with massive splenomegaly in Kumasi, Ghana previously
suggested the presence of a LPD, Tropical Splenic Lymphoma(TSL), which appeared to
share somesimilarities with hyper-reactive malarial splenomegaly (HMS)suggesting the
possibility of malaria as an aetiological factor in the development ofTSL (Bates & Bedu-
Addo, 1997a). Further work waslimited bya lackoflocally available diagnostic
techniques and difficulty transporting fresh samples to the UK for further investigation.
Recent improvements in diagnostic techniques available in the UK, as well as improved
communication systems, meanthat remoteinvestigation of patients with a suspected LPD
on stored tissue has becomefeasible.
Dueto the clear variations in LPDs between developing and developed countriesit is not
possible to extrapolate our knowledge and treatment modalities from developed to
developing countries. Information regarding the epidemiology and pathogenesis of LPDs
in developing countries may also help our understanding of lymphomagenesis which may
in turn improve the treatment ofLPDsthroughout the world. LPDsin developing
countries therefore need to be investigated as a matter of urgency.
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DrStephens’ interest and role in the project
Dr Stephens spent a two month medical student elective period at Bawku District
Hospital in North-East Ghana in 1997. Later, as a third year haematologyspecialist
registrar on the Leedsrotation, she considered career in tropical haematology.
Collaboration between HMDS,the Liverpool SchoolofTropical Medicine (LSTM)and
the two teaching hospitals in Ghana was being discussed. Dr Stephens expressed an
interest in becoming involved in the collaborative project and registered the project with
Liverpool University as an MD project.
As will be discussed in Chapter 2, Dr Stephensplayed key role in planning, obtaining
ethical approvalfor, setting up, undertaking and writing up the project. For the duration
of the project Dr Stephenslived in Kumasi, Ghana where she entered patients into the
project and worked as both a haematology specialist and as a lecturer. She also spent time
in Accra, entering patients there, as well as time at HMDS and LSTM.
Structure of the thesis
The thesis is divided into 7 Chapters and there are 9 Appendices.In the first chapter the
backgroundto the project is set out and the relevant published literature is reviewed. The
second chapter describes how the remote diagnostic service was set up and discusses
some ofthe challenges that were met in doingso. In the third chapter the characteristics
and diagnosesofthe patients that were entered into the project are described. The fourth
chapter focuses on thosepatients that were diagnosed with a LPD and comparesthe
spectrum of LPDsdiagnosed in Ghanato the spectrum of LPDs diagnosed at HMDSand
then divides the LPD diagnoses into 4 groups and discusses them in greater detail. In the
fifth chapter, 5 interesting cases are described and discussed andin the sixth chapter the
project is summarised and discussed including limitationsofthe project, potentialpitfalls
in the diagnosis of lymphomas,importantissues relating to research in developing
countries and future research potentials.
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Chapter 1 - Literature Review and Background Information
Introduction
This chapter presents information regarding health services in Ghana, LPDsin general
and in developing countries and finally models that exist for collaborative diagnosis
between developed and developing countries. The relevantliterature is reviewed to
provide a background to, and putin context, the work carried out in the project.
Background information about health service in Ghana
Geography and Demographics
Ghanais on the coast ofWest Africa bordered on the remaining three sides by
francophone countries — Céte d’Ivoire, Togo and Burkina Faso. (Figure 1.1) Ghana,
formerly the Gold Coast, wasthe first African colony to gain independence from colonial
rule in 1957.
Figure 1.1 — Map of Ghana (www.ashantiafricantours.com)
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The nationalstatistics are fairly impressive for a developing country (Table 1.1), but there
are large economic divides betweentherelatively affluentcities and the poor rural
regions, especially the northern regions. This is also reflected in inequalities in health
care provision, for example in 2001 the entire Northern region (population 1.9 million,
area 70 000km”) had 17 doctors compared to approximately 500 doctors in Greater Accra
(population 4 million) (Horton, 2001). There are also variations in disease prevalence
other than those due to local environmental factors. The national Human
Immunodeficiency Virus (HIV) prevalence in 2004 was 3.6%, but prevalence rates above
5% were recorded in the Central and Eastern regions in the same year (2005 Programme
of Work, www.ghanahealthservice.org).
Table 1.1 - Ghana: a development summary with UK comparisons (Horton, 2001;
Human DevelopmentReport, 2001)
 
 
  
Ghana UK
Population (millions) 18.9 59
Fertility rate 4.6 1.7
Life expectancy(yrs) 56.6 77.5
Adultliteracy rate (%) 29.7
School enrolment (%) 29.7 100
Health spending (% gross domestic product) 1.8 a9
Health spending percapita ($) 85 1532
Physicians/100 000 people 6 164
Infant mortality rate (per 1 000livebirths) 63 6
Adequate sanitation (%) 63 100
Births with skilled staff (%) 44 100
Malaria cases/100 000 11 941 0
Tuberculosis cases/100 000 53 10
Adults with HIV (%) 3.6 0.11    
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Structure ofthe health care system
There are two main teaching hospitals in Ghana - Korle Bu Teaching Hospital (KBTH)in
Accra and Komfo Anokye Teaching Hospital (KATH)in Kumasi. A third medicalschool
wasstarted in 1996 at the Northern Regional Hospital in Tamale.It does not, however,
have the facilities to teach beyondthe pre-clinical years and has been beset by difficulties
since it was built. There are a further 8 regional government hospitals, 91 district
hospitals (62 government, 29 mission) and 124 other hospitals. Ghana also has 558 health
centres, 1085 clinics and 320 maternity homes — these are a mixture of government,
mission and private run.
Access to andpaymentfor health care
Following Independencefrom British rule the governmentintroduced an almostfee free
healthcare system. In 1969 fees were reintroduced and in 1985 the “fee for service’
system wasintroduced. This system charged a set fee for services, for example an out
patient review or operation. A slightfall in clinic attendances wasnoticed atthis time, but
this became more pronouncedin the early 1990s with the introduction of the ‘cash and
carry’ system (Biritwum, 1994). In the cash and carry system all items, including drugs,
needles and syringes, had to be paid for at the point of delivery. A deposit was taken from
patients on admission to hospitalto try to avoid delaysin initial health care, but a study at
KATHfound that despite this, patients did not get the necessary initial investigations or
treatment (Appiah-Poku, 1996). Certain groups ofpatients, for example those with
tuberculosis or leprosy, were exempt from paying fees, but this was rarely implemented
(Nyonatoret al, 2001). A national health insurance system wascalled for by these
authors and this wasfinally in place in mostofthe country by January 2006,although it
had been introduced in somerural areas during 2005.
The national health insurance scheme requires people to register and pay an annualfee.
This meanstested fee is between 74 000 and 180 000 cedis per person per year (£4.65-
£11.25). Each personis issued with a card andthis entitles them to free health care.
Certain illnesses and proceduresare not included, for example treatment for some
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malignancies. The fees per procedure have risen significantly with the introduction ofthe
national insurance system, for example the fee for the administration of intravenous
chemotherapy hasrisen from 50 000 to 100 000 cedis. It is hoped that the national
insurance system will encourage patients to seek medicalcare earlier in their illness and
that this will improve outcome.
In order to truly improveaccess to health care howeverit needs to be more evenly
distributed throughout the country especially in rural areas. The Ghana Health Sector
2005 Programme of Worknotesthat from 1997 to 2003 outpatient services increased
from 0.36 to 0.55 per capita (www.ghanahealthservice.org). This is a large increase, but
reflects both an increase in the numberofpeople attending and the numberoftimes each
attended and does notjust reflect increased access to health care. Patients can be referred
to teaching hospitals from clinics and hospitals throughout the country, but due to lack of
referral, lack of money, transportation difficulties etc only a very small proportion of the
population accesstertiary level health care. There are no figures available, howeveras the
reasons are so complex.
The diagnosis and treatment ofmalignancies in Ghana
The diagnosis and treatment of malignancies in developing countries is becoming more
important as therapeutic modalities become available and manyofthe previous causes of
morbidity and mortality such as malnutrition are addressed (Greenberget al, 2001;
Mellstedt 2006). KBTHhasa fully functioning department of pathology, where samples
are processed and reported andpathologists trained, thus facilitating the diagnosis ofall
malignancies. KBTHhasalso had a radiotherapy departmentsince 1997. Until 2004,
whenthecurrent radiotherapy centre opened at KATH,this wasthe only fully
functioning radiotherapy centre in the country — the nearest centers were in Nigeria to the
east and Senegalto the west so patients came from the whole ofGhana,as well
neighbouring countries, to KBTH for radiotherapy.
At KATHthe pathology department wasunable to process and report histology
specimensfor many years including the 15 monthsofthis project. This hindered the
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diagnosis and treatment of malignancies as samples had to be sent outto private
laboratories with the associated extra cost to patients, delay in results and potential
concernsregarding quality of results. Until 2004 oncology clinics were held in the old
radiotherapy building wherea limited amountofradiotherapy wasalso given.
Haematologyclinics were held in the office of one of the specialists and patients were
referred to Accra for most radiotherapy. The new radiotherapy/oncology centre was
opened in 2004 — this included clinic roomsfor haematology and oncologyclinics as well
as a CT scanner andthe new radiotherapy equipment.
LPDsin General
Definition ofLPDs
LPDs, cancersofthe lymphoid system, are a heterogeneous group of neoplastic disorders
of the immunesystem including lymphomas (non-Hodgkin and Hodgkin), myeloma and
lymphoid leukaemias.
Diagnosis ofLPDs
The diagnosis of LPDsin developed countries has evolved as diagnostic techniques have
improved. Previously LPDs were described morphologically, but now
immunophenotyping and genotypingare part of routine diagnosis. Asa result thereis
now a multi-faceted approachto the diagnosis of LPDsin developed countries which
includestheclinical presentation, morphological features, immunophenotype and
genotype. (Figure 1.2) This has been incorporated in the evolution ofclassification
systems for LPDsaswill be discussed later. Diagnostic techniques are mentionedbriefly
below and described in greater detail in Appendix 1.
Morphology
Morphology remainscrucial in the diagnosis of LPDs. Stained peripheral blood (PB),
bone marrow aspirate (BMA)andfine needle aspirate (FNA) slides allow an assessment
of cell cytology. Cytology can confirm the probable diagnosis in some LPDs such as
chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and
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myeloma. These morphological diagnoses can be confirmed by immunophenotypingas
discussed below.In order to make a definitive diagnosis of most lymphomas, however,
histology of a biopsy specimenis necessary as this allows architectural features as well as
cytological features to be assessed. (Appendix 1)
Figure 1.2 - The diagnosis of LPDs
Cytology Histology Flow cytometry Immunohistochemistry     Baseline bloods PCRHistory Examination Cytogenetics FISH
Immunophenotyping
Immunophenotypingis the demonstration of antigens, expressed bycells, using labeled
monoclonalantibodies. Different techniques can be used to demonstrate both surface
antigen and cytoplasmic antigen. In recent years there has beena rapid increase in the
number of monoclonal antibodies available for diagnostic purposes as well as an increase
in knowledgebase regarding the patterns of antigens expressed both on normal
lymphocytes and LPDs. Immunophenotyping addsa great deal of information to basic
morphologyin the diagnosis ofhaematological malignancies, especially in the diagnosis
of LPDs.
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Flow cytometry allows rapid immunophenotyping of fresh samples for example PB,
BMA,cerebrospinal fluid (CSF), serous effusions and lymph nodebiopsies. Samples are
prepared bycell lysis or density gradient centrifugation and then conjugated with a panel
of antibodies labelled with a fluorescent dye. The fluorescent characteristics of the cells
are then assessed using a flow cytometer. (Appendix 1)
Immunocytochemistry and immunohistochemistry have advanced so much in recent
yearsthat it is now possible to use a much wider range ofantibodies to
immunophenotype cytology preparations and fixed samples. This has several advantages
over flow cytometry — includingthe ability to immunophenotype samples that cannotbe
transported to the laboratory within 24-48 hours, archive material and samplesthat have
been processed in other laboratories. (Appendix 1)
Molecular techniques
In conventional cytogenetics, stained chromosomes from metaphasepreparations are
examined. Samples mustbesentfresh to the laboratory and transportedin preservative
free heparin. In manyindolent or low-grade LPDsit is difficult to obtain enoughcells in
metaphase for conventional cytogenetics and so this techniqueis oflimited valuein the
diagnosis of LPDs. (Appendix 1)
Fluorescencein-situ hybridisation (FISH) allows genetic translocations, deletions and
additions to be identified with deoxyribonucleic acid nucleic acid (DNA) probes. Probes
are fluorochrome-boundoligonucleotides, labeled with chromosomes, orparts of
chromosomes, which are complementary to specific sequences on a chromosome. FISH
allows cytogenetic analysis to be performed on fresh, fixed or stored tissues. Both
interphase (non-dividing) and metaphase (dividing) preparations are suitable. This has
several advantages over conventional cytogenetics; firstly cell culture medium andrapid
analysis are not requiredfacilitating retrospective diagnosis, secondlyit is applicable to
indolent LPDsascells do not need to be in metaphase. (Appendix 1)
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Polymerase chain reaction (PCR) can be used in LPD diagnosis to detect certain
chromosomal abnormalities and demonstrateclonality. PCR is performed on DNAand so
can be performed retrospectivelyif cells are frozen at the time of diagnosis. (Appendix 1)
Aspart of the normaldifferentiation process B-cells undergo rearrangementoftheir
immunoglobulin (Ig) genes and T-cells undergo rearrangementoftheir T-cell receptor
(TCR)genes. Clonality can therefore be demonstrated by PCRanalysis of the Ig and
TCRgenes ofB and T-cell LPDsrespectively. Analysis of the immunoglobulin heavy
chain variable (IGHV) regionofa B-cell clone allows an assessment ofwhether thecell
of origin has undergone somatic hypermutation in the germinal centre and provides
evidenceofantigen-driven clonal selection (Kupperset al, 1999). This will be discussed
further in Chapter 4.
Imaging
Asimaging techniques have improvedthey have taken on a crucialrole in the diagnosis
and staging of LPDs. At present computed tomography (CT)scansare routinely used to
stage both Hodgkin lymphoma(HL) and non-Hodgkin lymphoma (NHL),as well as to
assess nodaland extra-nodal disease in plasmacytomas, ALL and CLL. The advancesin
CT scanningresults have meant that laparoscopic staging proceduresare no longer
necessary, nor are diagnostic splenectomies in HL. Plain x-rays are ofparticular use in
myelomato lookfor lytic bone lesions. Magnetic resonance imaging (MRI) is more
sensitive than plain x-rays at demonstrating bone disease and can also be useful when
investigating LPDs involving the central nervous system (CNS).
Ultrasound (US)scansare useful to demonstrate nodesin the neck andassess intra-
abdominaldisease, especially the liver, spleen and kidneys. US scans cannotbeusedto
assess retroperitoneal disease, however. Positive emissions tomography (PET) scanning
is becoming more readily available in developed countries andis likely to play an
importantrole in both staging disease and assessing response to treatment, especially
wherethere is a residual lesion post chemotherapy.
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Classification ofLPDs
LPDclassification systems have evolved over the years as diagnostic techniques have
improved and LPDshave becomebetter understood. Previously lymphoid leukaemias
were Classified separately to lymphomasand there were separate classification systems
for HL and NHL.Asunderstanding of LPDshas improvedit has been recognised that
these illnesses form a spectrum of disease and so they have been incorporatedinto the
sameclassification system, firstly in the Revised European-American Classification of
Lymphoid Neoplasms (REALclassification), published in 1994 andlater in the World
Health Organisation (WHO)Classification ofTumours ofthe Haematopoietic and
Lymphoid Tissues (Harris et al, 1994; Jaffe et al, 2001).
The REALclassification wasthe result of a meeting of the International Lymphoma
Study Group (ILSG),a group of 19 expert haematopathologists from North America,
Asia and Europe, in Berlin in 1993. It uses all available information — morphology,
immunophenotype, genetic features andclinical features to define a diseaseentity.
(Figure 1.2) Since its publication the REAL classification has been subjected to rigorous
review to verify its reproducibility and clinical relevance.
The WHOClassification of Tumours of the Haematopoietic and Lymphoid Tissuesis the
result of a collaborative project between the European Association for Haematopathology
and the Society for Haematopathology. Work on the WHOclassification started in 1995
and waspublished asa bookin 2001 (Jaffe et al, 2001). The WHOclassification ofNHL
is based on the REAL classification, but extendsthe principles of disease definition and
consensus building to myeloid, mast cell and histiocytic neoplasms. The development of
the WHOclassification involved a Clinical Advisory Committee made up of expert
haematologists and oncologists to advise the pathologists on clinical aspects of the
classification system. Theresult is a comprehensive, internationally accepted and
clinically relevant classification system incorporating all haematological neoplasmsthat
will be subject to continual assessment and revision as new techniques and information
becomeavailable.
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The WHOclassification recognises three major categories of lymphoid neoplasms: B-cell
neoplasms, T- and Natural Killer (NK)-cell neoplasms and HL. (Appendix 3) Both solid
and circulating phases are present in many lymphoid neoplasmstherefore lymphomas and
lymphoid leukaemiasare classified together. For example B-cell CLL and B-cell small
lymphocytic lymphomaare different manifestations of the same neoplasm,asare
lymphoblastic lymphomas and lymphoblastic leukaemias.
Lymphomagenesis andthe genetic changes underlying LPDs
As moreis understood about the normal development and function of lymphocytes, so
our understanding of lymphomagenesis has improved. Lymphoid precursorcells, derived
from bone marrowstem cells, undergo gene rearrangement in the bone marrow and
becomenaive B-cells that express surface Ig. Naive B-cells leave the bone marrow and
circulate in blood though lymph nodes until they encounter antigen and undergo blast
transformation. They then migrate to the centre of a primary follicle, the germinal centre;
they are now termed centroblasts. Here they undergo class switching and somatic
hypermutation and mature to become centrocytes. This results in cells that produce high
affinity IgG or IgA antibodies. Cells that do not achievethis die through apoptosis.
Centrocytes leave the germinal centre and become memory B-cells and then antibody
producing plasmacells.
This scheme of B-cell ontogeny can becorrelated with the cell of origin of the B-LPDs:
lymphoid precursor cells correspond with acute lymphoblastic leukaemia/lymphoma,
naive B-cells with CLL and Mantle cell lymphoma (MCL), germinal centre B-cells with
HL, Burkitt lymphoma(BL), Follicular lymphoma(FL), Diffuse large B-cell lymphoma
(DLBL), memory B-cells with marginal zone lymphoma (MZL)and plasmacells with
myeloma. Class switching and hypermutation are inherently risky; this is why the
germinalcentre is the source of so many B-cell LPDs. Genetic changes can be
translocations, deletions or additions of chromosomes. Translocations involving the
IGHVlocusat 14q32arecritical in lymphomagenesis. (Table 1.2)
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Table 1.2 — Translocationsinvolving the JGHVlocusresulting in LPDs
 
  
Translocation Abnormality Associated LPD
t(14;18) bel-2 FL, DLBL
t(11;14) cyclin D1 MCL, Myeloma
t(8;14) c-MYC BL,transformed FL
t(3;14) bel-6 DLBL
t(9;14) Pax5 MZL, DLBL, myeloma
(14:19) bel-3 MZL, CLL
t(4;14) Fgfr3 myeloma
t(14;16) CMAF myeloma
t(3;14) Fox P1 DLBL, MZL  
Translocations causing chimeric fusion genesalso result in LPDssuch ast(11;18)
resulting in API2-MALT1 in MZL,t(2;5) resulting in NPM-ALKin anaplastic large cell
lymphomaand t(9;22), t(12;21), t(4;11) and t(1;19) in ALL. Other translocations can also
result in LPDs suchas those involving bcl6 in DLBL.Deletions(-) and additions (+) of
chromosomesare also associated with LPDs. (Table 1.3)
Table 1.3 — Numerical chromosomechangesresulting in LPDs
 
  
Numerical change Associated LPD
-13q, -11q, -17p CLL
-13, -13q myeloma
-6q Waldestroms macroglobulinaemia
+3, +18 MZL
Hyperdiploidy ALL, myeloma
+12 CLL   
Geographicalvariation in LPDs and underlying genetic changes
There are marked geographicalvariations in the incidence and spectrum ofboth clinical
and sub-clinical LPDs, in particular mature B-cell, T-cell and NK-cell neoplasms
(Anderson et al, 1998; Parkin et al, 1999; Jaffe et al, 2001; Weisenburgeret al, 2005).
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Mature B-cell neoplasms are more commonin developed countries than in less developed
countries — the annualincidence of NHLin malesranges from 15.61/100 000 in North
America to 1.28/100 000 in China with intermediate rates elsewhere (Parkin et al,1999).
Thereis also significant geographical variation in the relative frequency of different types
of B-cell neoplasms, for example, FL is more commonin developed countries and is
uncommon in South America, Eastern Europe, Africa and Asia (Andersonetal, 1998;
Jaffe et al, 2001). BL, in contrast, is endemic in equatorial Africa, but accountsfor only
1-2% of lymphomasin the United States and Western Europe (Jaffe et al, 2001). Nasal
and nasal-type NK/T-cell lymphomasand aggressive NK/T-cell leukaemia are much
more commonin Asians than they are in other races (Andersonet al, 1998).
There are also geographicalvariations in the genetic changes underlying LPDs,for
examplethe t(14;18) translocation in FL. Biagi and Seymour (2002) found that although
up to 50% ofhealthy subjects in Asia and the West havebcl-2 rearrangements, the
incidenceofbcl-2 rearrangements in FL in Asian populations wassignificantly lower
than in the West. Shiramizu et a/ (1991) looked at chromosomalbreakpoints in endemic
versus sporadic BL andtheir relation to Epstein Barr virus (EBV). They foundthat c-
MYCbreakpoints differ significantly in endemic versus sporadic BL. Understanding
more about geographicalvariationsin the genetic changes underlying LPDs andthe
impact ofvariations in breakpoints will aid our understanding of lymphomagenesis.
Links between LPDsandinfections
There are established links between certain LPDsandinfections. (Table 1.4) Infectious
agents can cause LPDsin | of 3 ways; either by directly transforming lymphocytes(eg
EBV)or by causing immunosuppression (eg HIV) or by chronic immunestimulation (eg
Hepatitis C virus (HCV) andcertain bacteria) (Engels, 2007).
EBV Infection
An association betweeninfectious mononucleosis and HL wasfirst recognised in the
1950s, before EBV had been discovered (Ambinder, 2007). The link between EBV and
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endemic BL wasdescribed a decadelater (Epstein et al, 1964). Subsequent work has
shownthat EBVis associated with other LPDs, as well as several non-LPD neoplasms
including: nasopharyngeal carcinoma (NPC), somegastric carcinomas, foregut
lymphoepitheliomas, inflammatory pseudotumoursofthe liver and spleen and HIV-
associated smooth muscle neoplasms (Rezk & Weiss, 2007).
Following acute EBVinfection the virus enters a latent phase in circulating B-cells. 3
types of EBV latency have been described — type 1 (the latency programme) in which
only 2 latent genes are expressed, type 2 (the default programme)in which restricted
array of latent genes are expressed and type 3 (the growth programme) in whichall 9
latent genes are expressed (Thorley-Lawson, 2001; Heslop, 2005). It is thought that this
complex mechanism helps EBV-infectedcells to evade the immune system.
These latency typesalso correlate with the three groups of EBV-associated LPDs
(Heslop, 2005; Rezk & Weiss, 2007). First BL, which can occur in both
immunocompromised and immunocompetentpatients, tends to express type | latency.
Second, EBV-associated NHLsthat occur in immunocompetentpatients and EBV-
associated HLtend to express type 2 latency (Kapatai & Murray, 2007). Finally, EBV-
associated NHLsthat occur in immunocompromisedpatients tend to express type 3
latency — this group will be discussed later in the chapter.
The WHOclassification divides BL into endemic, sporadic and immunodeficiency-
associated subtypes(Jaffe er al, 2001). EBV is demonstrable byin situ hybridisation in
almost all endemic BL casesin African children, 15-20% of sporadic BL and 30- 40% of
HIV-associated BL (Prevotet al, 1992; Hamilton-Dutoit et al, 1993; Young & Rickinson,
2004). Translocation of the c-MYCgene underlies all types of BL; however the ,
breakpoints occurat different positions in the different forms ofBL probably due to
variations in pathogenesis (Brady et al, 2007).
Elevated antibody titres to EBV in patients with HL werefirst described in 1971 (Levine
et al, 1971). Since then, further work has shown that EBV is frequently associated with
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classical HL, especially mixed-cellularity (MC) HL,butrarely with nodular lymphocyte
predominant HL (Pallesen et al, 1991; Chan, 1999). EBV-associated HL appearsto be
related to immunocompetence- there is a higher incidence of EBV-positive casesin
developing countries and HIV-positive patients (Leoncinief al, 1996; Glaser et al, 2003).
There is also a bimodal age-distribution with EBV-positive cases being more commonin
the young andthe old, where the immune system is underdeveloped or ageing, and less
commonin adolescents, where the immunesystem is more robust(Jarrett et al, 1991).
The effect of highly active anti-retroviral therapy (HAART) onthe incidence ofEBV-
positive HIV-associated HL is complex with the incidence being greatest with moderate
immunosuppression and reducing when CD4 countsfall further or recover (Ambinder,
2007; Grogg et al; 2007). The reasonfor this is unclear; however the inflammatory
response appearsto play an importantrole in the pathogenesis of virus-associated HL.
Aggressive NK-cell leukaemia/lymphoma, extranodal NK/T-cell lymphoma, T-cell rich
B-cell lymphoma, angioimmunoblastic lymphoma, pyothorax-associated lymphoma
(PAL) and somecases ofDLBL and CD30positive anaplastic large cell lymphomaare
EBV-associated NHLsseen in immunocompetenthosts (Sasajima etal, 1993; Jaffe etal,
2001; Young & Rickinson, 2004; Heslop, 2005).
Chronic active EBV infection occurs in apparently immunocompetentindividuals and
predisposes to the development of haemophagocytic syndromes, organ dysfunction and
lymphoma (Kimura et al, 2001). There is an abnormal immuneresponse to EBV
infection resulting in a high viral load with fever, hepatosplenomegaly and pancytopenia
as well as a high associated mortality.
Otherviral infections
HIV-associated LPDs occur due to immunosupression as opposedto the virusitself, as
will be discussed later.
Kaposi sarcomaherpes virus (KSHV), also named humanherpesvirus8 (HHV8), is
closely related to EBV andis also lymphotrophic. KSHV/HHV8is consistently identified
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in primary effusion lymphoma (PEL), multicentric Castleman’s disease associated
plasmablastic lymphoma and multicentric Castleman’s disease — three HIV-associated
disorders (Soulier et al, 1995; Carboneet al, 1996; Dupin et al, 2000). Cases of
KSHV/HHVS8positive solid lymphomashavealso been reported in both HIV positive
and negative patients (Carboneef al, 2005a).
Human T-cell leukaemia virus type 1 (HTLV-1), a deltaretrovirus, is linked to the
developmentofadult T-cell leukaemia/lymphoma (ATLL)(Jarrett, 2006). The risk of
developing ATLL amongst HTLV-1 infected individuals is approximately 4% and there
is a long latency period between infection and development ofATLL, suggesting that
other factors are also involved (Shuh & Beilke, 2005).
HCVis lymphotrophic as well as being hepatotrophic and is associated with the
developmentoftype II mixed cryoglobulinaemia, an autoimmunedisorderthat, in about
10% ofpatients, may evolve into a malignant lymphoma (Zignegoet al, 1997; Misianiet
al, 1992; Agnello etal, 1992; Ferri et al, 1993; De Re etal, 2000).
HCVappearsto belinked to B-cell LPDs - one American and twoItalian groups showed
a significantly increased incidenceofhepatitis C infection in unselectedpatients with B-
cell LPDsversuslocal controls, however two British groups showed noincrease in
hepatitis C infection in patients with B-cell LPDs(Ferriet al, 1994; Silvestri et al, 1996;
Hanleyet al, 1996; McColl & Tait, 1996; Zuckermanet al, 1997). The difference may
reflect the relatively small numbersthat were included, especially in the British groups,
and geographical and/orethnic variation - of note 78% ofthe patients in the American
study were Hispanic. Gisbert et a/ (2003) performed a meta-analysis and review of48
studies evaluating the prevalence ofHCV in B-cell NHL; they found a prevalence of
approximately 15% in patients with B-cell NHL,higher than the general population
(1.5%) and patients with other haematological malignancies (2.9%). Again there
appeared to be a marked geographical variation in these numbers.
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Despite the fact that HCV is lymphotrophic, LPD developmentrelated to HCV seems to
be indirect probably due to chronic antigenic stimulation (Jarrett, 2006; De Re etal,
2000). HCV is mainly associated with low-grade B-cell lymphomas —FL, MZL,
extranodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma),althoughit
has beenreported in association with most subtypes ofboth B- and T-cell NHL (Engelset
al, 2004). Hermineet al (2002)treated nine patients with both splenic MZL (SMZL)and
hepatitis C with interferon alone or in combination with ribavirin and demonstrated a
complete remission in eight patients and partial remission in the ninthpatient.
A potential link between simian virus 40, a macaque polyomavirus, and LPDshas been
the subject of some debate. Polio vaccines administered to an estimated 150 million
people were inadvertently contaminated with simian virus 40 between 1955 and 1963.
Somegroups have shownevidence for a link (Martini et a/, 1998; Vilchez et al, 2002;
Shivapurkar et al, 2002; Nakatsuka et al, 2003; Vilchez et al, 2005). Others have shown
no evidence for such a link (MacKenzieet al, 2003; Capello et al, 2003; Broussetetal,
2004; Thu et al, 2006).
Measles and humanherpesvirus 6 (HHV6) havealso been linked with HL althoughthere
is conflicting evidence regardingthe latter (Benharroch et al, 2004; Cartwright &
Watkins 2004). Finally van den Bosch suggests that arbovirusesare likely cofactors for
the development of endemic BL, along with EBV andplantextracts, with malaria only
playing a small part; the reasonsfor this are mentioned later (van den Bosch, 2004).
Bacterial Infections
The responseto bacterial infections has been implicated in the aetiology of several types
ofMALT lymphoma(Jaffe, 2004; Parsonnet & Issacson, 2004; Guidbonietal, 2006).
The link between gastric MALT lymphomaand Helicobacter pylori infection is the best
studied of these. T-cells activated by H.pylori antigens are necessary for the continued
proliferation of gastric MALT lymphomacells (Hussell et a/, 1993). Interestingly,
immunoglobulins produced by gastric MALT lymphomacells appear to recognise
autoantigens, as opposedto H.pylori derived antigens, suggesting that perhaps H.pylori
antigens act as ‘molecular mimickers’ to trigger autoimmunereactivity (Qin et al, 1995;
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Negriniet al, 1996; Guidbonief al, 2006). Eradication of H. pylori with antibiotic
therapy has been shownto lead to remission of the lymphoma (Wotherspoonet al, 1993).
De Sanjoseet al (2004) found that H. pylori was associated with a 3-fold excess risk of
splenic marginal zone lymphoma. H.pylori has also been implicated in ocular adnexa
MALT-type lymphomas(Ferreriet al, 2006).
Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma showed
a complete responseto a standard H. pylori eradication regimen in five patients that were
H.pylori negative by culture, histology, serology and PCR (Morgnerefal, 2000).
Chlamydiaspecies are obligate intracellular bacteria that grow in eukaryotic cells and
tend to cause persistent infections — they therefore have the potential to cause chronic
antigenic stimulation resulting in tumour development (Guidboniet a/, 2006). Chlamydia
psittaci has also been implicated in ocular adnexal MZL.Ferreriet al (2004) found that
32 out of40 ocular adnexal lymphomabiopsies were positive for C.psittaci DNA
comparedto 0 out of20 non-neoplastic biopsies and 3 out of 26 reactive lymph node
biopsies. 9 out of 21 patients with C.psittaci positive lymphomashad C.psittaci in their
PB mononuclearcells compared to 0 out of 38 healthy individuals. They treated 7
patients with doxycycline and showedthat C.psittaci DNA wasnot detectable after three
weeksoftreatment in all 7; only 4 of these patients had a measurable mass and a response
was demonstrated in 2 of these. These results have not been reproducedin other centres
however (Daibata et al, 2005; Vargaset al, 2006; Rosadoet al, 2006; Chanudet etal,
2006; Mulderet al, 2006; De Cremoux etal, 2006).
Chlamydia pneumoniaehas been implicated in cutaneous T-cell lymphoma (CTCL)
(Abramset al, 1999 and 2001). Following treatment for CTCL cases becamelesspositive
for C. pneumoniae and the authors hypothesise that chronic infection with C. pneumoniae
leads to expansion of C. pneumoniae-specific T-cells, potentiating the development of
cutaneous lymphoma. Rossleret a/ (2003) were unable to replicate these findings in 24
patients with mycosis fungoides and so further work is needed to investigate the potential
link between C. pneumoniae and CTCL.
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Several Borrelia burgdorferi species have been associated with, and Borrelia DNA found
in, cases ofprimary cutaneous B-cell lymphoma (PCBCL) in Europe although response
to antibiotic therapy has been variable (Cerroniet al, 1997; Kutting et al, 1997; Jelic &
Filipovic-Ljeskovic, 1999; Goodlad et al, 2000; Slater, 2001; de la Fouchardiereeral,
2003). Interestingly no Borrelia DNA wasfoundin 24 cases of cutaneous MZL from
Asia and 34 cases from the USA although Borrelia DNA wasidentified in control
samplesin the latter study; this is thoughtto berelated to the distribution and type of
Borrelia present in these areas (Liet al, 2003; Woodetal, 2001).
Immunoproliferative small intestinal disease (IPSID), also known asalpha chain disease,
is particularly commonin the Mediterranean basin, the Middle East, the Far East and
North Africa (Lecuit et al, 2004). IPSID is a small intestinal MALT-lymphomathatis
associated with the production of truncated heavy chain proteins and tends to occur
mostly in older children and young adults of low socio-economic status (Al-Saleem &
Al-Mondhiry, 2005). IPSID showsexcellent response to antibiotics if treated in the early
stages of disease (Akbulutet al, 1997). Although patients with IPSID tend to have multi-
bacterial overgrowthin their intestines, the pathogen responsible for the development of
IPSID appears to be Campylobacter jejuni (Lecuit et al, 2004). Some doubt remainsas C.
jejuni, unlike bacteria implicated in other forms ofMALT lymphoma,is nota persistent
coloniser in humansandC.jejuni is very common, whereas IPSIDis rare and only occurs
in endemic areas (Parsonnet & Issacson, 2004; Guidboniet al, 2006).
PAL is a B-cell NHL that develops in the pleural cavity of patients following a long
history (>20 years) ofpyothorax resulting from previousartificial pneumothorax as
treatment for tuberculosis (Aozasaet al, 2005). PAL is also strongly associated with EBV
infection and most cases have been reported in Japan, whereartificial pneumothorax was
a relatively commontreatment for tuberculosis (Sasajimaef al, 1993; Aozasa et al, 2005).
Askling & Ekbom (2001) also report an increased incidence ofNHL amongstsurvivors
of severe tuberculosis diagnosed prior to 1953 and proposethat this may be a factor in the
increased incidence ofNHLthat has been seenin recent years.
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Oscier et al (2002) report a case of MALT-lymphomaofthe bladder that macroscopically
respondedto antibiotics for chronic urinary tract infection. This highlights the need for
further work looking into chronic antigenic stimulation in LPDsat varioussites and with
variousetiologic agents.
ProtozoalInfections
Links between malaria and LPD havebeenpostulated. In particular malaria appears to
play a part in the development of endemic BL (Facer & Playfair, 1989). This has,
however been disputed by van den Bosch (2004) who arguesthat if early EBV infection
and malaria were the only prerequisites for endemic BL it would be far more common
than it is and that arbovirus infection as a cofactor would explain the clustering and
cyclical nature of cases ofendemic BL,as well as the reduction in casesthat follows
malaria eradication programmes. A link between malaria infection andtropical splenic
lymphoma hasalso beenpostulated as will be discussed later in this chapter (Bates &
Bedu-Addo, 1997a).
Table 1.4 — Infections associated with various LPDs
 
Infection Associated LPDs References
 
Viruses - EBV BL- Endemic, Sporadic Epstein et al, 1964; Levine et al, 1971;
and Immunodeficiency Jarrett et al, 1991; Pallesen et al, 1991;
related, post-transplant and Prevot ef al, 1992; Hamilton-Dutoitetal,
other immunodeficiency 1993; Sasajima et al, 1993; Leoncini et
linked LPD, lymphomatoid al, 1996; Chan, 1999; Jaffe et al, 2001;
granulomatosis, aggressive Kimuraef al, 2001; Thorley-Lawson,
NK-cell leukaemia, nasal 2001; Glaser et al, 2003; Young &
NK/T-cell lymphoma, HL, Rickinson, 2004; Thorley-Lawson&
PAL Gross, 2004; Heslop, 2005; Ambinder,
2007; Brady et al, 2007; Grogget al;
2007; Kapatai & Murray, 2007; Rezk &
Weiss, 2007  
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Table 1.4 — Infections associated with various LPDs continued
 
 
Infection Associated LPDs References
KSHV/HHV8__ PEL,multicentric Soulier et al, 1995; Carboneetal, 1996;
Castleman’s disease Dupin et al, 2000; Carboneetal, 2005a
associated plasmablastic
lymphoma, multicentric
Castleman’s diasease, solid
lymphomas
HTLV-1 ATLL Jarrett, 2006; Shuh & Beilke, 2005
Simian virus 40 Various lymphomas Martini et al, 1998; Vilchez et al, 2002;
Shivapurkaref al, 2002; Nakatsukaetal,
2003; Vilchez et al, 2005; MacKenzie et
al, 2003; Capello et al, 2003; Brousset et
al, 2004; Thuet al, 2006
 
Measles HL Benharrochet al, 2004
HHV6 HL Cartwright & Watkins, 2004
Arboviruses Endemic BL van den Bosch, 2004
Bacteria —H Gastric MALT lymphoma,| Jaffe et al, 2004; Parsonnet & Issacson,
pylori SMZL,ocular adnexal
MZL
2004; Guidboniet a/, 2006; Hussell et al,
1993; Qin et al, 1995; Negrini et al,
1996; Wotherspoonet al, 1993; de
Sanjose et al, 2004; Ferreri et al, 2006
 
H.Heilmanni Gastric MALT lymphoma Morgneret al, 2000 Chlamydiapsitacci  Ocular adnexal MZL  Guidboniet al, 2006; Ferreri et al, 2004;Daibata et al, 2005; Vargaset al, 2006;Rosado et al, 2006; Chanudetet al, 2006;Mulderet al, 2006; De Cremoux et al,2006
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Table 1.4 — Infections associated with various LPDs continued
 
Infection Associated LPDs References
Chlamydia CTCL Abramset al, 1999; Abramsef al, 2001;
pneumoniae Rossleret al, 2003
Borrelia Primary cutaneous B-cell Cerroniet al, 1997; Jelic & Filipovic-
Burgdorferi lymphoma Ljeskovic 1999; Goodladet al, 2000;
Slater, 2001; de la Fouchardiereetal,
2003, Kutting et al, 1997; Li et al, 2003;
Woodet al, 2001
 
  
Campylobacter IPSID Lecuit et al, 2004; Al-Saleem & Al-
jejuni Mondhiry, 2005; Akbulutet al, 1997;
Parsonnet & Issacson, 2004; Guidboniet
al 2006
Mycobacterium PAL, NHL Aozasaet al, 2005; Sasajimaet al, 1993;
tuberculosis Askling & Ekbom, 2001
Unknown MALT lymphoma of Oscier et al, 2002
bladder
Protozoa — EndemicBL, Tropical Facer & Playfair, 1989; Bates & Bedu-
Malaria splenic lymphoma Addo, 1997a; van den Bosch, 2004  
Links between LPDs and immunodeficiency
The WHOclassification divides immunodeficiency-associated LPDs into 4 groups
depending on the underlying immunodeficiency: 1) primary immunodeficiency
syndromesand other primary immunedisorders (PIDs); 2) HIV infection; 3) iatrogenic
suppressionin patients’ post solid organ or bone marrowallografts; 4) iatrogenic
immunosuppression with methotrexate, commonly in autoimmunedisease (Jaffe er al,
2001). The underlying mechanism of lymphomagenesis in eachofthese groups varies
slightly with resulting variation in the different LPDs seen, however they are commonly
EBVorother oncovirus-related, extranodal (including a high incidence ofCNS
involvement) and aggressive LPDs.
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LPDsandprimary immunodeficiency syndromes and other PIDs
The immunedefect varies slightly in the different PIDs, resulting in a heterogeneous
group of LPDs(Jaffe et al, 2001, Kumaret al, 2006). (Table 1.5) PID-associated LPDs
usually present in childhood, commonly with general malaise - fever and fatigue.
DLBLis the commonest LPD in PID; other LPDsthat also occur in immunocompetent
patients, including HL,are also seen. LPDsseen in the context of immunodeficiencyalso
occur in PID including polymorphic lymphoproliferations resembling post-transplant
LPD (PTLD), fatal infectious mononucleosis (FIM) and lymphomatoid granulomatosis
(Jaffe et al, 2001). In ataxia telagiectasia T-cell LPDs are more commonthan B-cell
LPDs(Taylor et al, 1996). T-cell LPDs can also occur in someofthe other PIDs,
althoughless frequently than their B-cell counterparts.
Table 1.5 — Mechanisms underlying LPD development in some PIDs (Jaffeet al,
2001, Kumaret al, 2006)
 Primary immunedisorder Mechanism underlying development of LPD
X-linked lymphoproliferative
syndrome (Duncan syndrome)
Defect in SH2D1A resulting in uncontrolled T-cell
proliferation
Hyper IgM syndrome Mutations in CD40ligand affecting B-cell/T-cell
interactions and effective B-cell differentiation
Ataxia telangectasia Defective DNArepair due to ATM gene mutations
Autoimmune lymphoproliferative
syndrome
Defective apoptosis due to FAS gene mutations
 Nijmegen breakage syndrome Defects in DNA repair
Commonvariable
immunodeficiency
Chronic antigenic stimulation resulting lymphoid
hyperplasia which may predispose to the development
of lymphoid malignancy
Wiskott-Aldrich syndrome Mutation of Wiskott-Aldrich Syndromeprotein Chediak-Higashi syndrome  Mutations in LYST(a lysosomaltrafficking protein)
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FIM occurs due to an uncontrolled systemic proliferation of EBV-positive B-cells which
can result in potentially fatal haemophagocytosis (Jaffe et al, 2001). Lymphomatoid
granulomatosis is an EBV-associated LPD that can occur in apparently
immunocompetentindividuals; however thorough investigation of these patients
identifies an underlying immune defect commonly of T-cell function (Sordillo etal,
1982; Wilson et al, 1996).
LPDsandHIVinfection
HIV-associated LPDsalsofall into three categories (Jaffe et al, 2001). Thefirst category
includes LPDsthat also occur in the absence ofHIV infection — for example classical
HL, BL,peripheral T-cell lymphoma (PTCL), DLBL with centroblastic/immunoblastic
features (including primary cerebral lymphoma) and MALT lymphoma. The second
category contains LPDsthat are rare in the absence of HIV infection — PEL,
plasmablastic lymphomaofthe oral cavity and multi-centric Castlemandisease. The third
category covers LPDsthatalso occurin other immunodeficiency states — polymorphic B-
cell lymphoma and lymphomatoid granulomatosis (Jaffe et a/, 2001; Carboneetal,
2005b; Lim & Levine, 2005; Jarrett, 2006).
HIV-associated LPDsare thought to occur due to a combination ofreduced immune
surveillance of oncogenic viruses, such as EBV and HHV8,and the immunosuppression
and cytokine dysregulation that occursas a result of HIV infection (Grogg et al, 2007).
The transforming properties of the HIV virusitself have been postulated, but HIV
sequences havenot been demonstrated in most HIV-associated LPDsalthoughthereis
somein vitro evidence that HIV may in itself be oncogenic (Knowles, 2003; Groggetal,
2007)
Withthe introduction of HAARTtheoverall incidence of HIV-associated NHL in San
Diego fell from 29.6 per 1000 person-years to 6.5 per 1000 person-years (Diamondetal,
2006). In the context ofHIV infection centroblastic DLBL, BL andclassical HL are
associated with moderate immunosuppression whereas immunoblastic DLBL, primary
cerebral lymphomaand PELtendto occurlater in the disease when CD4 countsare very
low. With the introduction of HAARTtherelative proportions of the different HIV-
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associated LPDstherefore changed with an increase in centroblastic DLBL (21% to
44%), BL (4% to 9%) and classical HL(in particular nodular sclerosing (NS) HL) and a
reduction in immunoblastic DLBL (26% to 7%), primary cerebral lymphoma(28% to
17%) and PEL (Diamondetal, 2006; Grogget al, 2007).
HIV-associated NHLsusually present with advanced systemic disease often involving
extranodalsites (CNS,gastrointestinal tract, liver and bone marrow) and occasionally at
sites that are rarely involved other than in the context of HIV-infection such as the
anorectum andthe heart (Grogget al, 2007).
LPDSandiatrogenic suppression in patients post solid organ or bone marrowallografts
PTLDsare a heterogenousgroupofdisorders ranging from polyclonalproliferationsto
aggressive lymphomas. Theycan be subdivided into 4 categories (Jaffe et al; 2001):
1) Early lesions — reactive plasmacytic hyperplasia, infectious mononucleosis-like;
2) Polymorphic PTLD;
3) Monomorphic PTLD theseare sub-classified according to the WHOclassification
and include DLBL, BL, myeloma, plasmacytomas and PTCL;
4) HL and HL-like PTLD.
PTLDsoccur due to defective immunesurveillance due to immunosuppression as well as
chronic antigenic stimulation from the engrafted organ. Mostpost-transplant LPDsare
EBV-related and early lesions and polymorphic PTLDoftenregressifthe
immunosuppression is reduced or stopped. Therelative risk ofPTLD following solid
organ transplant varies from 240postheart-lung transplant to 13 post kidneytransplant
(Opelz & Dohler, 2004). This variation probably reflects the level of immunosuppression
used in the different transplant settings.
LPDsandiatrogenic immunosuppression with methotrexate
Therisk of LPDsin patients treated with methotrexate is due to both immunesuppression
induced by the drug, and the increased risk of lymphomasin patients with autoimmune
disorders whichis discussed later. Methotrexate-associated LPDsare as heterogeneousas
the other immunosuppression related LPDsand include DLBL, HL and tumours
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resembling polymorphous PTLD(Jaffe et al, 2001). These disorders are commonly EBV-
related and occasionally regress when methotrexate is stopped.
Otheraetiologicalfactors described in LPDs
Infection and immunosuppression are the best documentedaetiological factors in LPDs.
LPDincidencein the US rose by 3-4% per year from 1973 to the mid 1990s and a similar
rise was seen in other developed countries (Fisher & Fisher, 2004). Approximately 50%
of this increaseis felt to be due to improved diagnosis and reporting, altered classification
systems and HIV; howeverthe other 50% is largely unexplained. This has prompted
manyauthorsto huntfor other potential aetiological factors to explain this rise with a
view to developing new therapeutic and preventative strategies. In most cases ofLPD
however, an underlying cause cannotbe identified.
Links between LPDs andethnicity
Certain ethnic groups have been foundto havean increased predisposition to certain
diseases. These effects sometimes persist despite a change in environment for example
when people emigrate from their homeland. This implies that there is an increased
genetic susceptibility as opposed to environmentalfactors. Dueto shifts in populations
overthe yearsit is now possible to study someethnic orracial groupsliving in different
environments to their original homelands and compareto other ethnic groupsliving in the
same environmentor the sameethnic groupin the original environment.It is also
possible to lookat different ethnic groupsliving in the same environment where several
indigenous groups have co-existed with minimal intergroup reproduction thus
maintaining separate gene pools.
Lynchet al (2004) reviewed the available literature via a MedLine search and found that
Ashkenazi Jews had a higher incidence ofNHL and carcinomasofthe ovary, pancreas
and stomach,but lower incidence of carcinomasofthe lung, penis and cervix. Several
studies have lookedat the incidence ofCLL in Israel. Firstly Bartal et al (1978) found
80% of 288 cases ofCLL in Israelis were in Ashkenazi Jews (originated from European
countries) and 15% were in Sephardic Jews (from Asia and Africa). Shvidelet al (1998)
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have since reported 302 cases ofCLL andrelated disorders and found that 67% were
Ashkenazi Jews and 31% were Sephardic Jews. There may be manyreasonsfor this shift
including increased accessto health care and an increase in routine blood counts.
Thereis a higher incidence of myeloma in black-Americans than white-Americans
(Walker et al, 1995). Landgrenet al (2006) looked at the prevalence of monoclonal
gammopathy ofundetermined significance (MGUS) among four million African-
American and white male veterans admitted to Veterans Affairs hospitals and found the
age-adjusted prevalence ratio ofMGUS was3.0 (2.7-3.3 95% confidence interval) in
African-Americans compared to whites. They found similar rates ofprogression to
myelomain the two groups ofMGUSpatients and therefore concluded that the increased
incidence of myeloma amongstblack Africans is related to an increased incidence of
MGUSandnotincreased transformation. It has been suggested that racial differences in
immunogenetic factors may affect the risk ofdeveloping both MGUSand myeloma
(Morganet al, 2002). It has also been hypothesised that the increased rate of myelomain
African-Americans might berelatedto sickling traits with interleukin-6 as a commonlink
(Adegoke, 2003).
Auet al (2004, 2005) report on the incidence ofHL and NHLin Chinese migrants to
British Columbia. 24 cases ofHL were identified in Chinese migrants between 1970-
1994 with a crude and age-adjusted incidencerate of 0.91 and 1.14 per 100 000 per year
(Au et al, 2004). During the sameperiod the provincial crude and age-adjusted incidence
rates were 5.2 and 4.87 per 100 000 peryear and the figures for the Hong Kong Chinese
population were 0.32 and 0.31 per 100 000 per year. They concludethat although the
numbers are small and there may be many confounding factors there appears to be both
genetic and environmental factors involved as the incidence remains lowerin the
migrants than the provincial population, but is higher than that for a similar ethnic
population that remainedin the East.
211 cases ofNHL wereidentified in Chinese migrants to British Columbia between 1980
and 1997 (Auet al, 2005). The age-standardised incidence rate was 7.11 per 100 000 per
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year compared with Hong Kongand British Columbianrates of 7.91 and 11.88
respectively. They found that the standardized rates of FL remainedlow,butthat the
incidenceofgastric and nasal NK/T-cell lymphomawas lower than expected amongst the
migrants. They concludethat genetic factors appear to be stronger than environmental
factors in governing the overall incidence ofNHL in Chinese, but that environmental
factors may have playeda role in the reduced rates of some lymphoma subtypes.
Mills et al (2005) lookedat the incidence of cancer amongst the Hmong immigrant
group, from Southeast Asia, living in California. They found that the age-adjusted cancer
rate for the Hmong was 284 per 100 000 population compared to 362.6 and 478 per 100
000 population for the Asian/Pacific Islander and non-Hispanic white populationsalso
living in California, respectively. The age-adjusted incidencerates of cancer in the
Hmongwereincreased for hepatic, gastric, cervical and nasopharyngealcancers,
leukaemia and NHL.Rates were lower among the Hmong forcolorectal, lung, breast and
prostate cancers.
Lanier et al (2003) lookedat rates of childhood cancer amongst Alaskan natives and
found that once hepatocellular carcinoma secondary to hepatitis B infection was excluded
the overall rate of cancer in these children wasless than that in white American children
and that the rate ofHL wasparticularly low. This was reassuring especially given the
concerns regarding ionizing radiation in the area.
People ofNative American descent in Central and South America are genetically linked
to Asians and also have an increased risk for NK/T-cell neoplasms, however the evidence
points towards EBV being the important cofactor as opposedto race (Arberet al, 1993;
Elenitoba-Johnsonet al, 1998).
Links between LPDs and sex
NHLgenerally hasa slight male predominance (52-55% male); the main exceptionsare
mediastinal large B-cell lymphoma which has a moderate female predominance (66%),
FL which has a mild female predominance (58%) and MCL wherethereis a striking male
predominance (74%) (Jaffe et al, 2001). In ALL there is a male predominance except in
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infancy, wherethere is a slight female predominance (Biondiet a/, 2000). A male
predominanceoccursat all ages in HL, but is most pronouncedin childhood cases
(Lichtmanet al, 2006).
Links between LPDs and socioeconomicfactors
Links between socioeconomic factors and the development of LPDs have been proposed,
in particular for HL (Cartwright & Watkins, 2004). A link between HL and
socioeconomicstatus has been postulated since higher intelligence quotients were noted
in World WarII military personnel with HL comparedto the general army population
(LeShanet al, 1959). A study looking at the incidence rates ofHL in England and Wales
found that proximity to built-up areas and higher socio-economic status were significant
risk factors for the development ofHL (Alexanderetal, 1991). The link also appears to
vary between sub-types and ages groupsofpatients with HL. Clarke et al (2005) found
that the link between HL and socioeconomicstatus in California was strongest for young
adults with NS HL and older white and Hispanic male patients with MC HL. They
proposethat etiologically relevant exposures for young adult HL patients may be linked
to race or ethnicity as opposed to socioeconomicstatusperse.
A link between reduced exposureto infection in early childhood, secondary to improved
socioeconomicstatus, and the increasing incidence of both NHLandpaediatric ALL in
developed countries has been postulated (Vineis et al, 2000a; Smith er al, 1998).
Socioeconomicstatus is also linked to H.pylori prevalence with potential implications
for the development of gastric MALT-lymphoma and SMZL (Goodman & Correa, 2000;
De Sanjose et al, 2004). Socioeconomicstatus does not appearto influence delayed
diagnosis ofNHL in England — the only significant factor resulting in delayed diagnosis
was youngerage (Neal & Allgar, 2005).
Links between LPDs andotherfactors
Autoimmunedisorders are associated with a slightly increased risk ofNHL;this risk is
higher in patients with primary Sjogren syndromethan those with rheumatoid arthritis or
systemic lupus erythematosus (SLE) (Zintzaraset al, 2005). The link between coeliac
disease and enteropathy-type T-cell lymphomais well documented, but Smedbyefal
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(2005a) reviewed 11 650 patients with coeliac disease and found they also had an
increased incidence of B-cell NHL.
In a Swedish population-based case-control study a twofold increased risk ofNHL and
HL wasfound for individuals with a family history of haematopoietic malignancy, with
the link being stronger between siblings than parent-child (Chang et al, 2005b). Familial
CLLis well documented and at a molecularlevel is indistinguishable from sporadic CLL
favouring a genetic, rather than an environmental, aetiology (Crowther-Swanepoeletal,
2008).
Links between LPDsand manyother factors have been studied. Someofthese are
summarized in table 1.6.
Table 1.6 — Factors linked or not linked to the development of LPDs
 
References Factorsfelt to be linked to
the development of LPDs
Factors felt unlikely to be
linked to the development
of LPDs
Vineis et al, 2000b Previouspolio, SLE,
hepatitis, malaria in
childhood;history of
parental tuberculosis
Diabetes, tonsillectomy or
adenoidectomy
Cerhanet al, 1997, 2001,
2002, 2003
Adult-onset diabetes,
previous cancer and
previous bloodtransfusion,
current hormone
replacement therpay, Non-
steroidal anti-inflammatory
drugs (NSAIDs)
Menstrual and reproductive
factors, previous HRT
  Tavani et al, 1999; Chow &Holly, 2002a, 2002b; Zhu etal, 2003   Blood transfusion
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Table 1.6 — Factors linked or not linked to the development of LPDs continued
 References Factorsfelt to be linked Factors felt unlikely to be
to the developmentof linked to the development
LPDs of LPDs
Chang ef al 2005a >10 courses of antibiotics Other drugs
in adulthood, high
cumulative use of
NSAIDs
 Changet al, 2005c; Chiu et Diet containing a lot of Women whosediet
al, 1996; Tavaniet al, 1997; dairy products and fried contained a lot of fruit and
Zhanget al, 1999, 2000 red meat vegetables
Zheng et al, 1996 Tea consumption
Mortonet al, 2005; Briggset Alcohol ?wine more
al, 2002a protective than beer
Briggs, 2002b; Peach & Smoking with HL Smoking with NHL
Barnett, 2001
 Changet al, 2005d; Cerhan et
al, 2002; Kasim et al, 2004
Raised body mass index
with CLL
Raised body mass index
with lymphoma
Fritschi et al, 2005 Solvents, wood dust Other organic dusts, metals
and polychlorinated
biphenyls
Wong & Raabe, 2000 Benzene exposure
De Rooset al, 2003 Pesticides
Baris et al, 2004 Farmers, pharmacists and
roofers
 Freedman et al, 1997; Adami
et al, 1999; van Wijngaarden
et al, 2001; Hughesetal,
2004; Smedbyet al, 2005b
Sunlight van den Bosch, 2004  Euphorbiatirucalli — BL  
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LPDsin developing countries
In May 2003 the International Network of Cancer Treatment and Research held a
workshop looking at lymphomadiagnoses from several developing countries (India,
Egypt, Kuwait, Pakistan and Turkey) (Naresh et a/, 2004). The aim wasto highlight
variations in the spectrum of lymphomasandto identify areas for research. Most of the
centres involved in this conference had used some immunohistochemistry, but no
molecular data wasavailable. 82-88% of the NHLs were B-cell in origin. There waslittle
variation between countries regarding the proportions of CLL, mantle cell lymphoma and
plasmacytomacases, but there wasa significant variation between countries regarding the
proportion of casesoffollicular lymphoma. There wererelatively high frequencies ofBL
in Egypt and ofDLBL andprecursor T lymphoblastic lymphomain India. It was
concluded that since there were differences in proportions of lymphoma cases amongst
different developing countries, and further differences between developing countries and
that found in the rest of the world, further research looking at lymphomasin developing
countries should provide valuable insights into lymphomagenesis.
Thereis very little prospective published data on adult LPDs from sub-Saharan Africa
other than data from South Africa. South Africa has a more advancedhealthcare system
than the rest of sub-Saharan Africa and malaria is not endemicsothis data is not readily
translatable to Central, East and West Africa. The following subsections therefore present
the published data on LPDsdiagnosed in sub-Saharan Africa other than South Africa.
Wherepossible, paediatric cases have been excluded so that the data can be compared to
the project data. Figure 1.3 shows a map of Africa.
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Figure 1.3 — Map of Africa (www.mapsofworld.com)
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Current knowledge about lymphomas in sub-Saharan Africa
Kenya
A retrospective study of207 cases ofNHL, aged over 13 years, presenting in Nairobi,
Kenya between 1990 and 2000 found that 41% were not properly classified histologically
and only 15.3% of 105 evaluable patients were followed up for at least 36 months as most
werelost to follow-up (Othieno-Abinyaet a/, 2004). They also found that very few
patients could afford standard treatment, but that over the ten year period the treatment
and prognosis ofpatients presenting with NHL improved. The sameauthors also
reviewed 111 cases ofHL presenting during the same period oftime and foundthat
14.2% were lymphocyte predominate (LP), 23.6% were NS, 26.4% were MC, 17% were
lymphocyte depleted (LD) and 18.8% werehistologically unclassifiable (Othieno-Abinya
et al, 2005). 24.5% of cases were stageIIIB or IV; 1“ line treatment was evaluable in 99
patients ofwhich 87 had chemotherapyalone, 9 had radiotherapy alone, and | had both
chemotherapy and radiotherapy; median duration of follow-up was 10 months(range 0.5-
122 months). From the same centre, Mwandaetal (2004) report 54 cases of HIV-
associated NHLpresenting between 2001 and 2003. 15 were BL, 35 werelarge cell
lymphomaand 4 were intermediate grade lymphoma;primary sites at presentation were:
16 (30%) peripheral nodes, 15 (28%) abdominal, 11 (20%) pectoral/chest wall, 8 (15%)
CNS, 4 (7%) systemic.
The lymphomadiagnoses on 73 paraffin blocks from biopsies taken in 40 Kenyan
mission hospitals between March 1993 and November 1994, were reviewed,
immunophenotypedand studied for EBV in the United States (Cool & Bitter, 1997). The
male:female (M:F) ratio was 2.5:1 and the median age was 35 years (range 4-97 years, 19
patients <16 years) - age was notavailable in 9 patients. There were 21 cases ofBL (11
paediatric, 5 adult and 5 age unknown) and 13 cases ofHL (6 NS, 4 MC, 1 LD, 1 LP)
with an apparently preserved bi-modal age distribution. The other diagnoses were 11
DLBL, 9 small lymphocytic lymphoma,6 Burkitt’s-like high grade B-cell lymphoma, 2
FL, 2 MCL, 1 MZL,6 precursor T-cell lymphoblastic lymphoma/leuakemia and 2 PTCL.
Of39 cases that were assessable for EBV, 22 werepositive, includingall 17 assessable
cases ofBL.
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Uganda
A review ofthe biopsies of cases of lymphoma diagnosed in Uganda between 1966 and
1973 showedthat there was a low frequencyoffollicle-centre-cell lymphomasandthat
BL as well as non-Burkitt high grade NHL hada similar distribution to malaria (Schmauz
et al, 1990).
Blocks from 600 cases ofNHL from Ugandathat had been diagnosed between 1991 and
2000 were reviewed, of these 129 blocks werefelt suitable for immunohistochemistry, of
these 95 (74%) were BL, 19 (15%) were DLBL,4 (3%) were MCL and1 (0.8%) was B-
cell lymphoblastic lymphoma (Tumwineet al, 2008). 200 cases ofHL that had been
diagnosed between 1980 and 2000 werealso reviewedfirst with repeat histology and then
with immunohistochemistry (CD45, CD15, CD30 and CD20) (Tumwine, 2004). On
histology it was possible to confirm andclassify the diagnosis ofHL in 131 cases, 29
cases were unsuitable for assessment and immunohistochemistry was needed to make the
full diagnosis on 40 cases. The sensitivity and specificity of routine histology using
haematoxylin and eosin (H&E)stain was 76.6% and 92.3% respectively (Tumwineetal,
2003).
Ethiopia
83 lymphomasdiagnosed in Western Ethiopia between 1988 and 1999 were reviewed —
21 (25.3%) were HL, 61 (73.5%) were NHL and 1 case was unspecified; the M:F ratio
was 3.4:1 (Getachew, 2001). Ofthe HL 38.1% were LP, 33.3% were MC, 14.2% were
LD, 4.8% were NS and 9.5% were unclassified; of the NHL 6.6% were BL, 34.4% were
high grade NHL,9.8% were intermediate grade NHL, 32.8% were low grade NHL, 6.6%
were mycosis fungoides and 9.8% were unclassifiable.
Sudan
A prospective study of 92 patients presenting with cervical lymphadenopathy in Sudan
showed that 45% were dueto tuberculosis, 16% were lymphoma, 18% were a secondary
malignancy (Kheiry & Ahmed, 1992). It was not possible to delineate between the
patients with tuberculosis and lymphoma on symptomsalone emphasizing the need for
histological diagnosispriorto anti-tuberculous therapy.
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Rwanda
115 lymphomabiopsies from Rwanda between 1979 and 1987 were also reviewed-
83.5% were NHL, ofwhich 94.8% were B-cell in origin, and 16.5% were HL, ofwhich
57.9% were MC and 83.3% in the 15-40 year age group (Ngendahayo & Schmauz,
1992). Ofthe B-cell NHLs 47.3% were extranodal and 48.4% were high grade with an
increase in high grade and in particular BL casesin the secondhalf ofthe study period.
Tanzania
Kaaya etal (2006) prospectively investigated 22 Tanzanian patients with lymphoma
(HIV serology, immunohistochemistry, EBV/HHV8/HHV6/cytomegalovirus by PCR and
EBVbyin situ hybridisation). Ofthe 22 patients, 10 were >12 years old, of which 6 had
DLBL(2/5 HIV positive, 2/4 EBV positive), 3 had LD HL (2/3 HIV positive, 3/3 EBV
positive), 2 had MC HL (0/2 HIV positive, 1/1 EBV positive) and 1 had precursor B-
lymphoblastic lymphoma. 10/22 (45%) lymphomaswerepositive for HHV8 by PCR,but
not by immunostaining for HHV8 LANAand PCRpositivity was not specific for a
particular type of lymphomanorfor HIV status so they conclude that HHV8 wasnot
associated with HIV-associated lymphomapathogenesis. They also retrospectively
lookedat registry data for 167 lymphomasdiagnosed 1989-1996 and found only a slight
increase in incidence of lymphoma during the 7 year period, despite the HIV epidemic.
Zimbabwe
Levy prospectively investigated LPDs in Zimbabwefor 3 years and found less BL than
that reported from African countries nearer the equator, very little FL, but a preservation
of the bimodal age distribution ofHL (Levy, 1988a, b,c).
Nigeria
A review of 129 lymph nodebiopsies in Jos, Nigeria found that, once sarcomas and
carcinomas were excluded, tuberculosis accounted for 48% ofthe cases, NHL 22.7%, HL
6% and non-diagnostic 20.8% (Obafunwaet al, 1992). Another Nigerian review of 143
cases of lymphomain adult patients presenting to the teaching hospitalin Ife-Ife between
1989 and 1998 found that 74% of cases were NHL and 26% HLwith intermediate grade
tumours, especially DLBL, predominating amongst the cases ofNHL and MC amongst
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the cases ofHL (Adelusola et a/, 2001). The same author reviewed cases of non-Burkitt’s
NHLpresenting to the sameinstitution over a 5 year period and found that of 53 cases
54.7% were intermediate grade, 24.5% low grade and 20.8% high grade (Adelusola &
Durosinmi, 2004).
Omoti & Halim (2005) reviewed 205 cases, over the age of 18 years, with a histological
diagnosis of lymphomain Benin City, Nigeria between 1990 and 2003. Classified
according to the Working Formulation 20 were low grade NHL, 70 were intermediate
grade NHL, 50 were high grade NHL, 20 were unclassifiable NHL, 10 were other NHLs
and 35 were HL. The M:Fratio was 1:1.9, the median age for NHL was 39 years and for
HL was33 years. Of the patients with NHL 82.4% were stage 3-4 and 79.4% werein the
intermediate-high risk group (3-5) by international prognostic index (IPI).
Retrospective immunophenotyping (CD20, CD3, CD68) of 100 cases ofNHLthat had
been fixed and processed in Ibadan, Nigeria showed a clonal population in 87 - 75 B-cell
(CD 20 positive, CD3 negative), 12 T-cell (CD3 positive, CD20 negative) (Thomaset al,
1991). In 4 cases ofhigh grade lymphomathe tumourcells did not stain although
backgroundreactive cells stained and immunostaining failed completely in 9 cases. Of
the B-cell NHLs most were high grade and there were very few cases ofFL (Thomas,
1992).
Mali
14 cases ofCTCL presenting between 1992 and 1994 were reviewed in Bamako, Mali —
there were 3 cases ofATLL associated with HTLV-1, 3 of Sezary syndrome, 2 of
mycosis fungoides, 5 ofpleomorphic cutaneous lymphomaanda final case whereit was
notpossibleto differentiate between mycosis fungoides and pleomorphic cutaneous
lymphoma(Foucharde¢al, 1998).
Current knowledge about lymphomas in Ghana
Regarding lymphomadata from Ghanaa review of 330 autopsies performed during an 11
month period at KBTH in the 1960s found that there were 23 cases of malignant
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neoplasm, 7 ofwhich were lymphomas (Younn, 1964). The median ageofthe patients
was 28 years (range 11-43 years), the retroperitoneum and stomach were commonly
involved and similarities were noted between these tumours and ‘jaw tumoursofBurkitt’.
Twopapers, published a decade later, reviewed surgical material that had been sent to
KBTHbetween 1966 and 1971 (Anim, 1973a, 1973b). 391 cases were seen — 134 BL, 70
HL, 68 lymphosarcoma, 110 reticulum cell sarcoma and 9 unclassified (Anim, 1973a).
BLoccurred predominately 1-20 year age group with equal sex distribution whereas the
M:Fratio for both HL and lymphosarcomawas3:1 and for reticulum cell sarcomait was
2:1. Most cases were under 50 years of age with only 8 cases over the age of 70. There
wasan even distribution amongst the 4 main tribal groups when comparedto the 1960
census. The second paper focuses on HL with a review of45 ofthe 70 cases ofwhich 35
were MC,6 were NS, 3 were lymphocyte predominate and 1 was LD (Anim, 1973b).
Wiredu and Armah(2006) reviewed 3659 cancer deaths at KBTH between 1991 and
2000 from autopsy recordsandregistered causes of death. The M:F ratio was 1.2:1 witha
median age in men of 50 years and 48years in women. Haematological malignancy was
the second commonest malignant cause of death in women (14.7%) secondto breast
cancer (17.2%) and third commonest in men (15.6%) secondto liver (21.2%) and
prostate (17.4%) cancers. The frequenciesofthe different haematological malignancies
are not mentioned however.
Current knowledge about lymphoid leukaemias in sub-Saharan Africa
60 of the 167 (36.4%) cases of leukaemia diagnosed between 1995 and 2005 in Benin
City, Nigeria, were CLL (morphological diagnosis as immunophenotyping wasnot
available locally) (Omoti et al 2007). The M:F ratio of the CLL patients was 1:3 with a
median age of 56 years (range 20-84 years); interestingly the male patients (mean age
63.4 years) were generally older than the female patients (mean age 53 years). 91.7% had
lymphadenopathy, 58.3% anaemia, 58.3% abdominal swelling, 50% splenomegaly and
only 7 patients (11.7%) were Binet stage A; the 2 year survivalrate (from date of
diagnosisto date of death/last documentedvisit) was only 28%.
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A review of 102 cases of CLL presenting to the Tikur Anbessa hospital, Addis Ababa,
Ethiopia found the male to female ratio to be 3.6:1 and the age range 35-91 years with
56% of cases presenting with Rai stage III-IV disease (Shamebo & Gebremedhin, 1996).
Presenting symptoms weresimilar to those seen elsewhere, but they again found a high
default rate (69/102).
Ofthe 95 cases of leukaemia diagnosed between 1994 and 1998 in Blantyre, Malawi
there were 14 cases of ALL, 22 ofCLL and2 cases of hairy cell leukaemia (HCL) with
most of the cases ofALL occurring in children (Mukiibiet a/, 2001). Macharia (1996)
reviewed the available data looking at prognostic factors in childhood ALL presenting in
Africa compared to the knowndata for developed countries and found that there was a
higher white cell count (WCC)at presentation, a greater proportion with T-cell
immunophenotype (60% versus 17%) and CNS and mediastinal involvement.
Current knowledge about lymphoid leukaemias in Ghana
20 cases of paediatric ALL presenting to KBTH were matched by age and sex to cases
presenting to Hamburg Children’s Hospital, Germany (Ekem, 2000). The WCCat
presentation wasnot significantly different between the 2 groups. The Ghanaian children
presented with more organomegaly, were treated less intensively, had a greater default
rate (60%) and a shorter duration of follow-up (6 months versus 69 months) than the
Germanchildren. 75% ofthe Ghanaian children andall the German children wentinto
remission.
Current knowledge about myeloma in sub-Saharan Africa
A review of27 patients with myelomapresenting in Ife-Ife, Nigeria found similar
presenting features and age/sex distribution to that found in developed countries, but with
relatively short follow-up due to a high default rate as well as mortality due to renal
failure and anaemia (Salawu & Durosinni, 2005). Omoti & Omuemu (2007) presented 30
patients diagnosed with myelomain Benin City, Nigeria between 1993 and 2003. The
M<-Fratio was 2:1, the median age was 54 years and the median survival was 3 months
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with only 4 patients (13.3%)alive at 2 years. The authorsfelt that late presentation and
poor compliance with treatment contributed to the poor survival of patients. Similar
demographics and problemsrelating to late presentation were reported in 22 myeloma
patients presenting over a 10 year period in Dakar (Pouye ef al, 2004).
Current knowledge about myeloma in Ghana
There is no published data regarding myeloma in Ghana, however Landgrenetal (2007)
found that 59% of 917 Ghanaian men, aged 50-70 years, in Accra had a monoclonal band
on serum electropheresis giving an age-adjusted prevalence of 5.84 per 100 persons
which is 1.97 times higher than that found in a similar study ofmen from Minnesota
analysed in the same laboratory (Kyle et al, 2006). None ofthe Ghanaian patients had
evidence of myelomafrom their clinical history although further tests were not
performed.
Factors affecting the diagnosis and epidemiology ofLPDsin developing countries
Infection
People living in developing countries are exposed to more frequent and a greater range of
infections than thoseliving in developed countries. For example, in developed countries
10-20% of adults are infected with H.pylori by the age of 30, whereas in developing
countries most individuals are infected by the time they reach adolescence (Pounder &
Ng, 1995; Goodman & Correa, 2000). Someinfections that have beenvirtually eradicated
from most developed countries due to vaccination and vector control programmes, such
as polio and malaria, continue to be a problem in developing countries. People living in
developing countries also have less access to health care and thus infections may not be
as promptly or thoroughly treated. Given the strong links between variousinfections and
LPDsthis is likely to significantly impact on the epidemiology ofLPDs in developing
countries.
>90% ofthe world’s adult population are EBV seropositive; primary infection in
developed countries usually occurs in adolescence whereas in developing countries
primaryinfection tends to occur in childhood (de-Thé, 1976; Takenuchietal, 2006).
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Rasti et al (2005) lookedat cell-free EBV-DNAin plasma from 73 Ghanaian children (32
with acute malaria, 41 age-matched without malaria), as well as adult Ghanaians and
Italian children as controls, and found viral DNA in 47% ofthe Ghanaian children with
malaria and in 34% ofthe Ghanaian children without malaria, but not in the plasma ofthe
GhanaianadultsorItalian children. Thisis further evidence that the epidemiology of
EBVinfection andpersistence variesin different areas of the world; viral reactivation in
children living in malaria-endemic areas may contribute to the increased risk of endemic
BL.
The increased incidence of HIV in many developing countries is having an impact on the
developmentofcancers, especially LPDs (Mbanya, 2002; Mbulaiteye et a/, 2005; Orem
et al, 2006). Whereas in many developed countries the availability ofHAART and
increasing experiencetreating HIV related LPDs is improving outcome, in developing
countries these drugsare not yet as widely available norare treatment options for such
aggressive lymphomasalthoughfeasibility studies of simplified chemotherapy regimens
are underway (Lim & Levine, 2005; Kaayaet al, 2006; Orem et al, 2005 and 2006).
The Demographic and Health surveys assessed HIV prevalence in Ghanain 2003. 85% of
5345 men (aged 15-59 years) and 5949 women(aged 15-49 years)eligible for testing
weretested; the adjusted prevalence was 1.69 in men and 2.71 in women(the 95%
confidence intervals were 1.38-2.00 and 2.32-3.10 respectively) (Mishraet al, 2006).
This is slightly lower than the 3.2-3.6% HIV prevalence rates usually quoted for Ghana
which mayreflect the fact that most HIV prevalencerates are derived from surveillance
systemsin antenatal clinics which are useful for tracking trends in infection, butare a less
accurate reflection of the population as a whole (2005 Programme of Work,
www.ghanahealthservice.org; Mishra et al, 2006; Aikins, 2007).
A study of prison inmates andofficers in Ghana with an uptake of 18% (1336) of 7652
eligible inmates and 21% (445) of 2139 eligible officers showed an HIV seroprevalence
of 5.9% and 4.9% respectively, syphilis seroprevalence of 16.5% and 7.9% respectively
and HCVseroprevalence of 18.7% in both groups (Adjeiet al, 2007; Adjeiet al, 2008).
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As mentioned previously HTLV-1 is strongly associated with the development of ATLL.
A study of 3763 Ghanaians showedthat the prevalence of HTLV-1 antibodies was 1-2%
with no geographicalvariation; this prevalence was no different amongst 124 patients
with haematological malignancies including lymphoma(Biggaret al, 1993).
As also mentioned previously HHV8is associated with some HIV-associated lymphomas
as well as some occurring in the absence ofHIV infection. A study looking at
seroprevalence to HHV8in various countries showed that Ghanahadthe highest rate of
positivity at 42% compared with 1.3% in Trinidad, 4% in Thailand, India and Malaysia
and 5.2% in the United States (Ablasiet a/, 1999).
Socioeconomicfactors, supportive care and intensive therapies
Socioeconomic factors also play a majorrole in the diagnosis and treatment of LPDsin
developing countries (Eden, 2002; Metzgeret al, 2003; Hesselinget al, 2003;
Meremikwu et al, 2005; Howardetal, 2005). The difference is particularly striking in
diseases where, with modern diagnostic techniques and therapy, excellentresults are
often achieved with good long term prognosis — for example paediatric ALL and endemic
BL.
Hesselinget al (2003) report using a modified version of the LMB 89 group B protocol
for the treatment of endemic paediatric BL in Malawiat a cost of <$1000 per child. The
original LMB89 group B protocol has been shownto cure >80% of children with stage
III BL elsewhere, but involves more intensive treatment and requires greaterlevels of
supportive care than that available in Malawi. 44 children (10 stage I, 5 stage II and 29
stage III), with a median age of 7.2 years, were treated with an overall projected Kaplan-
Meier event free survival (EFS) of57% at 1 year (90% for stage I, 52% for stageIII).
There were 10 deaths dueto toxicity and delays in supportive care, 6 due to relapse and 2
due to progressive disease highlighting the need for adequate supportive care in such a
setting.
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Meremikwu et al (2005) report a similar cohort of41 children with suspected endemic
BL in Nigeria. They highlight other problemsrelated to socioeconomicstatus, in
particular presentation with advanced stage disease (20/41) and lack of moneyto pay for
basic diagnostic tests (9/41), for chemotherapy (8/41 — 1 patient was treated empirically
based ona clinical diagnosis) and for ongoing care once chemotherapystarted (13/33).
Metzgeret al (2003) looked at the outcome of 168 children with ALLtreated in
Honduras and found that abandonmentoftreatment (38/168) was the main cause of
treatmentfailure and wasassociated with prolongedtravel time to the treatment centre
and child age <4.5 years, with a further 35/168 patients dying from treatment-related
effects.
Howardetal (2005) discuss the strategies needed to improve outcomesofchildren with
cancer in low-income countries — the developmentofpaediatric cancer units, for
example,is crucial in order to educate staff and ensure uniform levels of care, use of
minimally toxic regimens, parent education and improved supportive care and provision
ofhousing and economic support to minimise abandonmentoftherapy.
In most developing countries patients, or their families, have to payforall their
diagnostic tests; therefore it is often difficult to diagnose or stage patients even when
diagnostic facilities are available in that country. This then makes treatment decisions
even moredifficult. Earlier in the chapter the difficulty making a complete histological
diagnosis based on histology alone was shown with manystudies finding 10-20% of
lymphomasunclassifiable on histology (Kheiry & Ahmed, 1992; Getachew, 2001;
Tumwineet al, 2003; Othieno-Abinyaet al, 2004; Tumwine, 2004; Omoti & Halim,
2005).
Biopsy and histology, although cheaper than immunohistochemistry, are too expensive
for manypatients in developing countries and FNAis often used. A prospective study in
Lusaka, Zambia used a modified FNA technique using a 19 gauge needle to assess lymph
nodeaspirates; this allowed more sample to be aspirated for review by the hospital
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histopathologist as they did not have a cytologist (Patil & Bem, 1993). Aspirates were
performed by the surgeon immediately priorto surgical biopsy ofthe node; the slides
were stained with H&Eand Zieh] Neelsonstains and the results compared with the
histological diagnosis. The positive predictive values were 96.8% for tuberculous
lymphadenitis, 83.8% for primary HIV lymphadenopathy, 50% for Kaposi’s disease and
71.4% for malignancy. They conclude that wide needle aspiration wasa useful
investigation that would have avoided the need for a biopsy in large proportion of
patients even in the absenceofa qualified cytologist. Where chemotherapy and
radiotherapy are available however, it is important to have a moreprecise diagnosis than
simply malignancy and so a lymph nodebiopsyis essential in these patients.
A review ofthe results of 808 lymph node FNAsat Jimma Teaching Hospital, Ethiopia
found the following: 536 (66.3%) tuberculous lymphadenitis, 155 (19.2%) reactive, 35
(4.3%) granulomatousinflammation, 27 (3.3%) pyogenic lymphadenitis, 22 (2.7%) NHL,
15 (1.9%) HL, 18 (2.2%) metastatic tumours (Bezabih & Mariam, 2003). The following
diagnostic criteria were used: NHL- cells were largely monotonous non-cohesive
neoplastic lymphoid cells; HL - Reed-Sternberg cells with the characteristic background
cells; metastatic carcinoma- looseto tight aggregates of epithelial cells. Again, when
considering chemotherapy andradiotherapya histological diagnosis is crucial.
Diagnosis ofindolent LPDs
In developed countries there has been a large increase in the numberoflaboratory,
radiology and endoscopic investigations performed per capita. In developing countries
the numberoftests performed hasalso increased, but routine testing is not done.
Asymptomatic disease such as asymptomatic CLL, smouldering myelomaandother
asymptomatic low grade LPDs,as well as pre-neoplastic disorders such as MGUS,are
therefore rarely diagnosed in developing countries.
Other Factors
Factors that were previously confined to developed countries, such as obesity, smoking,
alcohol and pollution/exposure to toxic substances, are now causing serious public health
problemsin developing countries (Sobngwiet a/, 2004; Boutayeb, 2006). Many factors
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are responsible for these changes including migration to urbanareas, industrialisation,
shifts in diet away from locally produced food to imported food stuffs and a lack of
control regarding the use of chemicals. El-Sadek & Hassan (1999) looked at Egyptian
farm workers exposed to pesticides compared to controls and found that although the
farm workers had higher lymphocyte counts than the non farm workers, and also higher
white cell and platelet counts, they did not have statistically significantly increased risk
of CLL.
Previous work on Tropical Splenic Lymphoma and Hyper-reactive Malarial
Splenomegaly
Massive splenomegaly, splenomegaly palpable at least ten centimetres below the costal
margin, is a commonfindingin tropical countries. The differential diagnosis for these
patients includes HMS,schistosomiasis, visceral leishmaniasis, haemoglobinopathies
including thalassaemia major, chronic myeloid leukaemia and myelofibrosis. Other
possible diagnosesare splenic cysts, splenic tumoursandlipid storage diseases. Causes of
moderate splenomegaly (palpable less than ten centimetres below the left costal margin)
include chronic haemolysis (commoncausesofthis include recurrent malaria and
haemoglobinopathies), portal hypertension, leukaemias, lymphomasand polycythaemia
vera (Fleming, 1996).
These conditions can bedifficult to investigate in a tropical setting due to lack of
diagnostic techniques. Clinicians use their knowledgeof local infections supplemented,
where available, by white cell counts and bloodfilm findings. Undiagnosed cases were
previously grouped togetheras ‘idiopathic tropical splenomegaly’ — from this group HMS
and TSL have emerged.
HMSwaspreviously knownastropical splenomegaly syndrome, but was renamed in
1983 as the links with malaria in its pathogenesis becameclear (Brycesonet al, 1983).
Criteria for the diagnosis of HMSwerefirst published in 1979, revised in 1981 and
reviewed in 1997 (Greenwood & Fakunle, 1979; Fakunle, 1981; Bates & Bedu-Addo,
1997b). Criteria for a diagnosis of HMSinclude: splenomegalyofat least ten centimetres
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below the costal margin, a serum IgM concentration at least 2SD above the normal mean
concentration for the area, a sustained response to malaria prophylaxis with a reduction in
the size of the spleen of at least 40%, evidence of the polyclonalnature of the
lymphocytes (Bates & Bedu-Addo, 1997b).
Polyclonal rearrangements of the immunoglobulin gene have beeninitially demonstrated
using Southern blotting and subsequently with PCR (Bateset al, 1991; Jimmyet al,
1996). Dueto a lack of diagnostic facilities, however, it has often been difficult to
delineate HMSpatients from those with LPDs. Overan eleven year period (1986-1997)
395 patients were referred to the ‘big spleen’ clinic at KATH (Bedu-Addo & Bates,
2002). 221 (56%) ofthese patients had adequate laboratory data and follow-up to allow
the authors to make a meaningful assessment. Ofthese 91 patients (41%) werefelt to
have HMS,48 (22%) to have B-LPDs, 32 (14%) to have other haematological disorders
and in 50 patients (23%) no diagnosis was made. The diagnosis ofHMS was made by
excluding other disorders both clinically and by showing no evidenceofa clonal
population of lymphocytes (by Southern blotting, PCR or immunophenotyping) followed
by demonstration of a sustained reduction in spleen size by 40% whentreated with anti-
malarial drugs. This study demonstrates some ofthe difficulties inherent in diagnosing
HMS-— namelythe lack ofa single, locally available diagnostic test and difficulties
regarding follow-up ofpatients in a tropical setting.
There has previously been some confusion regarding African patients that werefelt to
have CLL.It was noticed that there appeared to be two groups. Thefirst group were
mostly elderly males, with a marked lymphocytosis and some lymphadenopathyand the
second group were younger, predominately female and had splenomegaly (Essien, 1976;
Fleming, 1985). A link between the second group of ‘CLL’ patients and patients with
HMSwasfirst noticed in 1992 with the ‘CLL’patients being felt to have a type ofsplenic
lymphomawith villous lymphocytes (SLVL)(Bateset a/, 1992). Further investigation
has shown markedsimilarities between Ghanaian patients with HMSand ‘SLVL’. Firstly
both groupsofpatients have villous lymphocytes ontheir PB films and are predominately
female (Bates & Bedu-Addo, 1997a). Secondly both groups have markedly raised total
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IgM and antimalarial antibodies (Wallace et al, 1998). Finally both groups had markedly
raised EBV antibodies without an associated increase of viral genomesin the blood, but
no increase in HCVantibodies or HHV8antibodies (Bateset al, 2001).
Further work investigating the Ghanaian patients with ‘SLVL’ has shownthatthe cell of
origin appears to be a naive B-cell as opposed to the post-germinal centre B-cell that is
usually the cell of origin in patients with SLVL (Zhuet al, 1999). As a result the
Ghanaian ‘SLVLs’ have been named TSL pending furtherstudies.
Dueto the similarities between patients with HMSand those with TSL, and with the
improved knowledge regarding mechanisms of lymphomagenesis, it has been postulated
that HMScan evolve to become TSL (Bates& Bedu-Addo, 1997b). Further work to
describe TSL in greater detail and diagnose patients with certainty on a routine basis had
not been possible dueto a lack of diagnostic facilities.
Modelsthatexist for collaborative diagnosis between developed and developing
countries
Collaborations between developing and developed countries in diagnosing andtreating
paediatric acute lymphoblastic leukaemia
Such collaborations can focus ontraining staff and provision oftreatment and supportive
care suchas that reported firstly by Magrath between three Indian centres (Cancer
Institute Madras, Tata Memorial Hospital Bombayandthe All India Institute ofMedical
Sciences New Delhi) and the National CancerInstitute, Bethesda, USA, and secondly by
Masera, between La Mascota paediatric hospital in Managua, Nicaragua, and hospitals in
Monza and Milan,Italy and Bellinzona, Switzerland (Magrath ef al, 2005; Maseraet al,
1998). These collaborations focused on paediatric ALL whichis a significant cause of
paediatric mortality in developed countries and is emerging as a significant cause in
developing countries as preventable causes ofpaediatric mortality diminish, such as
infection and malnutrition. In these collaborative examples diagnosis was madelocally
although support in terms oftraining was provided.
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Bonilla and Ribeiro report a similar collaboration between Benjamin Bloom Hospital, E]
Salvador and St Jude Children’s Research Hospital (SJCRH), Memphis, USA (Greenberg
et al, 2001; Bonilla et al, 2000; Ribeiro et al, 1996). Primary objectives of this study were
to describe the clinical and biologic features of childhood ALL in El Salvadorand to
report the results of efforts aimed at developing effective treatment regimens for ALL in
El Salvadorthrough a partnership with SJCRH (Bonilla et al 2000). The feasibility of
performing special laboratory techniques on bone marrow samples sent by express
airmail from El Salvador to SJCRH and using this information in diagnosis and risk
assessment wasalso explored.
The project wasinitiated by a Salvadoran motherofa child acute myeloid leukaemia
(AML)that was treated at SJCRH in Memphis, but died. She raised some funds along
with some other volunteers and they then approached SJCRH to help establish a
paediatric cancer centre at the Benjamin Bloom Hospital, San Salvador. A local
paediatric haematologist was in charge of the programmeandhe, along with other health
care providers received additional training at SJCRH. A paediatric-oncologist from
SJCRH,who wasfluent in Spanish, provided telephone and e-mail advice. Morphology
and cytochemistry were performed locally. Bone marrow samples werealso sent via 2-3
day courier to SJCRH for immunophenotyping, DNA content analysis and molecular
genetics. Patients received a uniform remission induction regimen and were then
stratified into standard and high risk groups for further treatment — the El SalvadorI
(ELS-I) treatment protocol.
Only 40% ofthe 401 children admitted with ALL to the Benjamin Bloom hospital
between 1987 and 1993 received treatment and virtually none were cured (Ribeiroetal,
1996). Between 1994 and 1996 153 patients were enrolled into the ELS-I study. Of 151
evaluable patients 126 (83.4%) completed the induction regimen and went into remission,
11 (7.3%) were withdrawnby their families from treatment during induction and 14
(9.3%) were unable to complete the induction regimen due to complications. Ofthe 126
patients that went into remission, by 2001, 28 had relapsed, 5 had developed secondary
AMLand 22 had discontinued treatment during maintenance (Greenberg et al, 2001).
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The 4 year EFSestimates for patients at high risk and standard risk were 46+7% and
69415% respectively (Bonilla et al, 2000). Immunophenotyping was adequately
performed in 127 patients (83%), DNA index was adequately performed in 123 (80%)
and reverse transcription PCR was successful in 73 cases (48%). Problems encountered
with the remote analysis of samples included the inability to get repeat samples when
results were inconclusiveas patients had already started treatment, loss of samples during
in transit and delays in transit resulting in samples that were inadequate fortesting.
Asthe number of samples increased remote testing becameinefficient and costly and as a
result an experienced Guatemalan pathologist wastrained in flow cytometric analysis at
SJCRH. Immunophenotyping and DNAcontent analysis is now being performedlocally
with SJCRH providing quality control and ongoing training. This transfer oftechniques is
crucial in the set up of a long-term treatment programmeas described by Howardet al
(2005). Another importantaspect ofthis project was the level of local involvement. The
project wasinitiated by a local group and wasdirected by an enthusiastic localclinician.
Someofthe funding for the project wasalso raised by local fundraising.
Lessonslearnt from the ELS-I study have allowed the protocol to be modified and the
project has been extended to Honduras and Guatemala as the E] Salvador, Guatemala,
Honduras-II trial (Greenberg et al, 2001).
Benefits ofcollaborations between developed and developing countries
Collaborations between health care workers and scientists in developed and developing
countries are an excellent way to attempt to bridge the inequalities in health care and
diagnostic techniquesthat exist between these countries. Such collaborations can be
mutually beneficial — those in developing countries benefiting in terms of access to new
techniques, resources to help improve patient management and most importantly training
of staff to help improvepatient diagnosis and care as well as staff morale. The benefits
for those from developed countries involved in such collaborationsincludeinsight into
different aspects of the disease in question as well as a reassessment of whatis essential
and what can and must be adapted and streamlined (Maseraet a/, 1998). Furthermore,
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establishment of cancer treatment units in developing countries will attract more
physicians and researchers and provide more information abouttheclinical, biological
and epidemiological aspects of the disease in question (Greenberg ef a/, 2001).
There is no published data regarding similar collaborations to diagnose and treat LPDs in
adults in resource poor countries.
Key elements in the developmentofa diagnostic and therapeutic service as a
collaboration between developed and developing countries
Eden (2002) lookedat the feasibility of translating a cure for ALLtoall children and
outlines the key elements to the successful developmentofa service in a disadvantaged
country as follows:
e Recognition of a need in the centre/country itself.
e Mobilization of the local community (especially parents and families) to raise funds,
put pressure on medical services, administrators and politicians to recognize the need
and provide support, moral and ideally financial. Thepriority is to get attention and
start to activate priority setting by authorities.
e Find an external partner unit whichis already established and willing to help butwill
not dictate what is to happen in the country (orthe unit), i.e. like the St Jude or La
Mascota programmes.
e¢ Development of medical, nursing and paramedical expertise in the diseases to be
treated — this can often be donefirst by visiting fellowships wherebya short stay in an
established unit in an industrialized country will provide specific expertise but in the
long run must be developedin houseorat least in country. Both the St Jude and
Italian outreach programmeshave excelled in this but also developed regional
programmesbringing together countries with similar cultures and languages. The
initiation of long-term recruitment, training, accreditation and retention of trained
staff is important.
e Improvementofsupportive care facilities, especially protection from those with
infectious diseases and developmentofa safe and reliable blood transfusion service.
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e Developmentofsubsidised travel, home from homefacilities, etc. to lessen the
burden onparents.
e Developmentofappropriate protocols for each disease entity: these mustbe locally
practicable with minimum cost and maximum efficacy.
e The process can be greatly enhanced by the formation of a co-operative group
bringing togetherall the professionals involvedin the speciality within a country or
region to share expertise and develop training programmes.
e Such co-operative group should act as an advocate for children with cancer in
collaboration with civic groups and parent support groups, in order to lobby for the
optimalcare for children with life threatening conditions.
Collaborative diagnosis ofLPDs in developing countries
The ILSG lookedat‘the clinical characteristics and pathologicalclassification ofNHL in
developing countries’ and reviewed 206 cases ofNHL diagnosedat the Kuwait Cancer
Control Centre (Temmim et a/, 2004). Over a period oftwo years patients diagnosed with
NHLwereentered into the study. Clinical information was documented, a diagnosis was
madebylocal pathologists and a matching tissue block wassent to the ILSG referral
centre in Germany. Diagnosis was made according to the WHOclassification of
haematological neoplasmsandincluded routine staining as well as inmunophenotyping
using B- and T-cell markers (Jaffe et a/, 2001). Five ILSG pathologists reviewed the
blocks sent to Germanyusing the same panel of markers. Consensus diagnoses were
madebythe panel, first with limited clinical information and routinestains, then with the
addition of immunophenotypingresults and finally with full clinical information. In only
4 cases did the ILSG panel cometo a diagnosis that differed from the local pathologists.
In a further 4 cases the block that was sent to Germany wasfelt to be of too poor quality
for a diagnosis to be made. The authors conclude that the WHOclassification of
haematological neoplasmsis fully reproducible in their setting (Temmimefal, 2004).
This project shows that remote comprehensive lymphomadiagnosis is feasible, although
the ILSG panel diagnosis was maderetrospectively as facilities existed locally for routine
histology as well as immunophenotyping.
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Summary
e With the increasing availability of chemotherapy and radiotherapy in Ghana, and
other developing countries, there is an urgent need to improvethe diagnosis of
LPDs, and other malignancies, to ensure that appropriate treatmentis given
e Thereis evidence that the spectrum ofLPDsin Ghana, and other West African
countries, is likely to be different to that found elsewhere
e Therole of infection in the aetiology of LPDs in Ghanarequires further
investigation asthisis likely to influence treatment options
e Real-time collaborative diagnosis alongside research, with a view to transfer of
diagnostic skills and technology, would address these problemsin a practical and
sustainable manner
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Chapter 2 — Setting up the Service: Process and Challenges
Introduction
The project’s first objective was to set up a collaborative model between two teaching
hospitals in Ghana and HMDS,Leedsfor the diagnosis andclassification of LPDs. This
chapter describes how this was done and someofthe challenges that were addressed in
doing so.
The diagnosis of patients with a suspected LPD before the project was set up
Patients with suspected LPDsare referred to the haematology outpatient clinics at KATH
and KBTH.Patients are referred by other specialists within the respective teaching
hospitals, doctors working in the regional, district and other hospitals and those working
in health centres and clinics. There are nosetcriteria for referral — this is at the discretion
of the referring clinician, but includes leucocytosis, abdominal mass and
lymphadenopathy. Patients with a suspected LPDare seen, investigated and treated
according to the availability of tests and treatment and what the patient is able to afford,
at the discretion of the clinician involved.
At KATHthesepatients are seen by the two specialists in the department of medicine
with an interest in haematology, onealso has an interest in oncology. Oncologyclinics
are held on Monday mornings and haematology clinics on Wednesday mornings.
Althoughthere is not a department ofhaematology at KATH,out patient clinics are held,
and chemotherapy given, in a new, purposebuilt, radiotherapy building. In-patient care
takes place on the general medical wards underthe care of one ofthe five medical teams,
but is avoided where possibleas isolation facilities are not available.
Prior to the project commencing KATHdid not have a functioning histopathology
departmentand sobiopsies hadto be sent to one ofthe private laboratories in the town
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centre from where they weresentto laboratories in Accra to be processed and reported.
The oncology specialist performed and reported FNAs. BMAs were performed and
reported by both haematologyspecialists, who also reported blood films. Bone marrow
trephines wererarely doneas they had to be sent to the private laboratories for processing
and reporting.
KBTH,in contrast to KATH,has a haematology departmentas well as a functioning
histopathology department. Within the haematology departmentthere are 3
haematologists - a head of department and tworetired professors that continue to work in
the department. There are also several haematology residents working in the department
as part of the pathology rotation. Residents take the West African College of Pathology
exam prior to progressing to becomespecialists in their chosen area of pathology. BMAs,
and occasionally trephines, are done by the haematologyresidents on Tuesdays and
Thursday mornings in the haematology day unit. Thereis a direct referral system for bone
marrowsbyclinicians from KBTH and other hospitals and so patients are often not
referred to, or seen by, a haematologist for advice prior to their bone marrow.
Audit of patients seen at KATH in 2004 with a suspected diagnosis of LPD
In order to document how patients with a suspected LPD were investigated and treated
priorto the project being set up, Dr Stephens audited the folders ofpatients presenting
with a suspected LPD to the haematology and oncologyclinics at KATH in 2004.
Patients were identified by going throughtheclinic log books for 2004 andselecting
patients where a provisional diagnosis ofHMS, lymphoma, leukaemia, myeloma,
splenomegaly or lymphadenopathy wasentered and where, on review ofthe folder the
patient would havefulfilled the criteria for entering the project. (Figure 2.1)
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Figure 2.1 — Criteria for entry into the project
 
Thecriteria for project entry were: consenting patients, over the age of 12 years, with
a suspected LPD. Whether a patient was suspected to have a LPD wasat the discretion
of the entering clinician, but relevant symptomsandsigns included B symptoms
(fever, weight loss and sweats), lymphadenopathy, hepatomegaly, splenomegaly,
lymphocytosis, hypercalcaemia andlytic bonylesions. Patients with splenomegaly
alone wereentered if they had another suspicious feature or had failed to respond to
three monthsoftreatment for HMSwith proguanil.   
At KATH,patients have a separate folder for each hospital department and those for the
haematology and oncologyclinics are held in the Radiotherapy building. Only 63/80
folders were available howeverandtheclinic log book did not appear to be complete as
there wasa large variation in the numberofentries per clinic and someclinics were
missing.
It was not possible to audit the folders for the KBTHpatients as outpatient clinics were
held in the general outpatient area and there was no record of attendees with diagnoses.
Eachpatient also only had onefolderfor all the specialties within the hospital and these
were held in a central records area and were notaccessible.
In 2004 63 patients were seen at KATHfulfilling the above criteria. 21 were male and 42
were female. The median age was 48 years (range 12-80 years). 45 were seen in the
haematologyclinic and 18 in the oncology clinic. B symptoms(fever, sweats, significant
weight loss) were documented in 26 patients (41%) at presentation, but in 26 out of 63
patients (41%) there was no mention in the folder regarding the presence or absence ofB
symptoms. At presentation 44 patients (69%) had splenomegaly (median length below
the costophrenic angle 16cm, range 4-26cm), 27 patients (42%) had hepatomegaly
(median length 6cm, range 3-16cm), 18 patients (28%) had lymphadenopathy and 5
patients (8%) had masses elsewhere in the body.
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61 patients (87%) had a full blood count (FBC) and 31 (47%) had a blood film performed
as part of their initial investigation. 1 patient was found to be HIV positive, 1 HIV
negative, but the HIV status of the remaining 61 patients was unknown. FNAs were
performed in 11 patients and 5 had a biopsy (3 lymph nodes, 1 stomach and tonsil). 1
patient had both an FNA and a biopsyand | patient had a biopsy, but the result was not
available. 1 patient had a BMAperformed. This hadto be repeatedas the first sample
was non-diagnostic. The results of the FNAs, biopsies and BMA,as well as the diagnosis
after investigations, are shownin table 2.1. 43 patients (68%) werelost to follow-up, 37
(59%) within the first 6 months. 20 patients (32%) remained underfollow-up in clinic, of
which 4 had defaulted for a period of greater than 6 months during their follow-up.
Table 2.1 — 2004 Audit results - Diagnoses and how they were made
 
 
  
Diagnosis Numberof Diagnosis Diagnosis Diagnosis Diagnosis
patients with made made on made on made by
diagnosis clinically FNA biopsy BMA
HMS 28 28
NHL 13 6 5 2
HL 5 3 2
LPD 3 5*
CLL 5 5
Myeloma/ 4 2 1 1
plasmacytoma
ALL 1 1
Portal 1 1
hypertension
Metastatic 1 1
malignancy
Total 63 48 10 4 1     *1 had had a biopsy, but result was not available
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There wasa striking male to female ratio (1:2), relatively young age ofpatientsat
presentation (median age 48 years) and a high default rate from follow-up (59% within
the first 6 months). Splenomegaly was much more common(69% ofpatients) than one
would expect to see in the UK in unselected new patients with a suspected LPD. B
symptoms(41%) and hepatomegaly (42%) were also more commonthanseen in the UK.
Virtually all diagnoses were madeeither clinically or following suboptimal investigation
— BMAand FNAcytology.
Purposeof the project
The purposeofthe project was to set up a system to diagnose and categorise LPDsin
Ghana using modern diagnostic techniques, not currently available locally, in a clinically
meaningful way. Results would be used to inform treatment decisions, as well as provide
epidemiological data regarding LPDs in West Africa. This system would be robust and
sustainable so that local clinicians could continueto use it oncethe initial project had
finished and, as resources becameavailable locally, transfer of skills and techniques was
envisaged so that they could be performedlocally.
How we developed the model we used
The collaboration
The project was a collaboration between:
The Haematology Specialists at KATH, Kumasi;
The Head ofthe Department of Haematologyand one of the Haematology Residentsat
KBTH,Accra;
Dr Bates, Consultant Haematologist based at LSTM,Liverpool;
Dr Owen, Consultant Haematopathologist, HMDS, Leeds;
Dr Stephens, Haematology Specialist Registrar on the Leeds rotation, MD author.
Dr Bates spent 4 years working at KATH whilst she was a haematologyregistrar. She
worked with one of the haematology specialists, as described in chapter 1, investigating
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patients with splenomegaly and proposeda link between malaria, HMSand a low-grade
LPD which they described as TSL. Due to lack oflocally available tests they were
unable to fully immunophenotype or genotype these cases. They presented their workat
HMDSin 2001. As a result of this presentation Dr Owen becameinvolvedin the
collaboration. The Head ofthe Department ofHaematology at KBTH had also expressed
an interest in becoming involvedin further work investigating Ghanaian patients with
suspected LPDsand had previously presented work on LPDsat international
haematological meetings.
Background about HMDS
HMDSwasformedin 1993 by the amalgamation of the ‘Leukaemia Diagnosis Unit’
(which haditselfbeen established in 1983) and the Yorkshire Regional Cancer
Organisation Histopathology Laboratory.It is a fully integrated laboratory bringing
almostall aspects ofhaematological malignant diagnostics together including flow
cytometry, histology and molecular genetics. Scientists work alongside
haematopathologists and results are reviewed by two senior scientists or consultants
before being authorised.
All biopsy samples on patients suspected to have a haematological malignancyare sentto
HMDSfrom the Yorkshire and Humberside Cancer Networks covering a population of
four million. This includes lymph node biopsies, bone marrow aspirates and trephines,
CSF,pleuralaspirates and skin biopsies. Results are e-mailed to clinicians, available via a
passwordprotected website, sent out by post and discussed at multi-disciplinary team
meetings throughout the region. HMDSis primarily a diagnostic service, but also has a
strong research base, especially in the field of LPDs.
Planningtrips to set-up the project
Dr Owenvisited KATH and KBTH with Dr Bates in November2003 to discuss the
possibility of carrying out a collaborative project and meet localclinicians. Dr Stephens
also visited with Dr Bates for a week in March 2004 and metthe collaborators as well
and the Head of the Immunology Departmentat the Noguchi MemorialInstitute for
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Medical Research (NMIMR).Plans for the project were discussed although the timing
and funding of the project had not beenfinalized at that stage. A haematology resident
spent three weeks at HMDSin June 2004 learning about diagnostic techniques such as
flow cytometry and FISH.
Funding applications
Dr Stephensapplied for funding for the project from the British Society ofHaematology
(BSH), the Leukaemia Research Fund, the Elimination of Leukaemia Fund, the LSTM
Research and Development Fund and the Kay Kendall Fund, but was unsuccessful. Dr
Stephens received a BSHtravel grant to fund her planning trip and further funding for
travel and consumables wasreceived from the Myre Sim Fundand the Jean Clayton
Fundsvia the Royal College of Physicians Edinburgh and LSTM respectively.
Unrestricted educational grants were also received from Roche, Chugai-Pharma and
Amgen. MDfees were paid by Dr Stephens.
The main problem encountered when applying for funding wasthat the project fell
between funding for cancer research — for which the grants are for UK based projects,
and funding for tropical research projects — for which the grants are mainly for
preventable diseases and not for cancer-related research projects. It was possible to carry
out the project, however, as Dr Stephens was employed asa lecturer at the Kwame
NkrumahUniversity of Science and Technology (KNUST) Kumasi and no charge was
made for sample processing and reporting at HMDS.
Ethical approval
The project was approvedbythe ethical committees ofLSTM, KATHandthe University
of Ghana, Accra. As the patients were not subjected to any procedures other than those
that form part ofthe usual investigation of patients suspected to have a LPD there were
no significant ethical issues raised. The University of Ghana ethics committee required a
more detailed consent form than that used at KATH.(Appendices 4 and 5) The KBTH
consent form wastherefore submitted and approved as an addendum by the LSTMethics
committee.
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Laboratory trainingprior to theproject commencing
Prior to the project commencing, Dr Stephens was taught how to prepare samples for
flow cytometry, acquire and analyse data. Further telephone and e-mail support was
provided byscientists at HMDS whenflow cytometry was attempted in Ghana as well as
assistance preparing and analysing samples whenthey were brought back to the UK.
Training in other laboratory aspects wasalso given such as processing and embedding
trephines and lymph nodebiopsies, immunohistochemistry, PCR and FISH.
Internet andpostal services
In recent years there have been major advancesin internet availability worldwide. In
Ghana most towns have an internet café and whilst the project was taking place a hospital
network system wasinstalled at KATH. Before this happened there wasa dial-up internet
connection in the Department of Medicine library. This meant that the collaborators were
able to stay in regular contact and that results were rapidly and reliably e-mailed back to
Ghana. Samples were sent to the UK via United Postal Services (UPS). Each package
weighing less than 500g cost 341 500 cedis (£21.34) to post and arrived at HMDSwithin
3-4 working days. All 25 parcels sent arrived intact and so this wasa reliable and cost
effective service. Alternative carriers are available at a similar cost — for example DHL,
but we did not investigate this further as we had no problems with UPS.Thereare also
companiesthatare able to transport samples on dry ice, but this is more complicated and
much more expensive and wasnot necessary for our project.
Sourcing consumables
Wherepossible, consumables were sourcedlocally in Ghana. Other consumables were
donated by HMDS.Needles, syringes, gauze, tape, lignocaine, skin preparation liquid,
distilled water and gloves (both sterile and non-sterile) were readily available at both
KATHand KBTH.Ethylenediaminetetra-acetic acid (EDTA)tubes, serum tubes,slides,
phosphate buffered solution (PBS) powder, and ammonium chloride (NH4Cl) powder
were sourced from local suppliers via laboratory staff.
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Formalin pots were initially donated by HMDS,but formalin was subsequently obtained
from the medical school anatomy department KNUSTandsyringed into eppendorfs for
bone marrowtrephines. Larger pots were used for lymph nodebiopsies. For lymph node
biopsies at KATH somesurgical implements were available in the department, others
were bought from local surgical suppliers as were sutures. Eppendorfs, parafilm, test
tubes with caps, pastettes and antibodies for flow cytometry were all donated by HMDS
as it was notpossible to source these locally in Ghana. (Appendix 6)
Bone marrowneedles
Reusable bone marrow aspirate and trephine needles were in use at both KATH and
KBTHpriorto the project commencing. The needlesat both hospitals were relatively old
and had becomequite blunt. They were washedandsterilised between patients. We
investigated sourcing disposable aspirate and trephine needles, butat a cost of
approximately £5 per disposable aspirate needle and £10 per disposable trephine needle
(despite a 30% discount), this was too expensive to be sustainable. A box ofdiscontinued,
disposable, trephine needles were donated by one company,but it was not possible to
obtain donations of any further needles, either disposable or reusable, from any other
companies. We were, however, given approximately twenty pairs of reusable aspirate and
trephine needles by haematologists from several UK hospitals. Some ofthese had never
been used having been broughtjustprior to the switch from reusable to disposable
needles. Most hospitals in the UK moved over from using reusable needles to disposable
needles in the 1990s.
Access to laboratory space and equipment
In order to process the samples for freezing, laboratory bench space, a centrifuge and a
water bath or incubator at 37°C were required. At KATHthe water bath in the
haematology laboratory was used along with bench space and a centrifuge in the
Department ofMedicine and the freezer in the Head of Department’soffice.
Unfortunately the water bath was therefore on the groundfloor andthe rest of the
processing wasonthe third floor. At KBTHlaboratory space with an incubator,
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centrifuge and freezer was available in a room in the haematology department as well a
laboratory technician who processed the samples.
Setting up and running the LPD clinic at KATH
As mentionedearlier the haematology clinic at KATH was held on Wednesday mornings
and an oncologyclinic with FNA service was held on Monday mornings. Onarrivalat
KATHa secondclinic room wasprepared so that Dr Stephens could also take part in the
haematology clinic on Wednesday mornings and enterrelevant patients into the study. Dr
Stephensalso started a LPD clinic on Monday morningsand, as necessary, on Friday
morningssothat patients from the oncology clinic and ward could be entered into the
project. Bone marrows and lymph node biopsies were performed on the couch in this
room and trolley was set up to store the bone marrow equipment.
Patient entry
From the 1° March 2005 at KATH and 1*July 2005 at KBTH,consentingpatients, aged
>12 years, presenting to the haematology departments with a suspected LPD were
included. The entering clinician decided if the patient waseligible for inclusion. (Figure
2.1) Patients were entered by the haematology resident in Accra and Dr Stephens,
although patients were highlighted for entry by the other local collaborators.
The project was discussed with eligible patients, via an interpreter where necessary, using
the appropriate project consent form andifthey consented the patient signed or
thumbprinted the form. (Appendices 4 and 5) If the patient was under 16 years of age a
parent or guardianalso signed or thumbprinted the form. A project pro formafor that
patient was commenced and completed in as muchdetail as possible whenthepatient
entered the project and outstanding results were completed as they becameavailable.
(Appendix 7) The signed consent form wasstapledto the front of the patient’s pro forma.
When HMDSresults were e-mailed back to Ghana two copies were printed off— one was
filed in the patient’s folder and the other was stapled to the back of the patient’s pro
forma. As the forms contained clinical information and the patient was identifiable by
Page 71
name, hospital numberand date ofbirth, they were kept in a locked drawer and a locked
cupboard at KATH and KBTHrespectively. Only the project clinicians had access to
these forms.
Appropriate blood tests for the presenting symptoms were requested, for example, FBC
with differential (dif) and film, lactate dehydrogenase (LDH), urea, creatinine and
electrolytes, liver function tests, calcium, erythrocyte sedimentation rate (ESR).
Appropriate scans and x-rays were also booked.If the patient had lymph nodesthat were
amenableto biopsy this was booked.
At six months and twelve monthsafter entry into the project, clinical details and response
to treatment were documented along with the repeatfull blood countplusdifferential.
Database
Data was entered by Dr Stephens onto a password protected excel spreadsheet on her
laptop. Patients were allocated a project numberandthis wasusedto enter their data onto
the database. Patient name and hospital number werenot entered onto the database to
preserve anonymity. A single paper copy of the patient name against project number was
kept.
Bone marrow and lymphnoderesults were added to the database as soon as they were
available as were the six and twelve month follow-ups. From the outset the database was
set up to facilitate studying the results utilising code where necessary. The laptop was
backed up weekly. Back up CDs were kept at two separatesites.
Sample collection
Blood and bone marrowcollection
Samples were collected in the outpatient department at KATH andin the haematology
day unit at KBTH,unlessthe patient was an inpatient and too unwellto leave the ward.
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Samples for flow cytometry need to be analysed within 48 hours ofbeing taken. This
therefore dictated the timing of marrows whenflow cytometry wasbeing attempted
locally. When flow cytometry was performed at HMDSsamples were taken at KATH on
Wednesday morning, at KBTH on Thursday morning and were processed at HMDS on
Friday morning. This gave satisfactory results.
Approximately 6mls ofPB wastaken — 4 slides were made, 4mls was put into an EDTA
tube and 2mls into a serum tube. Bone marrow aspirate and trephine were performed.
Approximately 2mls ofBMA wastaken. 4slides were made for the project; others were
madeforlocal reporting. The remaining sample wasput into an EDTAtube. The trephine
sample wasput into an eppendorfcontaining formalin.
Lymph nodes
At KATH lymphnodebiopsies were performed in the haematology outpatient clinic by
one of the surgical residents. The node wassliced into approximately 2-3 millimetre thick
slices to allow fixation by formalin. The lymph node sample was sent to HMDSvia UPS.
If the patient had had a lymph nodebiopsy reported by oneofthe private laboratories
prior to entry into the project, the laboratory was approached to ask if they would release
a block for immunohistochemistry. A system wasalready in place at KBTHforreferring
patients with lymphadenopathy for biopsy which was then processed and reported by the
hospital pathologists. Unfortunately it was not possible to obtain the KBTH pathology
department blocks.
Sample processing and storage
Slides were allowed to dry before being wrappedtightly in parafilm to ensure that there
wereno trapped air bubbles. Approximately 1m] of serum wastransferred into a clean
eppendorfusing a pastette. 2mls ofPB was washed twice with PBSandthentransferred
to an eppendorf. 2mls ofPB and 2mls ofBMA werelysed twice using NH,C]land then
washed three times with PBS. Theresidualpellets were transferred to eppendorfs.
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(Appendix 2) The wrappedslides and four eppendorfs per patient were kept in a minus
20°C freezer until they were transported, packaged in a cool box according to
International Air Transport Association regulations, back to HMDSby DrStephens. At
HMDStheywere stored in the minus 20°C freezer.
Handing overthe project
Dr Stephens was in Ghana from the beginning of January 2005 until the end ofMarch
2006. The first three months were spent acclimatising and setting up the project. The final
three months were spent continuingto enter patients, but also handing overthe project to
local colleagues to allow patient entry to continue.
A laboratory technician at KBTH,had been processing the samples for freezing there.
The haematology resident at KBTH had beenentering patients into the project. The
trephines were sent to Kumasi by bus for Dr Stephensto post to the UK with the samples
from KATH.Dr Stephens madeproject packs for patient entry at KBTH containing all
the consumables necessary for one patient’s samples to be processed and stored as well as
a consent form and pro forma. Twenty five packs were made and empty bags were
refilled in Kumasi and sent back to Accra. The haematologyresident at KBTH took over
entering the data onto the database and a new, password protected database wasset up on
their laptop for ongoing patient entry in Accra.
At KATHa laboratory technician was identified and trained to process the samples. One
of the haematology specialists took over entering data onto the database and a new,
passwordprotected database wasset up on his computer for ongoing patient entry in
Kumasi. Extra consumables were brought over from HMDSandlocally available
consumables were stocked up. Funds to cover posting samples back to the UK, further
consumables, photocopying and paying nurses, the surgeon andlaboratory technician
wereavailable locally.
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Problems encountered
Setting up the project in two centres
Although the medical system in Ghanais based on the UK system there are some
differences andat times it was a challenge to adapt the project to suit local circumstances.
For example platelet transfusions are not available at KATHandonly occasionally
available at KBTHandso this needed to be borne in mind when deciding about doing
bone marrow trephines and lymphnodebiopsies on thrombocytopenicpatients. As it had
been so difficult to make a histological diagnosis at KATH someofthe clinicians had
becomeusedto treating patients empirically without making a diagnosis first and so they
needed to be encouragedto refer the patients for investigation before treating them.
Patientslost tofollow-up
In the 2004 audit 59% ofpatients were lost to follow-up at 6 months.In the project 55%
of patients were lost to follow-up at 6 months. On two occasionsrelatives returned to the
clinic to let us knowthat the patient had died — both of these had aggressive disease and
were receiving chemotherapy. Locally important reasonsfor failure to attend follow-up
includethe difficulty and cost of getting to the hospital for appointments, the cost of
review appointments, lost wages for the patient or carer whilst attending the hospital, the
cost of investigations and or medications, partial or complete resolution of symptoms.
Patients, or their families, sometimes decided to switch from conventionalto traditional
medicine, which wasalso costly.
Communication problems
The official language in Ghana is English, but there are at least 75 local languages of
which Twiis the most widely spoken. Around Accra Fanti and Ga are also commonly
spoken as well as other languages so English is quite widely spokenas a language
commonto many. In the Ashanti region, including Kumasi, Twiis the main local
language and is sometimesused in schools, so English is not as widely spoken asit is
elsewhere in the country. Despite this most young people speak at least some English as
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do older people who wentto school. People that do not speak English sometimes brought
a relative to clinic with them to actas aninterpreter. If this did not happen a nurse or
student would act as an interpreter. Sometimes this would work well, other times it would
not — for example sometimesit wasclear that the person interpreting wasusing their
discretion and altering what wassaid.
Someparts ofthe pro forma presented more problemsthan others. Obtaining a
medication history was usually very difficult. Many patients were able to say that they
were on medications, but did not know whatfor; others were able to say that they were
on medications for malaria or blood pressure, for example, but not which medication.
Patients were asked how manytimesa year they got malaria; for some this wasfairly
easy to quantify, many patients said that they never got malaria, but for others it was a
difficult question to answer. The words for fever and malaria are the same in Twi and as a
result are indistinguishable by patients. In Ghana almostall diagnoses of malaria are
madeclinically and not confirmed by laboratory testing.
Patients unable to payfor tests and treatment
Aspatients had to pay forall investigations it was not possible to request all the tests one
might wishto carry out, for example haematinics, Coombe’stests or tests to complete
staging. Clinicians in developing countries therefore use their discretion when ordering
investigations and have to bear in mind how muchtheyfeelthe result will alter the
patient’s management and whatthey judge or know the patient can afford. There is
therefore a greater reliance on clinical findings supplemented, where appropriate, with
relevant investigations. On a couple of occasions whenpatients could notafford a test
that would significantly contribute to their investigation this was paid for from project
funds, also the cost of checking the LDH wascovered byproject funds in approximately
10 patients to assist calculating the IPI. At KATH a FBCcost 31 000 cedis (£1.93), renal
function cost 45 000 cedis (£2.81) and LDH cost 20 000 cedis (£1.25). An abdominal US
scan cost 45 000 cedis, a chest x-ray 30 000 cedis and a CT scan requiring contrast cost 1
million cedis (£62.50).
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Patient’s also had to pay a fee for each clinic appointment, although it was sometimes
possible to arrange for this fee to be waived, for example if the patient had returned just
to have a bone marrow done. Treatmentalso had to be adapted accordingto the patient’s
ability to pay.
Althoughpatients haveto payfor all their tests and treatment, the extended family system
usually meansthatrelatives will contribute to the cost. This works best for older members
of society with large extended families. Often the youngerpatients struggled the most to
pay for investigations and treatment, especially those living away from the family home
in order to find work.
Concerns regarding the quality oftest results
Although quality control measures were in place in the hospital laboratories and
departments ofpharmacyandradiology, problems occasionally arose. For exampleit
becameevident that all the LDH results were above the normal range — even those on
healthy individuals such as the biochemistry laboratory staff and membersoftheir
families. This was investigated and rectified after discussion with the manufacturers of
the machine. It was evident howeverthat results and drugs from outside the hospital
could not necessarily be relied upon, and were often more expensive than the in hospital
tariff, so patients were encouragedto get their investigations done and buy their drugs
within the hospital where possible.
Flow cytometry
As has been mentioned in the previous chapter immunophenotyping is crucial in the
diagnosis ofLPDs. The Immunology Department at NMIMRin Accra has a flow
cytometer which is mostly used during the malaria season for research work lookingat
immuneresponsesto malaria. Permission was granted by the Head of the Department of
Immunology at NMIMR,to use the flow cytometer. Many problems were encountered
however, including difficulties calibrating the cytometer and getting the settings correct,
difficulties recording and transferring data as the printer and CD driveattachedto the
cytometer computer were broken and the computer wasnotlinkedto the internet. After
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many attempts at correcting the settings it was decided to not continue with flow
cytometry locally. Immunohistochemistry on the trephines and lymph nodes gave good
results and where further information was necessary PB and BMA samples were taken
fresh to HMDSfor flow cytometry on trips back to the UK.
It is hoped that the preliminary results of this project, which clearly demonstrates the
need for local provision of flow cytometry, will facilitate future applications for funding
to support such a service in Ghana.
Poor documentation
Documentationin the clinical notes was frequently not as clear or as comprehensive as
occurs in the UK, largely dueto the extra time pressures that clinicians are under. This
maderetrospectively reviewing the notes difficult. Also there was not a systemic filing
system so it was sometimesdifficult to locate test results in the folders. There were no
computerised results systemsso if the paperresult for a test was lost one would have to
rely on the transcribed copyofthe result written in the laboratory or radiology log book
and occasionally this was not complete.
Summary
e A collaborative model wasset up to comprehensively diagnose LPDs in Ghana
e Localclinicians and technicians were closely involved with the design and
running of the project with a view to the model being continued whentheinitial
MDproject finished
e Full diagnostic work up was performed on samples sent to the UK andthe results
were available to clinicians in Ghanain clinically relevant time span
e Transfer ofskills and technology is envisaged over the coming years to improve
the diagnostic facilities available locally
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Chapter 3 — Patient Characteristics and Diagnoses
Introduction
The project’s second objective was to diagnose andclassify patients presenting with a
suspected LPD to KATH and KBTH.Inthis chapter the characteristics and diagnoses of
the patients entered into the project are presented and discussed.
Methods
As described in Chapter 1, LPD diagnostic techniques available in developed countries
have advancedsignificantly in recent years. The diagnosis andclassification of LPDs
combinesclinical details with morphology, immunophenotype(assessed by flow
cytometry and/or immunohistochemistry) and genotype (assessed by conventional
cytogenetics, FISH or PCR). (Figure 1.2, Chapter 1) The entry criteria for the project are
described in Figure 2.1 (Chapter 2) and the methods that were used to diagnose the
suspected LPDsare described in Chapter 1 and Appendix 1.
As described in Chapters | and 2, before the project commenced, manyofthese
techniques werenotavailable to clinicians diagnosing LPDs in Ghana. In Kumasi the
diagnosis of a LPD wasusually based onclinical details, basic blood tests and, where
relevant, FNAs. Occasionally BMA,and very occasionally histology reported in private
laboratories, were available. In Accra more information was available as more BMAs
were performed and biopsy samples (trephines/lymph nodes) were processed and
reported in the hospital pathology department.
Whenpatients entered the project, all available clinical information as well as basic
demographic and socioeconomic details were documented on patient pro formas. This
information wasthen entered into a database along with HMDSresults and, where
possible, patient follow-up. The results are presented below.
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Results
To allow comparisonofthe results the patients were divided, based ontheir final
diagnosis (Table 3.8), into 4 groups. The patients with a LPD weredividedinto those
with SMZL (n=18) and those with other LPDs (non-SMZL LPDs, n=43) as SMZL was
the largest single category of LPD. Thepatients that did not have a LPD weredivided
into those with palpable splenomegaly, but a non-diagnostic marrow (SND,n=29) and
those with other diagnoses (n=60).
Patients with splenomegaly wereonly entered into the project if they had another feature
suggestive of a LPD,oriftheir spleen size had failed to respond to 3 months of
proguanil. (Figure 2.1, Chapter 2) This was done to exclude mostpatients with
splenomegaly due to HMS, however many ofthe SND groupofpatients may have had
HMSand a second pathology causing lymphadenopathy or B symptoms.
As discussed in chapter | the criteria for the diagnosis ofHMSincludes splenomegaly of
at least ten centimetres below the costal margin, a serum IgM concentration at least 2SD
above the normal mean concentration for the area, a sustained response to malaria
prophylaxis with a reduction in the size of the spleenofat least 40% and evidenceofthe
polyclonalnature of the lymphocytes. We did not measure the serum IgM levels of the
patients, but none of these SND patients had a clonal lymphoid population and in 25/29
(86%) patients the spleen wasat least ten centimetres below the costal margin. Ofthe 29
patients with splenomegaly and a non-diagnostic marrow 27 (93%) had another feature
suggestive of a LPD and 2 (7%) had beenentered into the study as they had not
responded to 3 months malaria prophylaxis with proguanil.
The ‘other diagnoses’ group includes the following diagnoses: AML, Refractory
Anaemia with Excess Blasts, MGUS,tuberculosis, Rosai Dorfman, metastatic
carcinomas, as well as patients with a reactive marrow,but no splenomegalyandpatients
with no, or an inadequate, trephine. (Table 3.7)
Page 80
The results for the 4 groups were analysedto look forstatistically significant differences
between the groups.In the following tables the p value is given and wherethis is
significant (<0.05) this is in bold. Also whether Kruskal Wallis Test (KW)(for ordinal
data) or Pearson Chi-Square Test (PCS) (for nominal data) was usedis indicated.
Patient demographics
150 patients were entered into the project - 71 male, 79 female. The median age was 46
years (range 12-83 years). 117 were entered at KATH and 33 were entered at KBTH. 100
patients were referred from within the 2 teaching hospitals, 50 from other hospitals or
clinics. (Table 3.1)
Table 3.1 - Patient demographics
 
  
All SMZL Non- SND Other p
patients SMZL diagnoses
LPDs
Number 150 18 43 29 60
Male:Female 71:79 4:14 21:22 13:16 33:27 0.26
PCS
Median age yrs 46 64.5 58 35 33.5 <0.0001
(range) (12-83) (40-78) (12-80) (12-70) (12-83) KW
Entered
KATH: 117:33 17:1 34:9 26:3 39:21 0.028
Entered KBTH PCS
Referred within
hosp:referred 100:50 12:6 27:16 22:7 39:21 0.677
outside hosp PCS      
Socioeconomic data wasalso recorded and analysed. Statistically significant differences
between the groups were found for residence (p=0.0001 KW), education (p=0.005 KW),
roofing material on accommodation (p=0.013 KW)and access at hometo a stove
(p=0.006 PCS), a television (p=0.034)and electicity (p=0.033). (Figures 3.1-3.4) There
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werenostatistically significant differences for marital status, co-habitees, dependents, job
and transport to the hospital. (Appendix 8)
Figure 3.1 — Residence
 
 
 
 
O Rural
B® Peri-urban
® Urban    Allpatients SMZL Non-SMZL SND OtherLPDs diagnoses
Figure 3.2 - Education
B Unwersity
@ Adult education
 Allpatients SMZL Non-SMZLLPDs SND Otherdiagnoses  
O Postgraduate education
@ Completed senior secondary school
B Started, but not completed senior
secondary school
@ Completed junior secondary school
D Started, but not completed, junior
secondary school
Completed primary education
B Started, but not completed, primary
education
B No education   
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Figure 3.3 - Roofing material on accommodation
 
 
B Grass/ bamboo
@ Apartment block with concrete roof
Wood
Tiles
B Corrugatedroofing sheet with
finished ceiling
B Corrugatedroofing sheet with
unfinished ceiling   
 
Allpatients SMZL Non-SMZL SND Other
LPDs diagnoses   
Figure 3.4 - Access to at home
 
60% O Refrigerator
Stove
@ Television
B Electricity   
20%
0%
All patients SMZL Non-SMZL SND Other
LPDs diagnoses   
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Presenting symptoms
The presenting complaint was abdominalpain, distension or mass in 53/150 (35%)
patients, lymphadenopathy in 32/150 (21%) and B symptoms(fevers, sweats or
significant weightloss) in 20/150 (13%). The remaining 45 patients presented with other
symptomsincluding fatigue, breathlessness, bone pain, headache and rash. Ondirect
questioning at presentation 83/150 (55%) reported fevers, 78/150 (52%) reported sweats
and 95/150 (63%) reported moderate-severe weight loss. Only 14/150 (9%) patients had
no B symptoms whenthey were entered into the project. (Table 3.2)
Table 3.2 — Symptomsat presentation
 
 
 
All SMZL Non- SND Other p
patients SMZL diagnoses
n=150 n=18 LPDs n=29 n=60
n=43
Abdominalpain/ 55 14 11 17 13 <0.0001
distension/mass (37%) (78%) (26%) (59%) (22%) PCS
Symptomatic 32 1 13 2 16 0.010
lymphadenopathy (21%) (6%) (30%) (7%) (27%) PCS
Ondirect 83 9 24 22 28 0.066
questioning (55%) (50%) (56%) (76%) (47%) PCS
reported fevers
Ondirect 78 12 25 15 26 0.298
questioning (52%) (67%) (53%) (52%) (43%) PCS
reported sweats
Ondirect
questioning 95 11 34 17 36 0.533
reported (63%) (61%) (72%) (59%) (60%) PCS
significant
weight loss       
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13 (9%) patients were performancestatus 0 (asymptomatic), 91 (61%) patients were
performancestatus 1 (symptoms, but ambulatory), 11 (7%) were performancestatus 2
(bedriddenfor less than half of each day), 20 (13%) were performancestatus 3
(bedridden for greater than half of each day) and 14 (9%) were performancestatus 4
(chronically bedridden). There wasnota statistically significant difference regarding
performancestatus between the 4 groups (p=0.195 KW). (Figure 3.5)
Figure 3.5 — Performancestatus of patients
 
 
@ Performancestatus 4
OD Performancestatus 3
D Performancestatus 2
B Performancestatus |   B Performance status 0
 
All patients SMZL Non-SMZL SND Other
LPDs diagnoses   
Presenting signs
Clinical signs at presentation included palpable splenomegaly, hepatomegaly and
lymphadenopathy. Splenomegaly was documented in centimetres palpable from the
costophrenic angle and measured using a previously validated uniform technique to
maintain consistency betweenclinicians (Bedu-Addo & Bates 2002). Other signsat
presentation included pallor (22/150 patients), cachexia (6/150 patients) and jaundice
(3/150 patients). (Table 3.3)
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Table 3.3 — Presenting signs
 
  
All SMZL_ Non-SMZL SND Other Pp
patients LPDs diagnoses
n=150 n=18 n=43 n=29 n=60
Palpable 83 18 20 2 16
splenomegaly (55%) (100%) (47%) (100%) (27%)
Size - median 13cm 17cm 11.5cm 14cm 6cm 0.003
(range) (2-33cm) (6-30cm) (3-25cm) (2-33cm) (2-3lcm) KW
Palpable 60 15 15 19 11
hepatomegaly (40%) (83%) (35%) (66%) (18%)
Size - median 4cm Scm 6cm 4cm 4cm 0.160
(range) (1-22cm) (2-17cm) (3-22cm) (2-7cm) (1-10cm) KW
Palpable nodes 60 3 22 9 26 0.003
>Ilcm diameter (40%) (17%) (51%) (31%) (43%) PCS      
Medication and malaria history
Whenthey were entered into the project 67% of patients were taking prescribed
medications and 40% had had herbal medications in the previous six months. There was
no significant difference regarding this between the four groups. The SMZL patients
reported having had a median of 3 episodes of malaria (range 0-24) in the previous year.
The group with SND andthe group with ‘other diagnoses’ each reported a median ofonly
1 episode of malaria (range 0-20 and 0-24 respectively). This difference was of
borderline statistical significant (p=0.067 KW).
Investigation results available locally at diagnosis
Almostall the patients (95%) had a FBC performedat diagnosis and mostofthese also
had a blood film comment. Approximately half the patients had their renal function
checked and half had a LDH. HIVtest results were available in 43%, liver function in
37% and an ESR in 35%. There wasnosignificant variation between the 4 groupsin
these frequencies. 33% ofpatients had an US scan, 16% an x-ray and 3% a CT scan,
again with no significant variation between the 4 groups. There wasa statistically
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significant difference between the 4 groups regarding those that had an FNA reported
locally, but not for those that had a biopsy reported locally (Table 3.4).
Table 3.4 — Investigation results that were available locally at diagnosis
 
 
All SMZL_ Non-SMZL SND Other p
patients LPDs diagnoses
n=150 n=18 n=43 n=29 n=60
Biopsy 16 1 6 0 9 0.052
reported (11%) (6%) (14%) (15%) PCS
locally
FNA 21 0 6 1 14 0.017
(14%) (0%) (14%) (3%) (23%) PCS      
There wasa significant difference in the FBC results between the 4 groups, but no
significant difference in the other blood results between the 4 groups. (Table 3.5)
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Table 3.5 — The results of the blood tests that were available locally at diagnosis
 
 
  
All SMZL Non- SND Other p
patients SMZL diagnoses
LPDs
n=150 n=18 n=43 n=29 n=60
Haemoglobin (g/dl) 8.6 8.5 8.2 Ted 10.4 0.003
median (range) (2.1-15) (3.6-13.5) (2.1-15) (2.5-12.7) (3.5-13.5) KW
WCC(x107/1) 7.5 53.7 10.8 3.3 7.3 <0.0001
median (range) (1.0-UR) (2.8-UR) (1.4-UR) (1.0-26.1) (2.0-264.0) KW
Platelets(x107/1) 137 114 128 72 228 <0.0001
median(range) (3-682) (14-181) (6-518) (6-317) (3-682) KW
Creatinine (umol/I) 88 7 88 62 88 0.221
median (range) (27-212) (35-141) (32-186) (27-177) (35-212) KW
Bilirubin (umol/1) be 15 19 22 14 0.213
median (range) (3-125) (10-125) (7-34) (8-56) (3-109) KW
Alanine tranaminase 21 20 16 21 28 0.864
(U/l) median (range) (10-334) (12-56) (11-334) (11-47) (10-80) KW
ESR (mn/hr) 80 114 136 a7 65 0.424
median (range) (4->140) (16->140) (4->140) (12->140) (15->140) KW
LDH (U/1) 378 424 372 401 356 0.924
median (range) (91-5629) (167-585) (110-2735) (122-1928) (91-5629) KW
Positive HIV 7/65 0/8 1/21 4/14 2/22 0.513
test/numbertested (11%) (0%) (5%) (29%) (9%) KW      Normal ranges: Haemoglobin 11.1-18 g/dl, WCC 2.5-10 x10°/1, Platelets 140-440 x107/1,
Creatinine 53-124 umol/I, Bilirubin 3.4-22.2 umol/l, Alanine tranaminase 10-40 U/l, ESR
<20mm/hr, LDH 100-190 U/l. UR=unrecordable.
HMDSresults
Mostpatients (88.7%) had a bone marrowaspirate and trephine reported at HMDS,2
patients (1.3%) had just PB assessed at HMDSand 15 (10%) had neither PB nor bone
marrow assessed at HMDS.Thereasonsfor not having a bone marrow included the
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patient being lost to follow-up or dying before the bone marrow wasperformed, being too
thrombocytopenic for a trephine to befelt to be safe or patient preference. (Table 3.6)
The median turnaround time for bone marrowresults from HMDSwas13 days (range 6-
62 days) from when the sample waspostedto the result being available to the clinician in
Ghanaand 15 days (range 7-62 days) from when the sample wastakento the result being
available.
For biopsyresults, the median turnaround time from HMDSwas10.5 days (range 3-27
days). This is the time from when the sample waspostedto the result being available to
the clinician in Ghana. Someofthe biopsy samples were sent as blocks sometime after
the biopsy had originally been taken and sothe time from the sample being taken does
not reflect the HMDSturnaround.
Table 3.6 — Samples processed at HMDS
 
        
All SMZL Non- SND Other Pp
patients SMZL diagnoses
LPDs
n=150 n=18 n=43 n=29 n=60
Peripheral blood for 2 1 1 0.799
flow cytometry, no 0 0(1.3%) (23%) (1.7%) PCSbone marrow
Bone marrow 133 18 42 29 44 <0.0001
aspirate and trephine (88.7%) (100%) (97.7%) (100%) (73%) PCS
Lymphnode biopsy 28 ‘ 12 2 14 0.018
(18.7%) (27.9%) (69%) (23%) PCS
Breakdown by diagnosis
Table 3.8 shows the demographicsofpatients with the various diagnoses for comparison.
The patients with LPDswill be discussedin greater detail in chapters 4 and 5 (cases | and
5). 3 patients with non-LPD diagnoses are presented in chapter 5 (cases 2-4).
Page 89
 
Table 3.8 - Breakdownby diagnosis
 
 
 
  
Diagnosis Number of Age yrs Sex % patients % WCCx10°/1
patients median M:F with B patients median
with (range) symptoms with a (range)
diagnosis at palpable
Total=150 presentation spleen
SMZL 18 64.5 4:14 94% 100% 53:7
(40-78) (2.8-UR)
CLL 12 60.5 li2 92% 67% 66.9
(45-80) (4.1-UR)
HL 7 18 3:4 100% 1% 3.2
(14-69) (1.4-21.9)
Myeloma 6 61 1:1 100% 17% 6.5
(50-74) (3.6-10.8)
DLBL 4 55 1:1 80% 25% 4.7
(13-79) (3.9-8.6)
T-ALL 3 23 zal 100% 33% 20.7
(16-62) (3-100)
Peripheral T 3 30 3:0 67% 0% 6.9
cell lymphoma (12-69) (5.9-16.3)
B-ALL zZ 30 1:1 100% 50% 33.8
(12-48) (27.3-40.2)
FL zZ 60.5 1:1 100% 50% 26
(56-65) (7.7-44.3)
BL 2 33 1:1 100% 0% 7.7
(13-50) (3.1-12.3)
MCL 1 70 1:0 100% 100% UR
NKcell LPD 1 67 0:1 100% 100% 30.4
AML 4 25 I:1 75% 50% 129.2
(12-40) (43.3-240)      
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Table 3.8 - Breakdown by diagnosis continued
 
 
  
Diagnosis Number of Age yrs Sex % patients % WCCx10"/1
patients median M:F with B patients median
with (range) symptoms with a (range)
diagnosis at palpable
Total=150 presentation spleen
Refractory 2 69 I: 100% 50% 34.9
Anaemia with (69-70) (9.2-60.6)
Excess Blasts
MGUS 1 65 0:1 100% 0% unknown
Tuberculosis 4 32 3:1 75% 0% 9.7
(18-83) (6.7-9.4)
Rosai Dorfman 1 30 1:0 100% 0% 5.3
Metastatic 8 55 7:1 100% 13% 7.5
carcinoma (18-78) (2-18)
SND 29 35 13:16 93% 66% 33
(12-70) (1-26.1)
Reactive 22 32 1:1 77% 0% 6.1
marrow no (13-77) (3.6-49.1)
splenomegaly
No/inadequate 18 32.5 8:10 94% 71% 6.7
trephine (12-64) (3.6-241)      
Comparison betweeninitial andfinal diagnoses
The benefit (or not) ofhaving diagnostic support for LPDs in Ghana from HMDS was
determined by assessing whetherthe final pathological diagnosisaltered patient
management comparedto the initial, largely clinical, diagnosis which was made based on
locally available diagnostic tools. Patients were divided into 5 groups depending on the
relationship betweenthe initial and final diagnoses. (Table 3.7)
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Table 3.7 — Initial comparedto final diagnoses
 
    
Group Initial diagnosis Effect of final diagnosis on patient
(N=) management
1 (48) Initial and final diagnosis the same Noalteration in management
2 (23) Nofirm initial diagnosis made; Final diagnosis informed management
correct final diagnosis included in
initial differential diagnosis
3 (16) Final diagnosis notincludedin initial Final diagnosis did not affect
differential diagnosis management
4 (23) Final diagnosis notincludedin initial Final diagnosis informed management
differential diagnosis
5 (40) Patient died, lost to follow-up or Final diagnosis did notaffect
inadequate/ unobtainable sample management
Follow-up
Follow-up details were documented, where possible, when patients attended forclinic
review at 6 and 12 months. Further follow-up wasalso planned at 18 months. Only 7
patients had beenin the study for 12 months before the end ofMarch 2006 and of these 4
(57%) were followed up; the other 3 (43%) patients had been lost to follow-up within 6
monthsofentering the project.
76 (51%) patients had been in the study for 6 months before the end of March 2006 and
of these 33 (43%) had a 6 month follow-up. Of the remaining 43, 13 (17%) had died and
30 (40%) had beenlost to follow-up. (Table 3.9) By the end ofMarch 2006, of all 150
patients enteredinto the project, 21 (14%) had died and 35 (23%)had been lostto follow-
up.
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Table 3.9 — Follow-up at 6 months
 
  
All SMZL Non- SND Other p
patients SMZL diagnoses
LPDs
EligibleSth 76/150 10/19 21/43 16/29 29159 0.897
mt (51%) (53%) (49%) (55%) (49%) PCS
follow-up
Followed‘ 33/76 5/19 9/21 9/17 10/29 0.431
up at (43%) (26%) (43%) (53%) (35%) PCS
months
Died
before 6 13/76 0/19 6/21 3/17 4/29 0.304
month (17%) (0%) (29%) (18%) (14%) PCS
follow-up       
Discussion of results
Patient demographics
There wasa significant difference between the 4 groups of patients in terms of age with
the 2 groups ofpatients with LPDsbeing significantly older than the 2 groupsofpatients
without a LPD (p=<0.0001 KW). As most LPDs, especially low grade LPDssuch as
SMZL,tend to occur in patients over the age of 50, this is not surprising. There was no
significant difference in the sex ratios between the 4 groups, howeverthesex ratio in the
SMZLgroupwasstriking and will be discussed further in chapter 4.
As Dr Stephens was based at KATH andpatient entry to the project started earlier there,
morepatients were entered at KATH than at KBTH. Although it was notstatistically
significant, the proportion of patients entered at KATH versus KBTHis moststriking for
those presenting with big spleens — the SMZL and the SND groups. The work done by Dr
Bates and others at KATH,investigating patients with big spleens had increased
awareness amongstlocal clinicians, both at KATH andin local clinics and hospitals, thus
Page 93
 
encouraging the referral ofpatients with splenomegaly to the haematologyclinic.It is
also not possible to exclude a real difference in the incidence of splenomegaly between
Kumasi and Accrain a studyofthis size and design.
Mostpatients were referred from within the hospital as clinics tended to refer to the main
outpatient areas, for example the polyclinic at KATH, where the doctors would do
baseline investigations and refer patients on to specialist clinics as appropriate. The
polyclinic also functioned as a primary care service for those patients living within the
vicinity of the hospital as patients did not need referral in order to be seen there.
The moststriking andstatistically significant differences in the socioeconomicdetails
were the numberofpatients with SMZLthat lived rurally, had no education and did not
have access to a stove comparedto the other groups. ‘Stove’ refers to a conventional
oven inside the house; in Ghanathose that do not have access to a stove do their cooking
outdoors in a pot over fire. These patients were therefore morelikely to be susceptible
to infections andless likely to receive prompt and through treatmentof infection than
those with more education, indoor cooking facilities and better access to healthcare
facilities. This is potentially important when considering potential aetiological factors for
SMZL,in particular malaria.
Presenting symptomsand signs
In just overa third ofall patients, and in 78% of SMZL and 59% of SNDpatients, the
presenting complaint was abdominalpain or mass — given the median palpable size of
spleen in those that had splenomegaly (13cm, 17cm and 14 cm respectively) this is
unsurprising. On direct questioning most patients (91%) reported the presence ofB
symptoms. Thereare several possible reasonsfor this including late presentation ofLPD
patients, patients presenting with infection as a cause of their symptoms andsigns(e.g.
those with tuberculosis) and patients presenting with an active infection and being found
to have lymphadenopathy, organomegaly etc as an incidentalfinding.
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Medication and malaria history
Twothirds of the patients reported that they were taking medications at presentation and
twofifths that they had taken herbal medications within the past six months. Thisreflects
the fact that patients were seen as secondaryandtertiary referrals and that traditional
medicineis still widely used in Ghana, even amongst those patients that can access
medical services. We attempted to gauge how frequently patients were unwell with
malaria — this was often a difficult question for the patients to answer and so must be
interpreted with caution, but overall the SMZL group presented with a median of3
episodes of malaria a year, 2 episodes in the other LPD group and 1 episode a year in the
remaining groups. This wasofborderline statistical significant difference.
Investigation results available locally at diagnosis
Ofthe results that were available locally at diagnosis the FBC results were the only
results that were significantly different between the 4 groups, in particular for the WCC
and the platelet count. The WCC was muchhigherin the SMZL group (median 53.7
x10°/l) than in the other groups andthe platelet count was lowest in the group with
splenomegaly, but a non-diagnostic marrow.Interestingly the patients with
splenomegaly, but a non-diagnostic marrow were more pancytopenicas a result of
hypersplenism than the patients with SMZL who had both marrowinfiltration and
hypersplenism.
HMDSresults
The project turn around time for results was very rapid especially comparedtothe local
turn around time for histology samples processed in private laboratories which wasat
best a few weeks and in manycases several months. Rapid turnaround in the HMDS
laboratory is facilitated by screening on samplearrival, so that the most appropriate
investigations are performedin a timely manneralong with resin embedding oftrephine
biopsies whichis significantly shorter than standard decalcification and paraffin
embedding. Samples are then reported by two haematopathologists. Results were e-
mailed back to Ghana.
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Breakdownby diagnosis
LPDdiagnosesare discussedin detail in chapter 4. Of the non-LPD diagnoseseight
metastatic carcinomas were diagnosed — ofthese five were diagnosed on bone marrow
trephine reflecting late presentation of disease. The primary sites of these five cases were:
one prostate carcinoma(the patient also had a lymph node biopsy showingprostate
carcinoma), one probable gastrointestinal carcinoma and three adenocarcinomas of
unknown primary (one patient also had a lymph node biopsy showing adenocarcinoma).
Ofthe three carcinomas diagnosed on lymph nodebiopsy alone one was an EBV-related
NPC,one wasa poorly differentiated metastatic carcinoma andthe third was a poorly
differentiated carcinoma consistent with a lymphoepithelial carcinoma.
There were also four patients with AML and twowith refractory anaemia with excess
blasts; all six had peripheral blasts and so had been entered into the study as possible
cases of ALL. Cytosine (the chemotherapy drug thatis the mainstay oftreatment for
AML)wasnotavailable in Ghana, but vincristine, cyclophosphamide, doxorubicin and
prednisolone (drugs used to treat ALL) were. Therefore whenever there was uncertainty
regarding the lineageofblast cells it was assumed that they were lymphoid in origin and
the patientoffered trial of vincristine and prednisolone, as AML wasnottreatable. As
platelet transfusions, inpatient isolation facilities and drugs, such as growth factors and
antifungals, were not available at KATH adult acute leukaemiapatients had a very poor
prognosis and generally died within a few days ofdiagnosis from bleeding or infection.
Whenit waspossible to confirm the diagnosis ofAML, for example if Auer rods were
visible or a result was available from HMDS,this often raised an ethical dilemmafor
local clinicians. The conceptofpalliative care was not something that most Ghanaian
families understood and therefore if a patient with an untreatable illness such as AML
were allowed hometo die the family would often resort to paying large amounts of
moneyto the localhealer in the hopeofa miracle cure. Asa result local clinicians, faced
with a terminal untreatable illness tended not to discharge patients and rather allow them
to die in hospital where they could attemptto alleviate their symptoms, although sadly
even drugs such as morphine, were very costly.
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Comparison betweeninitial andfinal diagnoses
In almost third of patients (n=48) the diagnosis made based onlocally available
information and the diagnosis made once the HMDSresults were available were the same
— 10 of these diagnoses were madeontheclinical picture alone and 18 onthe clinical
picture plus bloodfilm. This reflects the clinical acumenoflocal physicians who are used
to having to make diagnosesandtreat patients based on limited investigation results. In
15% of patients the HMDSdiagnosis waspart ofthe differential diagnosis madelocally,
but it would not have been possible to make to appropriate treatment decisions without
the additional results. In a further 15% ofpatients the HMDSdiagnosis had not been part
of the initial differential diagnosis andthis altered patient management — of these one
third of the local diagnoses had been made based on FNA appearances.
FNAcytology aloneis unreliable in the diagnosis of LPDs, butis a rapid, cheap and non-
invasive investigation and therefore readily applicable to the developing country setting
wherepatients often present late and cannot afford expensive investigations. As discussed
in Chapter | both Patil & Bem (1993) and Bezabih & Mariam (2003) found FNAresults
were useful as a first line investigation of lymphadenopathy,but did not allow an accurate
enough diagnosis for the correct chemotherapy or radiotherapy regimensto be chosen.
Wherefacilities for flow cytometry are available locally, immunophenotyperesults can
give useful information in addition to FNA cytology (Jorgensen, 2005). Swart et al
(2007) performed FNAsin 124 cases of suspected lymphomain Capetown, South Africa
and assessed the aspirate by both cytology and flow cytometry. Patients also had a biopsy
and bone marrowaspirate and trephine and the FNA results were compared with the
histological diagnoses. It was not possible to do this in 43 cases (35%) howeveras in 17
cases (13.7%) insufficient cells were aspirated for both cytological and
immunophenotypic assessment and in 26 cases (21%) there was no confirmatory
diagnosis.
In the 81 cases (65%) whereit was possible to verify the FNA result with a biopsy result
there were 13 true negative results (2 tuberculosis, 8 reactive, 3 granulomatousinfection),
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2 false negatives (one T-cell lymphomaand one FL diagnosed on biopsy) both ofwhich
werefelt on review to be due to FNA samplingerror and 2 false positives giving a
sensitivity of 96.9%, specificity of 86.7%, positive predictive value of 96.9% and
negative predictive value of 86.7%. In 64 cases (51.6%) an accurate diagnosis of
lymphomahad been made on FNA.The authorsdid not give a full break down ofthe
diagnoses, but report that of the 6 cases of HL, 4 were correctly diagnosed on cytology
and 2 required biopsy. They also commentthat it was easier to make a confident
diagnosis of DLBL,anaplastic large cell lymphoma and SLL on FNA,and more
challenging to diagnose MALT lymphoma and MCL.Thisis interesting as MCLis a
LPDthat could potentially be diagnosed on FNAif facilities were available for both flow
cytometry and FISH looking for the t(11;14) translocation.
Thefacilities to perform flow cytometry are not available in most hospitals in sub-
Saharan Africa and many donot have a pathologist expert in cytology reporting therefore
it is not yet possible to use these techniques with this level ofaccuracy in most other sub-
Saharan African countries. FNAs, even in expert hands with the addition of flow
cytometry, remain insufficient for the diagnosis of LPDsand histological diagnosis
remainscrucial especially in HL and FL (Hehn etal, 2004). In the resource poorsetting
wherethere is a functioning histopathologyservice in place, it is cheaper and easier to
introduce immunohistochemistry than flow cytometry, as the latter requires the purchase
and ongoing maintenanceofa flow cytometer. Where there is no functioning
histopathology service in place then remote diagnosis of LPDs, suchas in our project,
needs to be considered.
Follow-up
39% ofthe patients that were eligible for 6 month follow-up had already beenlost to
follow-up. This is a commonproblem in developing countries and as discussed in
Chapter 2 there are manyreasonsfor patients not attending for follow-up.
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Summary
e It was possible to remotely diagnose andclassify patients presenting with a
suspected LPD in clinically relevant time scale
e Theuse of state of the art diagnostic techniques improved diagnosis and the
management ofmanypatients, even in a setting where there were limited
therapeutic options
e 41% ofpatients with a suspected LPD had a LPD, 13% had other diagnoses and
in 46% there remained some diagnostic uncertainty
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Chapter4 - Lymphoproliferative Disorders
Introduction
The aetiology, diagnosis and classification ofLPDsare discussed in Chapter 1. The way
the project wasset up is described in Chapter 2 and the laboratory methods used are
described in Appendix 1. The patient details and characteristicsof all the patients entered
into the project are presented in Chapter 3. In total 61 (40%) patients in the project were
diagnosed as having a LPD.This chapter describes these patients in greater detail and
discusses relevant aspects of the LPDs diagnosed.Firstly the spectrum of LPDs
diagnosedin the project will be compared to the spectrum of LPDs diagnosed at HMDS
and then the diagnoseswill be discussed in greater detail - SMZL, CLL, aggressive
lymphomasand other LPDs.
Spectrum of LPDs diagnosed in project
61 LPDs were diagnosedin the project in Ghana between 1March 2005 and 31% March
2006. Figures 4.1 and 4.2 show a comparison between these and the 1392 LPDs
diagnosedin adult patients at HMDS between 1* April 2007 and 31% March 2008. There
are several striking differences and some unexpectedsimilarities between the 2 groups,
although the numbersin the project were small. The 2 groups were compared using the
Simple Proportions Test to look for statistically significant (p value of<0.05, highlighted
in bold) differences between the proportions of patients with the different diagnoses in
each group.
Firstly the proportion of cases of SMZLin the project population was morethan 6 times
that in the HMDSpopulation (29.5% versus 4.7%, p<0.0001). This is despite a similar
proportion of cases ofCLL in the 2 populations (19.7% versus 28.4% respectively,
p=0.1355). The HMDSresults are consistent with those ofThieblemontet a/, who
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reported that 81 out of 3038 (2.7%) patients with NHL in Lyon, France had SMZL
(2003).
Figure 4.1 — Spectrum of LPDs diagnosed in project (n=61)
 
 
BSMZL29.5%
B CLL 19.7%
OHL 11.5%
O Myeloma 9.8%
@ DLBL 6.6%
B T-ALL 4.9%
@ PTCL4.9%
FL 3.3%
BBL 3.3%
BBALL3.3%
ONK cell LPD 1.6%
B MCL 1.6%   
 
  
Figure 4.2 Spectrum of LPDs diagnosed at HMDS(n=1392)
 
@ SMZL 4.7%
@ CLL 28.4%
HL7%
O Myeloma 19%
@ DLBCL21.8%
BT-ALL04%
@ PTCL1.2%
OFL7.4%
@ BL2.2%
BBALL1%
GO MCL2.2%
B Extranodal MZL 2.2%
@ HCL 1.4%
@ T-PLL0.4%
@ Cutaneous TCL0.7%     
HCL=Hairy cell leukaemia, PLL=Prolymphocytic leukaemia, TCL=T-cell lymphoma
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Comparison of cases ofDLBL also showeda striking difference between the two
populations of patients with only 6.6% of the project population having DLBL compared
with 21.8% of the HMDSpopulation (p=0.0043). This is again despite similar
proportions of HL being diagnosedin the two groups (11.5% and 7% respectively
p=0.1814). The relative proportion of cases ofDLBL:HL wastherefore very different
between the two groups(1:1.8 in the project population, 3.1:1 in the HMDSpopulation).
Regarding T-cell LPDs the numbersin the project population are small but the ratio of
T:B cell LPDs was unusual. In the project population there were more cases ofT-ALL
than B-ALL (4.9% vs 3.3%) whereas the reverse is usually seen (0.4% vs 1% in the
HMDSpopulation). There were also almost as many cases ofPTCL as DLBLin the
project population (4.9% vs 6.6%) whereas PTCLis considerably less common than
DLBLin the UK (1.2% vs 21.8% in the HMDSpopulation). Comparing the diagnoses in
the 2 groupsthere wasa statistically significant difference for T-ALL (p<0.0001) and for
PTCL (p=0.0153), but not for B-ALL (p=0.0959).
Wehad expectedto see a higher proportion ofBL amongst the project LPD patients than
the 3.3% seen. Thisis similar to the proportion of cases seen at HMDS(2.2% of LPDs,
p=0.5895).
In the project there were no cases ofHCL or extranodal MZL.This is probably due to a
combinationofthe rarity of these conditions and the small numbersin the project, as well
as the very indolent nature of these conditions. Extranodal MZL is commonly diagnosed
on upper gastrointestinal endoscopyso the lack of a routine endoscopyservice in Ghana,
as discussed in Chapter 1, probably also contributed.
SMZL
Clinicalfeatures
In the 18 patients with SMZL,there was a 1:3.5 M:F ratio. The median age was 64.5
years (range 40-78 years). Abdominal symptoms (pain, distension or the sensation of an
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abdominal mass) were the presenting complaint in 14 patients (78%). Only | patient
presented with symptomatic lymphadenopathy. 3 patients presented with other non-
specific symptoms. On direct questioning 17 patients (94%) reported B symptoms. 17
patients (94%) were performancestatus 1 and | patient was performancestatus3.
All the patients with SMZL had palpable splenomegaly at presentation with a median of
17cm palpable (range 6-30cm). 15 patients (83%) had palpable hepatomegaly in addition
to their splenomegaly with a median of5cm palpable (range 2-17cm). 3 patients (17%)
had palpable lymphadenopathy >1cm in diameter. 16/18 patients (89%) had a
lymphocytosis, 6/7 (86%) had an elevated LDH but noneofthe 8 patients tested for HIV
were foundto be positive. Unfortunately it was not possible to perform serum protein
electropheresis or measure immunoglobulin or beta-2 microglobulin levels locally. The
other blood results at presentation are shownintable 4.1.
Table 4.1 - SMZL patients’ blood results at presentation
 
  
Haemoglobin (g/dl) median (range) 8.5 (3.6-13.5)
WCC(x107/l) median (range) 53.7 (2.8-UR)
Platelets(x10°/l) median (range) 114 (14-181)
Lymphocytes (x10°/l) median (range) 30.1 (1.3-121.3)
Creatinine (mol/l) median (range) 97.2 (35-141)
LDH (U/l) median (range) 424 (167-585)   Normalranges: Haemoglobin 11.1-18 g/dl, WCC 2.5-10 x107/I, Platelets 140-440 x10°/1,
Lymphocytes 0.6-4.1 x10°/l, Creatinine 53-124 umol/I, LDH 100-190 U/L.
UR=unrecordable.
Pathologicalfeatures
All the SMZLpatients had marrow involvementat diagnosis. The lymphocytes were
small, round and hada lowrate ofproliferation (median Ki-67 positive fraction 5%).
Cytoplasmic projections were noted in a minority of patients. Marrow infiltration was
diffuse with a loss offat spaces in 7 (39%),interstitial with preservation offat spaces in 3
(17%), nodular in 4 (22%), both interstitial and nodular in 3 (17%) and bothinterstitial
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and intrasinusoidal inl (6%). No patients with an exclusively intrasinusoidal pattern of
infiltration were noted.
Phenotypicfeatures
All cases were assessed by standard streptavidin-biotin immunohistochemistry using the
following panel of antibodies - CD3, CD5, CD10, CD20, CD23, CD79, Cyclin D1,
BCL2, BCL6, MUM1, Ki-67. All cases expressed the pan B cell antigens CD20 and
CD79 as well as BCL2, but were typically negative with CDS, CD10, CD23, Cyclin D1,
BCL6 and MUM1.
Genotypicfeatures
Cases wereinitially screened for /GH rearrangement using an /GH breakapart probe set
and for deletions of 6q21 and 7q31. Normal patterns were obtained in 12 of the 18 cases
assessed. In 6 cases the /GH breakapart probe set gave an abnormalpattern. This
comprised an unbalanced rearrangementin 2 cases, low level rearrangementin 3 cases
and apparent monosomy 14 in | case. These cases were further investigated with
CYCLIN D1I/CCNDI, PAX-5 and MALT] breakapart probesets although no
rearrangements were seen. 7q deletions were demonstrated in 4 patients (22%) whilst 1
patient had a 6q deletion and a further patient had additional copies of the probe
suspiciousoftrisomy 6.
IGHVsequencing
IGHVsequencing was performed in 15 cases — 9 were considered to be unmutated and 6
mutated using the conventional cut-off of2%. The divergence and junctional analysis
results are shownin table 4.3. The majority of cases utilised VH3 family genes. Within
the mutated group the overall mutation load wasrelatively low — median 3.2% (range 3-
4.2%).
Page 104
Table 4.3 -SMZL IGHVsequencingresults
 
   
Unmutated cases Mutated cases
Divergence (homology) Divergence (homology)
3/248bp from VH4-31 (98.8%) 9/241 bp from VH4-39 (96.3%)
1/269bp from VH3-11 (99%) 7/227bp from VH3-30 (96.9%)
3/243bp from VH3-33 (98.7%) 8/217bp from VH2-70 (97%)
0/245bp from VH4-39 (100%) 9/214bp from VH3-11 (95.8%)
0/242bp from VH3-23 (100%) 8/246bp from VH3-21 (96.7%)
1/243bp divergence from VH3-7 (99%) 7/241bp from VH3-48 (97%)
2/240bp from VH3-7 (99%)
2/246bp from VH3-21 (99.2%)
2/247bp from VH3-23 (99%)  
Discussion ofresults in patients with SMZL
The term SMZL,first used by Schmid et a/ in 1992, wasa provisionalentity in the REAL
classification andlater a distinct clinicopathological entity in the WHOclassification
(Schmidet al, 1992; Harris et al, 1994; Jaffe et al, 2001). SMZL,as classified by the
WHO,is a B-cell neoplasm comprising small lymphocytes which surround and replace
the splenic white pulp germinal centres, efface the follicle mantle and merge with a
peripheral (marginal) zone of larger cells including scattered transformed blasts, with
both small andlarger cells infiltrating the red pulp (Jaffe et al, 2001).
Matuteset a/ (2008) recently published proposals for a revision of SMZL diagnostic,
staging and therapeutic criteria. (Figure 4.1) Although intrasinusoidal marrowinfiltration
is included as one ofthe diagnostic criteria, the authors note that in advanced cases there
is a combination of intrasinusoidal and nodularinfiltration and that in a minority of cases
interstitial infiltration also occurs. Spleen histology wasnotavailable in our patients as
splenic biopsy wasnotavailable locally therefore the patients were diagnosed onclinical
features and bone marrowfindingsalone. As the patients had such advanced disease most
(94%) no longerhadanintrasinusoidalpattern of infiltration on their trephinesalthough
they had a typical blood and marrow morphology and immunophenotype.
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Figure 4.1 — Minimum diagnostic criteria for SMZL (Matuteset al, 2008)
 
Either:
1) spleen histology + immunophenotype with a ‘CLL score’ of 2 orless, or
2) typical blood and bone marrow morphology + immunophenotype +
intrasinusoidal infiltration by CD20-positive cells (if spleen histology is
unavailable).   
In developed countries SMZL patients have a median ageat diagnosis of 65 years and an
equal male to female ratio (Oscieret al, 2005; Matutes ef a/, 2008). The median age in
our cohort of Ghanaian SMZLpatients was 64.5 years. There wasa striking difference to
the published data in the male to female ratio which was1:3.5 in our cohort. This female
preponderanceappearsto be confined to youngerpatients (see table 4.4 — patients split
into Group A - patients less than 58 years and Group B — patients 58 years and older).
Table 4.4 — Sex ratio and age of SMZLpatient subgroups
 
 
M:F Medianage (range)
Group A 0:7 48 years (40-57 years)
Group B 4:7 75 years (58-78 years)   
It is therefore possible that the cause of the excess cases of SMZLin this population
might be something to which young womenareparticularly susceptible, for example
malaria. Malaria is endemic in Ghana andthere is an altered immunological response to
malaria during pregnancy (Rogersonef al, 2007). This altered immunological response
might accountfor the increased number of cases of SMZL we found in women compared
to men. As discussed in chapter1, an infectious aetiology has been postulated in other
subtypes ofMZLandsoit is possible that an infection accounts for the excess cases of
SMZLseenin this project and perhaps also accountsfor the atypical sex ratio seen.
The role of antigenic stimulation is well established in MALT lymphoma(see Chapter1).
In SMZLantigenic stimulation due to HCV infection has been implicated in some studies
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(Hermineet al, 2002). In this context a possible relationship between chronic malaria
infection, HMS and lymphomahasbeen suggested (Bates et al, 1992; Bates & Bedu-
Addo, 1997a; Wallaceet al, 1998; Bates et al, 2001). There are, however, many possible
causes of splenomegalyin tropical setting such as schistosomiasis, leishmaniasis,
haemoglobinopathies as well as other haematological disorders.It is therefore not
possible to diagnose SMZLsimply on the basis of splenomegaly that has not responded
to proguanil.
In developed countries SMZL maybe an asymptomatic finding — for example the
detection of mild splenomegaly or asymptomatic lymphocytosis on routine medical
screening, or it may present with symptoms — frequently those of symptomatic
splenomegaly, commonly with associated B symptoms (Thieblemontet a/, 2003). All of
the patients in our group were symptomatic at presentation and most presented with both
abdominal symptoms and B symptoms. Very little routine health screening occurs in
Ghanaandtherefore patients do not tend to be diagnosed with asymptomatic disease.
1 patient in our group presented with symptomatic lymphadenopathyand 2 others had 1
or more palpable nodes >2cm in diameter. There has been somediscussion as to whether
patients with enlarged nodes,at sites other than the splenic hilum, should beclassified as
SMZLas opposed to nodal MZL. The WHOclassification suggests that patients with
SMZLdo not have enlarged nodesother than those at the splenic hilum — someauthors
do not agree, howeverand includepatients with enlarged nodes in the SMZLdiagnostic
category if they have a predominately splenic presentation along with the other features
of SMZL (Jaffe et al, 2001; Thieblemontet al, 2003; Chaconet al, 2002).
The patient that presented with symptomatic lymphadenopathy had extensive diseaseat
presentation - 19 cm palpable, but asymptomatic splenomegaly and extensive intra-
abdominal nodes on ultrasound scan — it is likely that he had had asymptomatic SMZL
for sometime, but that it had progressed overtime to include nodalareas. In the 2
patients with clinically significant, but localised lymphadenopathy, splenic enlargement
wasthe predominantfeature of their disease - their palpable spleen sizes were 17 and 23
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cm and they presented with abdominalpain.It is therefore appropriate to classify these 3
patients as having SMZLasopposed to nodal MZL.
89% of the patients were anaemic. In Europeanliterature, cytopenias occurring in
patients with SMZLtypically reflect hypersplenism, but in our cohort marrow infiltration
wasalso a factor (Matutes et a/, 2008). Other factors such as haematinic and other
vitamin deficiencies, thalassaemias and infections probably also contributed, although
there was no obvious haemolysis. There was a wide range in WCC — from low dueto
hypersplenism, to high dueto late presentation with heavy marrow involvement and
peripheral blood overspill. There is discussion in the literature regarding whetherpatients
with peripheral blood involvement should be classified as SLVL rather than SMZL
(Thieblemontet al, 2002). The WHOclassification however does not have a separate
SLVLcategory and includes patients with peripheral blood involvementin the SMZL
category (Jaffe et al, 2001).
As LDHresults were only available in 7 of our SMZLpatients and albumin in 4, it was
not possible to accurately score the patients according to the SMZL prognostic scoring
described by Arcainiet a/ (2006). This scoring system places patients into low (no
adverse factors), intermediate (1 adverse factor) and highrisk (2 or 3 adverse factors)
groups based on haemoglobin, LDH and albumin results with a 5 year cause-specific
survival of 88%, 73% and 50% respectively. Using the results that were available,
however, most of the patients were probably high risk as even with the limited results
only | patient was possibly low risk (pending both LDH andalbuminresults), 11 were at
least intermediate risk (8 pending both albumin and LDHresults) and at least 6 were high
risk.
SMZLdoesnot have a disease defining immunophenotype and diagnosesare through
exclusion with SMZLtypically lacking markers seen in CLL (CD5 and CD23) and FL
(CD10 and BCL6)(Isaacsonet al, 1994; Matuteset al, 1994; Troussardet al, 1996;
Oscieret al, 2005). Our cases were positive for CD19, CD20, CD22, CD79b, FMC7,Bcl-
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2 and negative for CD5, CD10, CD23, BCL6 and CYCLIN D1 with a low rate of
proliferation.
SMZLdoesnot have a specific underlying genotypic abnormality; however 83% of cases
have chromosomegainsor losses by comparative genomic hybridization with a median
of4 abnormalities per case (Matuteset al, 2008). The most commoncytogenetic change
detected by FISH is chromosome7q deletion (30-40% of cases — commonlyloss of 7q32)
(Matutes et al, 2008). Numerous other cytogenetic abnormalities have been reported
particularly gain of 3q and 12g,buttranslocations involving Ig heavy and lightloci are
uncommon(Andersenet al, 2004; Matutes et al, 2008).
Conventional cytogenetic analysis was not possible in ourpatients. Interphase FISH was
therefore performed on blood and marrow smears. In our cohort of patients we
demonstrated del 7q in 22%. Analysis ofJGH in our series demonstrated an apparent
unbalanced rearrangementin 2 patients and low level rearrangementin a further 3
patients. The significance of these findings is unclear. There was, on further assessment,
no evidence of CCND1, BCL2 or PAX5 rearrangements in these cases. Similarly there
was no evidence ofMALT/ rearrangements using a dual colour breakapart assay.
When JGHVsequenceanalysis wasfirst performed on 5 cases of SLVL,all 5 cases
showed somatic mutation from germline sequences, but no clonal heterogeneity was
detected (Zhu ef al, 1995). Subsequent work on a further 156 SMZLcases has however
shownthat approximately twothirds of the cases are mutated and one third are unmutated
as shownin table 4.5. We found slightly higher proportion ofunmutated cases (9/15,
60%). This mayreflect late presentation and possibly poor prognostic disease in our
cases. Ruiz-Ballesteros et al (2005) in series ofpost-splenectomy SMZLpatients found
that unmutated cases had a worse prognosis than mutated cases, similar to that found in
CLL; howeverother authors have not confirmed these findings.
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Table 4.5 —- Summary of published JGHV sequence analysis results in SMZL
 
 
  
Reference Number Mutated: Comments
ofcases Unmutated
Zhuet al, 1995 5 5:0 SLVLcases
Tierenset al, 1998 4 4:0 Compared SMZLcaseswith
other MZL subtypes
Dunn-Walters et al, 1998 4 4:0
Mirandaet al, 1999 4 3:1 Preferential use of VH; family
genes noted
Bahler et al, 2002 8 4:4
Zhuet al, 2002 4 1:3 Evidence ofinitiation of
somatic mutation in vivo
Algara et al, 2002 35 18:17 18/40 sequences used VH}-2
segment
Tierens ef al, 2003 23 16:7 11 mutated cases showed
evidence ofAg selection
Traverse-Glehenet al, 2005 35 24:11 VH, usedin 13, Ag driven in 8
Papadaki etal, 2007 34 21:13 VH, family in 15 cases, VH3
family in 9 cases and VH)-2 in
3 cases
Total 156 100:56    
In our group ofpatients VH3 predominates in line with the distribution in normalcells
(Brezinschek et al, 1997). Preferential use ofVH1-2, as reported in someseries, was not
seen (Miranda etal, 1999; Algara et al, 2002; Traverse-Glehen etal, 2005).
The mutation load wasrelatively low in our cases (median 3.2%, range 3-4.2%)
compared to the publishedliterature - in the 45 mutated cases reported by Papadakiet al
(2007) and Traverse-Glehenet al (2005), the median mutation load was 7% (range 2.1-
13.5%).
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IGHVsequence analysis is a powerful investigative tool which can provide insight into
the pathogenesis of B-cell LPDsandin particular the role of antigens or superantigens in
driving neoplastic transformation (Ghia et al, 2009). The presence ofJGHV mutations per
se is howevernot evidenceofantigenic drive but merely demonstrates that the clonal
cells have at some stage encountered antigen and undergonethe process of somatic
hypermutation. A restricted repertoire ofJGHVgenesused by individual tumours when
compared to the normalB cell repertoire supports the role of antigen in pathogenesis and
an example ofthis is the preferential use ofVH1-69 in CLL,salivary MZL and HCV
associated LPDs.
This concept has been extended with the concept of so-called ‘stereotyped receptors’. By
screening a large number ofCLLcasesit has been possible to demonstrate specific
groupsofcases with highly homologousB-cell receptors. This wasfirst demonstrated in
CLL whena significant proportionofpatients utilizing the IGHV3-21 gene were found to
have highly homologous CDR3regionsandrestricted use of IGHJ6 and IGLV3-21
joining andlight chain genes respectively (Ghia et al, 2009).
Further analysis involving almost 2000 patients has identified evidenceofrestricted or
stereotyped receptors in 26% ofCLL cases (Ghiaet al, 2009). Other examples include
the JGHV1-69, IGHD3-16, IGHJ3 and IGKV3-20 combination and the JGHV4-39,
IGHD6-13, IGHJ5 and IGK1-39 / IGKV1D-39 (Ghia et al, 2009). Interestingly the
combinations seem correlate to some extent with the clinical phenotype (Ghiaet al,
2009). For example the latter combination is predominately seen in IgG positive CLL
cases in whichthere is a female preponderance and aggressiveclinical course. This is an
interesting observation given the sex bias seen in our cases of SMZL.A further
interesting observation is that the /GHV3-21 stereotype appearsto be restricted to
northern Europe which further supports the role of specific antigen in these cases (Ghia ef
al, 2009).
Criteria for defining stereotyped receptors have been developed and these suggest that
they are defined by the use of the same JGHV/D/J germline genes, usage of the same
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IGHDreading frame and VH CDR3 aminoacid identity >60% (Ghia et al, 2009). It is
has also becomeclear that the CDR3 amino acid sequence homologycan also be
achieved using different but phylogenetically related germline JGHV genes. Weplan in
the first instance to sequence the immunoglobulin light chain genes in our cases although
large numbersofcasesare likely to be required for a definitive assessment.
CLL
Clinicalfeatures
In the 12 patients with CLL the median age was 60.5 years (range 45-80 years) and the
M-F ratio was 1:2. The presenting complaint was symptomatic lymphadenopathyin 5
patients (42%), abdominal symptomsin 3 (25%) and non specific symptomsin 4 (33%).
Ondirect questioning 11 patients (92%) reported B symptoms. 11 patients (92%) were
performancestatus | and | patient was performancestatus 2.
8 of the CLL patients (67%) had palpable splenomegaly with a median of 8.5cm palpable
(range 4-22cm), 6 (50%) had palpable hepatomegaly with a median of 3.5cm palpable
(range 3-7cm) and 7 (58%) had significant palpable lymphadenopathy. Mostofthe
patients were anaemic and had a lymphocytosis (8/12 and 10/12 respectively). The 2
patients with low level marrowinfiltration did not have a lymphocytosis however and had
predominately nodal disease. The LDH waselevatedin all 8 patients that were tested, but
noneofthe 3 patients tested for HIV were foundto be positive. Unfortunately it was not
possible to perform serum protein electropheresis or measure immunoglobulin or beta 2
microglobulin levels locally. The other blood results and Binet staging at presentation are
shownin table 4.6.
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Table 4.6 —- CLL patients’ blood results and Binet Stage at presentation
 
  
Haemoglobin (g/dl) median (range) 9.8 (2.1-15)
WCC(x107/l) median (range) 66.8 (4.1-265)
Platelets(x10°/l) median (range) 145 (37-244)
Lymphocytes (x107/l) median (range) 55.4 (1.7-201.8)
Creatinine (mol/l) median (range) 106 (62-132)
LDH (U/l) median (range) 326 (221-1192)
Binet Stage A 2/12 (17%)
Binet Stage B 2/12 (17%)
Binet Stage C 8/12 (66%)   Normal ranges: Haemoglobin 11.1-18 g/dl, WCC 2.5-10 x10°/l, Platelets 140-440 x10°/1,
Lymphocytes 0.6-4.1 x10°/l, Creatinine 53-124 mol/I, LDH 100-190 U/L.
Pathologicalfeatures
1 patient was diagnosed on PB flow cytometry and did not have a bone marrowas she
waselderly, frail and had a high WCC.In 9 patients there was extensive primarily diffuse
infiltration while low level interstitial infiltration was noted in the remaining 2 patients.
2 patients had lymph nodebiopsies and these demonstrated the typical morphological
features ofCLL as they both containedill-defined proliferation centres or pseudofollicles
containing larger nucleolated cells. The rate of cell proliferation was low in all cases (Ki-
67 typically <10%).
Phenotypicfeatures
2 cases were assessed by PB or BMAflow cytometry, 9 by immunohistochemistry on the
trephine and both modalities were performedin | case. In addition,
immunohistochemistry was performed on lymph nodesections in 2 cases. The majority
of cases were characterised by the standard immunophenotypic features seen in CLL
although one case had weak CD5 expression while another lacked expression ofCD23.
All cases lacked CYCLIN D1 protein.
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Genotypicfeatures
FISH studies were not performed. Weconsidered that the small numbersofcases
available precluded a meaningful assessmentofthe relative frequency of the known
cytogenetic prognostic factors namely deletions of 11q, 13q and 17p.
IGHVsequencing
IGHVsequencing was performed in 10 cases — 7 were considered unmutated and 3
mutated using the conventional 2% cut-off. The divergence and junctional analysis
results are shownin table 4.7.
Table 4.7 - CLL IGHVsequencing results
 Unmutatedcases Mutated cases
Divergence (homology) Divergence (homology)
0/253bp from VH6-1 (100%) 17/243bp from VH4-61 (93%)
1/236bp from VH1-69 (99%) 17/248bp from VH3-43 (93%)
2/237bp from VH1-69 (99.2%) 10/238bp from VH4-39 (95.8%)
3/236bp from VH1-69 (98.7%)
 1/236bp from VH1-69 (99%)
1/250bp from VH1-2 (99%)  0/244bp from VH4-34 (100%)
Discussion ofresults in patients with CLL
Although the numbersare small, with only 12 patients diagnosed with CLL,the sex ratio
is the reverse of that seen in CLL in the Westas there were twice as many female patients
as male (Oscieret al, 2004). A similar result was found in Benin City, Nigeria where the
M-Fratio of 60 patients diagnosed with CLL between 1995 and 2005 was 1:3 (Omoti et
al, 2007). As the Nigerian patients were diagnosed on morphologyalone, and as malaria
is epidemic in Nigeria,it is possible that this group may have included somepatients with
SMZLas opposed to CLL andas discussed earlier this may contribute to the excess
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numbers of female patients. The median age wassimilar to that usually found in CLL
(Oscier et al, 2004).
Asdiscussed earlierall the patients were symptomatic at diagnosis as routine bloodtests
are rarely done in Ghana so asymptomatic diseaseis rarely, if ever, diagnosed. Thisis in
contrast to the west where 70-80% of CLLpatients are diagnosedas an incidental finding
on a routine FBC (Oscier et al, 2004). Two thirds of the Ghanaian CLL patients were
Binet stage C compared to one tenth ofUK CLLpatients probablyreflecting late
presentation (Oscieret al, 2004). It would therefore be very difficult to compare the
epidemiology ofCLL in Ghana with that in the West by simply comparing the number of
diagnoses made. One wayto see whetherthere is a true difference in the incidence of
CLL in Ghana comparedto the published literature would be to look for occult disease in
asymptomatic patients. Approximately 4% ofthe population of the UK have occult CLL
by flow cytometry (Rawstronet al, 2002). A similar study in Ghana would be very
informative and would bethe only wayto see if there wasa real difference in the
incidence ofCLL between the two countries. This has been done to some extent with
MGUSasdiscussed in Chapter | (Landgrenet al, 2006).
There wasa higher incidence of VH1-69 in our cohort than expected (Hamblin et al,
1999). This is a high risk feature in CLL (Guarini et a/, 2003). An antigen driven process
can be implied from the presence of stereotyped CDRIII regions, therefore sequencing a
large numberofcasesis therefore likely to be very informative (Stamatopoulosef al,
2007).
Aggressive Lymphomas
Clinicalfeatures
16 patients were diagnosed with histologically aggressive lymphoma — 7 with HL,4 with
DLBL,3 with PTCL and 2 with BL. The demographics, presenting symptomsandsigns,
blood results, stage and prognostic index for these patients are shownin tables 4.8 and
4.9.
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Table 4.8 — Clinical features of patients with aggressive lymphomas
 
 
 
  
HL N=7_ DLBL N=4 PTCLN=3 BL N=2
Age years median( range) 18 (14-69) 55 (37-79) 30 (12-69) 33 (13-50)
M:F 1:1.3 1:1 3:0 1:1
Abdominal symptoms 3 (42%) 0 (0%) 0 (0%) 0 (0%)
Symptomatic nodes/masses 2 (29%) 4 (100%) 2 (66%) 1 (50%)
Non-specific presentation 2 (29%) 0 (0%) 1 (33%) 1 (50%)
B symptoms present 7 (100%) 3 (75%) 2 (66%) 2 (100%)
Performancestatus 0-1 3 (43%) 3 (75%) 2 (66%) 1 (50%)
Performancestatus 2-3 2 (29%) 1 (25%) 1 (33%) 1 (50%)
Performancestatus 4 2 (29%) 0 (0%) 0 (0%) 0 (0%)
Palpable splenomegaly 5 (71%) 1 (25%) 0 (0%) 0 (0%)
Palpable hepatomegaly 4 (57%) 1 (25%) 1 (3%) 0 (0%)
Palpable nodes >1cm diameter 4 (57%) 4 (100%) 3 (100%) 0 (0%)
Haemoglobin (g/dl) median 5.8 10.3 13.3 9.1
(range) (4.7-6.8) (5-10.4) (11.1-14.7) (6.1-12.2)
WCC(x107/1) median 3.2 4.7 6.9 7.7
(range) (1.4-21.9) (3.9-8.6) (5.9-15.3) (3.1-12.3)
Platelets(x10°/l) median 39 158 289 229
(range) (6-518) (31-433) (211-295) (200-258)
Creatinine (mol/l) median 74 133 88.4 110
(range) (53-88.4) (80-185) (71-150)
LDH (U/1) median(range) 606 315 764 622
(372-840) (226-405) (384-1144)
LDHelevated/numbertested 2/2 3/3 a2 1/1
Positive HIV test/numbertested 0/7 (0%) 0/4 (0%) 0/1 (0%) 1/1
BMinvolvementat diagnosis 6 (86%) 2 (50%) 1 (33%) 1 (50%)    Normalranges: Haemoglobin 11.1-18 g/dl, WCC 2.5-10 x107/I, Platelets 140-440 x107/1,
Creatinine 53-124 umol/l, LDH 100-190 U/.
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Table 4.9 —-Stage and IPI of patients with aggressive lymphomas
 
 
HL N=7 DLBL N=4 PTCL N=3 BL N=2
Ann Arbor 2B - 14% 1B-—25% 3B — 33% 4B — 100%
Stage 4B - 86% 2A —25% 4A — 33%
4B — 50% 4B —- 33%
IPI (where Notapplicable 1HI, 1LI, 2 HI 1 HI
LDHavailable) 1 low    
HI=high intermediate, LI=low intermediate
Pathological and immunophenotypicfeatures
Diagnosis ofHL was confirmed using the following immunohistochemistry panel: CD3,
CD20, CD15, CD30, MUM1, OCT2, BOB1. Cases were typically CD30 positive, CD20
negative and MUMIpositive with variable expression ofCD15 and the immunoglobulin
transcription factors OCT2 and BOB1. Ofthe 7 patients with HL all had classical HL - 5
were NSand 2 were MC.Thediagnosis in 5 patients was made on bone marrowtrephine.
1 of these had also had a lymph nodebiopsyreported locally, but unfortunately we were
unable to obtain the tissue block. This patientis discussed in detail in Chapter5, case 1.
1 patient with NSHL wasdiagnosed on both node biopsy and bone marrowtrephine,
another was diagnosed on a lymph node biopsy and did not have marrow involvement.
This patient had had a lymph nodebiopsyreported locally as showing granulomatous
lymphadenitis and been commencedonanti-tuberculosis treatment, but had continued to
deteriorate clinically so was referred back to the haematologyclinic and a repeat biopsy
wasarranged. Again we were unable to obtain the tissue block from the first biospy.
3 of the 4 DLBL diagnoses were made on lymph nodebiopsies. Of these, | patient also
had marrow involvement, | did not andin the third the trephine was not adequate for
staging. The 4"" patient had had a lymphnodebiopsyreported locally as showing NHL
(“immunoblastic sarcoma”) and had marrow involvementontheir trephine. All cases
were characterized by the following immunohistochemistry panel: CD3, CD5, CD10,
CD20, CD23, CD79, BCL2, BCL6, MUM1, FOXP1, Ki-67. Only 1 case had a germinal
Page 117
 
centre immunophenotypeasperthe criteria published by Hansef al (2004). The other 3
cases had a non-germinal centre immunophenotypeindicative ofpoor overall survival
(Hanset al, 2004). All cases expressed FOXP1 whichis associated with adverse outcome
in DLBL (Barranset al, 2004).
The PTCL cases were characterised using the following immunohistochemistry panel:
CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD30 and Ki-67. Ofthe 3 cases of PTCL, 1
had had a lymph nodebiopsy reported locally as showing high grade NHL —
immunohistochemistry and review ofthe tissue block at HMDS demonstrated PTCL.
This patient did not have marrow involvement. The lymph nodebiopsyin the 2™patient
wasnecrotic, but PTCL was diagnosed onthe trephine. In the 34 patient the diagnosis
was made on lymph nodebiopsy and the trephine was not adequate for staging.
Oneofthe patients with BL was diagnosed on bone marrowtrephine and the other was
diagnosed on breast massbiopsy and did not have marrow involvement. Both cases were
characterised by typical Burkitt morphology and immunophenotype: CD10 positive,
CD20 positive, BCL2 negative, BCL6 positive, p53 positive, p21 negative, Ki-67 100%.
The t(8;14) was demonstrated in the patient with the breast masses. It was not possible to
demonstrate t(8;14) in the other BL patient as the only tissue available wasresin
embedded bone marrowtrephine whichis unsuitable for FISH.
Discussion ofresults in patients with aggressive lymphomas
86% ofthe patients with HL and 50% of those with DLBL had marrow involvementat
presentation. This is very different to that seen in the West where marrow involvement
occurs in ~5% ofpatients with HL and ~27% ofpatients with DLBL (Howellet al, 2002;
Campbell et al, 2006). This is probably due to patients presenting late in the course of
their disease. Although the numbersare small the presenting symptomsin the patients
with HL werealso atypical- only 2/7 (29%) HL patients presented with symptomatic
lymphadenopathy; the rest presented with abdominal or non-specific symptoms. In the
West, 75% of cases of Classical HL present with cervical lymphadenopathy (Jaffe et al,
2001).
Page 118
In this cohort ofpatients there was an apparentrelative excess ofHL and PTCL over
DLBL when compared to the HMDSdata. This may be due to chance given the small
numbers,but is certainly worthy offurther study.
Anotherinteresting observation in this study wasthe relatively low incidence ofBL. A
minimum age of 12 years was deliberately chosen in order to exclude patients with
classical endemic BL. Of the twopatients in this cohort one was aged 13 years and had
the typical features of advanced endemic BL with multiple abdominal masses and
pancytopenia and the other was HIV positive and presented with bilateral breast masses.
It is interesting to note that prolactin receptors have been reported on BL cells and so
bilateral breast involvement is not an uncommonpresentation ofBL during pregnancy
and puberty, although neither wasthe case in this patient (Jaffe et al, 2001).
Other LPDs
Myeloma
6 patients had myelomawith a median age of 61 years (range 50-74 years) and an equal
M-Fratio. 2 patients were performance status 1 and 4 were performancestatus 3-4. 1
patient had palpable hepatosplenomegaly,the rest had no organomegaly or
lymphadenopathy. All the patients were anaemic with a median Haemoglobin 7.65 g/dl
(range 5.1-8.4g/dl). Serum creatinine waselevated in 2/5 patients tested and calcium was
elevated in 2/4. Lytic lesions were present in 3 patients (50%). There was extensive
marrowinfiltration by plasmacells in all and diagnoses were confirmed by demonstrating
cytoplasmic light chain restriction and/or aberrant plasma cell phenotype in all cases. We
werenotable to calculate the International Staging System as we were unable to measure
beta-2 microglobulin (Greipp et al, 2005). We werealso unable to do immunoglobulin
quantification as well as serum andurine electropheresis. FISH studies were not
performedas there were too few cases to make a meaningful assessment ofknown
cytogenetic abnormalities, particularly deletion of chromosome 13 and t(4;14).
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ALL
5 patients had ALL — 3 T-lineage and 2 B-lineage.In all cases there was extensive
marrowinfiltration by lymphoid blast cells with B- or T- precursor immunophenotypes
and expression of tdt. The median age was 25 years (range 12-62 years) and the M:Fratio
was 3:2. 2 patients (40%) had palpable splenomegaly and 4 (80%)had significant
lymphadenopathy. The median haemoglobin was 7.1 g/dl (range 3.4-11.4 g/dl), median
WCC 30x107/I (range 3-100x107/l) and medianplatelet count 21x10°/1 (range 13-
158x107/l).
FL, MCL and NKcellLPD
2 patients had FL, | had MCL and 1 had NKcell LPD. Thepatient with NK cell LPD is
presented in Chapter 5 (case 5). Significant splenomegaly wasnotedin the patient with
MCLand oneofthe patients with FL confirming the value of formal
haematopathological assessment in patients with splenomegaly.
Discussion ofresults in patients with other LPDs
The numberofpatients in this cohort is too small to make any meaningful assessment
aboutthe relative incidence rates of myeloma, ALL and other LPD’s. Howeverit is
interesting to note that a relative excess of T-lineage ALL has previously been reported in
somestudies from Egypt and Morocco (Kameletal, 1989; Hussein et al, 2004; Dakkaet
al, 2007).
Summary
e This study has demonstrated that it is possible to perform complex
immunophenotypic, cytogenetic and molecular analysis in West Africa
e This small cohort of patients has provided an insight into the spectrum of LPDs
seen in Ghana
e Further study is clearly worthwhile andutilising the model we have developed it
should be possible to make a definitive assessment of LPDsin Africa
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Chapter 5 — Interesting cases
Introduction
In this chapter 5 interesting cases are presented and discussed as each highlights different
aspects of the impact of the project on patient management.
Case 1
Case summary
18 year old patient with stage 4B HL.This case illustrates the common problem oflate
presentation and the need for pragmatism in clinical decision making. The project
enabled the diagnosis to be confirmed and informed the decision regarding treatment
duration.
Presentation
An 18 yr old, single, female, student presented with her parents (a midwife and a
businessman) to medical outpatients at KATH on 23November 2004 with fevers,
sweats, weight loss, fatigue and a 3 cm left submandibular node. She had a history of a
transient occipital node when she was5 years old followed bya persistentleft
supraclavicular node when she was 12'4. This was removedsurgically, but was not sent
for histology as the family could notaffordit at the time. A further left supraclavicular
node was removed whenshe was14 years old, but not sent for histology as the family
again could notaffordit.
The patient was referred from medical outpatients to the surgeons for a further biopsy
which was performed on 1* December 2004 and reported bya private laboratory on 12"
February 2005 as showing NS HL.She wasreferred to the haematology outpatient
department and entered into the LPD study on 14" March 2005. On examination she had
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3 pea-sizedleft supraclavicular nodes and 3 biopsy scars. No disease waspalpable
elsewhere.
Investigation results
Onentry to the project the following results were available locally: haemoglobin 6.5 g/dl,
WCC5.7 x10°/I, platelets 255 x10°/1, MCV 73.1 fl, creatinine 53 mol/l, ALT 41U/1,
HIVtest negative. No radiological investigations were performed. The lymph node
biopsy had been reported as above and we requested the block from the pathologist
without success. Bone marrow aspirate and trephine were performed and reported at
HMDS.Thetrephine showed NS HL with near maximalcellularity. Normal
haematopoesis wasreplaced by dense fibrosis with a background population ofreactive T
cells and histiocytes. Scattered throughout were large numbers mononuclear Hodgkin
cells and classical bi-nucleate Reed Sternberg cells. (Figures 5.1-5.3)
Figure 5.1 — Case 1 Hodgkin Lymphoma — H&Esection x20 magnification
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Figure 5.2 — Case 1 Hodgkin Lymphoma — H&Esection x60 magnification
 
Figure 5.3 — Case 1 Hodgkin Lymphoma — CD30 Immunohistochemistry
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Treatment
She wastransfused and commenced combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine, prednisolone (CHOP). After | cycle ofchemotherapy the
previous pea-sized nodeshadfully resolved and after 4 cycles a repeat bone marrow
trephine showednoevidenceofinfiltration. She received a total of 6 cycles ofCHOP
chemotherapy, which, although expensive, her parents werejustable to afford. At 6
month follow-up she was well and her blood count was normalother than a persisting
microcytosis(likely alpha thalassaemiatrait). At 12 month follow-up she remained well
with no evidence of disease recurrence and a stable blood count.
Discussion
This case raises someissues for discussion. Thefirst is that of late presentation of disease
either due to a delay in seeking medicalattentionor, as in this case, dueto aninability to
afford investigation or treatment. It is likely that her long term prognosis would have
been better if she had been treated earlier, when her disease would have beenless
extensive, possibly even localised.
Regarding the other cases of HLin the study the late presentation also affected the
outcome.4 out of the 7 cases ofHL presented with pancytopenia and
hepatosplenomegaly, but withoutsignificant palpable lymphadenopathy and the diagnosis
was made on bone marrowtrephine alone. These patients had a particularly poor outcome
— 1 wasan outpatient and did not attend for any follow-up after her bone marrow biopsy.
The other 3 were inpatients and died shortly (median 5 days) after entry into the study
despite supportive care including corticosteroids. If the diagnosis had been madeearlier
in the disease process and chemotherapy started their outcome would probably have been
better.
As mentioned in chapter 4, 6 out of the 7 (86%) cases ofHL in this project had marrow
involvementat diagnosis. This probably reflects late disease presentation. In the UK,
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marrow involvementat diagnosis is seen in 5% of classical HL cases (Howell etal,
2002).
The secondissueis that of the cost of tests for diagnosis and staging. In this case 2
previousbiopsies had not been sent for histology because the family could notafford it. It
wasalso not feasible to stage this patient with a CT scan as it was such a costly
investigation and it would not have changedthe clinical stage or altered managementof
her disease. Given the contiguous nature ofHL spread,it is likely she had extensive
lymphadenopathy. We were able to demonstrate a good response to chemotherapy by
repeating the trephine. In the absence of secondline therapy, staging and follow-up scans
are less relevant, although one might have considered local radiotherapy if there had been
bulky disease at presentation on CTora localised residual mass following chemotherapy.
Thethird issue is that of treatment availability, feasibility and cost. Combination
chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD)is the
standard treatment for advanced stage HL in developed countries but bleomycin and
dacarbazine are not available in Ghana. CHOP chemotherapy wasusedinsteadasall the
drugs were available. These drugs are included in many HL regimensincluding
ChIVPP/PABLOE, ChIVPP/EVAand Stanford V (Johnson et al, 2005; Hehn & Miller,
2004). Within the department the nurses also had some experience ofgiving CHOP and
looking after patients with CHOP chemotherapyinducedsideeffects.
2 further cases ofHL were treated with CHOP — thefirst presented with
lymphadenopathy without marrow involvementandinitially responded well to CHOP,
but then her lymphadenopathystarted to progress between cycles of chemotherapy. The
secondpatient presentedas an inpatient, performancestatus 3, with a five month history
ofbreathlessness, oedema and fever. He had cervical lymphadenopathy and
pancytopenia. HL wasconfirmed on bone marrow trephine and lymph node biopsy and
he was given CHOP chemotherapyas an inpatient. Heinitially improved and was
discharged, but then died at home, probably from neutropenic sepsis, prior to his second
cycle of chemotherapy.
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In summary,patients in the project with HL tended to present late and have advanced
disease at presentation. Full staging wasnotpossible as it was too expensive for patients
to afford and conventional HL treatment wasnot available. Despite this the patient
described responded well to treatment although remission duration is not yet known.
Case 2
Case summary
30 year old presented with a 14 month history of a massin theright side of his neck, but
no systemic symptoms. Clinically a malignancy was suspected, but the lymph node
biopsy demonstrated the typical morphological features of sinus histiocytosis with
massive lymphadenopathy (Rosai-Dorfmandisease).
Presentation
A 30 year old, single, male, trader presented to the surgical outpatients at KATHin
October 2004 with a 3 month history of a right neck mass. In July 2004 he had developed
a right sided headacheand attendeda local hospital. He was given an intramuscular
gluteal injection of analgesia. The following day noticed a massonthe right side ofhis
neck. He was otherwise well with no fevers, sweats or weight loss. The nodal massin his
neck wasbiopsied in October 2004 andreported by a private laboratory as showing sinus
histiocytosis. He was therefore referred to the haematology outpatient department and
entered into the LPD study on 13" September 2005. He hadbilateral cervical nodes the
largest measuring 7x3cm ontheright. He also had an enlarged right supraclavicular node
measuring 2x4cm. (Figure 5.4)
Page 126
Figure 5.4 — Case 2 Rosai Dorfman- Bilateral cervical lymphadenopathy
 
Investigation results
His blood results were unremarkable: haemoglobin 13g/dl, WCC 5.3x109/I,platelets
346x109/1, ESR 48mm/min and HIVtest negative. No radiological investigations were
performed. Bone marrowaspirate and trephine and a repeat biopsy of the neck mass were
sent to HMDS. The bone marrow showedreactive changes, but no evidenceofinfiltration
and the neck biopsy confirmedsinus histicytosis. The capsule in places showed marked
thickening. Overall lymph node architecture was generally preserved. There were
numerous small B-cell follicles. The most striking feature however, wasthat of sinus
histiocytosis, expressing CD68 and s100 protein. (Figures 5.5-5.8) A numberofthe
histiocytes were actively phagocytosing lymphocytes, plasmacells and granulocytes. The
features were considered to be consistent with sinus histiocytosis with massive
lymphadenopathy (Rosai Dorfman).
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Figure 5.5 — Case 2 Rosai Dorfman — H&E x10 magnification showing prominent
sinus histiocytosis
 
Figure 5.6 — Case 2 Rosai Dorfman — H&E x60 magnification showing histiocytes
phagocytosing lymphocytes andplasma ia stiaimuanic ;
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Figure 5.7 — Case 2 Rosai Dorfman — Immunohistochemistry s100 protein
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Treatment
The diagnosis was explainedto the patient and the lymph node massstarted to slowly
decrease in size. No specific treatment was necessary and the patient waslost to follow-
up in January 2006.
Discussion
Sinus histiocytosis with massive lymphadenopathy (SHML), or Rosai Dorfman
syndrome,is a benign, usually self-limiting disorder ofunknownaetiology that wasfirst
described in 1969 (Rosai & Dorfman, 1969). It typically affects children and young
adults, but can occur at any age. It commonly presents with massive,bilateral, painless
cervical lymphadenopathy with or without involvementofother nodalsites. Extranodal
involvementalso occursin almost half the cases. There is often associated fever and
occasionally weight loss. SHMLdoesnotusually require any treatment, but can be
recurrentor progressive andin rare cases canbe fatal. Treatment options, where
necessary,includesteroids, chemotherapy, radiotherapy, excision, antibiotics and other
agents such as thalidomide and o-IFN, howeverresponsesare variable (Pulsonietal,
2002; Tjiu et al, 2003; Hargett & Bassett, 2005; Aoubaet al, 2006; Ocheniet al, 2007;
Pagel et al, 2007; Utikal et al, 2007).
Patients with SHMLoften havea reactive blood picture with a raised ESR, anaemia,
neutrophilia and polyclonal hypergammaglobulinaemia. The marrowis notusually
involved. Histology is crucial for diagnosis - there is typically marked fibrosis in the
capsular andperi-capsular areas and distension and engorgement of medullary and
subcapsular sinusoids by phagocytic histiocytes. Other features of SHMLinclude
lymphophagocytosis and erythrophagocytosis by histiocytes in the lymph nodesinus. The
active histiocytes are positive for S100 protein, CD11c, CD14, CD33, CD68, acid
phosphatase and non-specific esterase (Eisen et al 1990, Paulli er al 1992).
SHMLcantherefore clinically mimic a malignant process and highlights the importance
of making a definitive diagnosis before starting treatment with chemotherapy and
radiotherapy with associated cost andside effects. The local private laboratory had
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already madethe correct diagnosis and this was confirmed on repeat biopsy. Since his
nodes wereso large it wasdifficult to convey the benign nature of the disease to him and
as they werealso so visible they were makingit difficult for him to find work. A further
concern wasthat he would not understandthat no treatment was necessary and would get
frustrated with our watch and wait plan and goto local herbal practitioner instead with
associated costs and side effects. This may have happenedasthe patient waslostto
follow-up.
Case 3
Case summary
18 year old presented with a 14 month history offluctuating bilateral neck nodes. FNA
was not diagnostic. Biopsy showed EBV-associated NPC. The patient responded to
radiotherapy and went on to have consolidation chemotherapy underthe care of the
oncologists.
Presentation
An 18 year old, single, male, student was referred from his localdistrict hospital to
KATHpolyclinic in May 2005. In April 2004 he had felt generally unwell and noticed a
pain in the right side of his neck. This resolved with antibiotics; howeverin June 2004 he
noticed a swelling in the left side of his neck. This persisted despite antibiotics. In
January 2005 a punchbiopsyofthe left neck node was attempted, but only skin was
biopsied. He wasreferred from polyclinic to the haematology outpatients and wasseen in
June 2005. Hehad twolarge left cervical nodes measuring 4x4cm and 3x3cm. He had no
fevers or sweats and only mild weightloss.
Investigation results
Hewasslightly anaemic with haemoglobin 10.7 g/dl and LDH wasraised at 517 U/las
was ESRat 88 mm/min. Other blood results were normal and HIV test wasnegative.
Chest xray was normaland an FNAofthe left neck node showed no malignant cells.
Bone marrow aspirate and trephine showed no evidenceofinfiltration. Lymph node
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biopsy was performed on 21“ June 2005 and showed EBV associated NPC. There was
extensive replacement by metastatic tumour consisting ofcohesive sheets oftumour cells
with large oval nuclei and prominenteosinophilic nucleoli. (Figure 5.9) There was no
evidence ofCD45 expression and epithelial origin was confirmed by demonstrating
expression ofthe pan-cytokeratin MNF116 although both CK7 and CK20 were negative.
(Figure 5.10) Expression ofEBV-associated latent membraneprotein-1 (LMP-1) was
demonstrable in a significant proportion oftumour cells. (Figure 5.11)
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Figure 5.10 — Case 3 Nasopharyngeal carcinoma — Immunohistochemistry MNF116
 
Figure 5.11 — Case 3 Nasopharyngeal carcinoma — Immunohistochemistry LMP-1
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Treatment
The diagnosis was explained to the patient and he wasreferred to the oncologists for local
radiotherapy. He respondedto this and went on to have chemotherapy with 5-fluorouracil
and cisplatin.
Discussion
NPCis a highly radiosensitive and chemosensitive tumour that develops from the
epithelium of the nasopharynx, usually originating in the fossa of Rosenmuller (Tao &
Chan, 2007).It has a striking geographical and ethnic distribution worldwide being
particularly prevalent in Southern China and southest Asia, especially in the Cantonese
‘boat people’ where the incidence ofNPC is 54.7/100 000/year (Tao & Chan, 2007). The
incidence in non-highrisk populationsis less than 1/100 000/year. Some North African
populations (Algeria, Morocco and Tunisia) fall into higher risk groups, but other African
populations are not known to be high risk (Yu & Yuan, 2002). The M:F ratio in most
populations is approximately 2-3:1 and incidence usually increases with age until a peak
between 45 and 54 years (Yu & Yuan, 2002). Increased incidence ofNPC occurs in
populations where there is consumption ofpreserved foods in early childhood and a move
awayfrom this practice has been linked with a fall in incidence (Yu & Yuan, 2002).
A clearlink with EBV in tumour pathogenesis has also been demonstrated and wasfirst
described in 1966 (zur Hausener al, 1970). Further work suggests a multistep process in
the pathogenesis and development of NPC,involving a combination ofgenetic
susceptibility, EBV infection and upperrespiratory tract infection and inflammation (Tao
& Chan, 2007). Subsequent defects of apoptosis and DNArepair results in the
transformation of a pre-malignant lesion (carcinomain situ) to a malignant NPC (Tao &
Chan, 2007).
NPC waslow onthelist of differential diagnoses in this patient prior to the biopsy. This
demonstrates the importance ofbeing able to make accurate and timely histological
diagnosesin suchpatients so that appropriate treatment can be given.Ifthe project had
not been available when he presented potential options would have included:
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1) Observation with a view to repeat FNAresulting in a delay in diagnosis;
2) Referral to the surgeonsfor a biopsy with the sample sent to a private laboratory in
Accra again resulting in a delayed and costly diagnosis;
3) Empirical therapy for presumed tuberculosis or lymphoma— neither ofwhich would
have been the correct managementfor his diagnosis.
Case 4
Case summary
30 year old presented with a 1 month history ofright neck swelling. FNA ofthe node was
suggestive of lymphoma,but lymph node biopsy showed granulomata. The patient was
referred to the tuberculosis clinic for treatment.
Presentation
A 30 yearold, single, female, trader presented to the ear, nose and throat departmentat
KATHon 19"January 2006 with a 1 month history of enlarged right neck nodes. She
also reported having lost weight 1 month previously, but had already regainedthis and
had no fevers or sweats. On examination she had 2 posterior cervical nodesontheright
side of her neck, but no other palpable nodes. She had no past medicalhistory of note, but
had been taking herbal medications until 1 week previously.
Investigation results
Bloodresults were fairly unremarkable with haemoglobin 11.4g/dl, WCC 8.3x107/1,
platelets 270x10°/1, LDH 152 U/l, although ESR wasraised at 120 mm/min. FNA ofone
of the enlarged nodes was performed on 23"? January 2006 and showed lymphocyte
proliferation and severallarge cells with bluish nucleoli and reddish cytoplasm. The
differential diagnosis was reported as being HL or NHL. The patient was entered into the
study on 31‘ January 2006 and a lymph nodebiopsy wasperformed on | 1" February
2006. This showed coalescent necrotising granulomata. (Figures 5.12 and 5.13) There
was no evidence of malignancy. Although Ziehl-Neelsonstains were negative the
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findings were consistent with mycobacterial infection. The bone marrow showed
extensive necrosis. No radiological investigations were performed.
Figure 5.12 — Case 4 Tuberculosis - H&E x10
 
Figure 5.13 — Case 4 Tuberculosis - H&E x40
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Treatment
The patient wasreferred to the tuberculosis clinic for treatment and did not receive any
chemotherapy.
Discussion
This case shows how importantit is to make the correct diagnosis prior to commencing
treatment and that histological diagnosis is crucial in the diagnosis of suspected LPDs. In
this study of 150 patients suspected to have a LPD wediagnosed 4 cases of tuberculosis.
2 of these cases had had an FNA — thefirst, described above, was suggestive of a LPD,
the second wasnot diagnostic. The 2 cases that did not have an FNA wereclinically felt
to have a LPD.They both had large disseminated nodal masses, one patient was HIV
positive and the other, at 83 years, was the oldest patient in the study. Clinicians in Ghana
have a great deal of experience diagnosing tuberculosisclinically andso patients that
werefelt by local clinicians to have tuberculosis, as opposed to a LPD, were not entered
into the study.
Ourstudy also included a patient that had had a lymph nodebiopsyreported locally as
showing granulomatous lymphadenitis. The patient had been treated with anti-
tuberculosis treatment with no improvement in her symptoms or lymphadenopathy. A
repeat biopsy reported at HMDS showed HL. Wewere unable to obtain the original block
to verify whether there had been dual pathology accounting for her symptoms andsigns.
This seems unlikely, however, as the patient had deteriorated on anti-tuberculosis
medications, but responded to CHOP chemotherapy.
It is knownthat dual pathologies concerning LPDsand tuberculosis can and do occur,
especially in areas with a high prevalence of tuberculosis (Fangourgiakis et al, 2008).
This meansthat patients diagnosed as having a LPD in suchsettings must be observed
carefully and if dual pathology is confirmed or suspected they needto receive anti-
tuberculosis treatment with their chemotherapy. Anti-tuberculosis treatment in Ghanais
free and well supervised to improve compliance.
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Thereverseis also true and the patients diagnosed as having tuberculosis need to be
followed up carefully to ensure that their nodes and symptoms improve with the anti-
tuberculosis treatment. If they do not improve further biopsyis indicated. Thisis difficult
in a setting where so manypatientsare lost to follow-up andit is not feasible for patients
to remain under follow-up in twoclinics due to the cost and travelling that would involve
for the patient. Education of both clinicians treating tuberculosis and lymphomasand
patients is therefore important.
This patient’s biopsy was negative on Ziehl-Neelsonstain, but had other features
consistent with tuberculosis. This is a commonproblem as Ziehl-Neelsonstain is only
positive if there are approximately 10* to 10° bacteria per milliliter of tissue specimen;
PCRontissue blocks can be usedto increase the sensitivity of diagnosis (Li et al, 2000).
Case 5
Case summary
67 year old with hepatosplemomegaly and peripheral blood lymphocytosis. This case
illustrates how the model we developedfacilitated making a complex diagnosis.
Presentation
A 67 yearold, married, female, farmer presented to KATH polyclinic on 24" March 2005
with abdominalpain, loose stool, sweats and weight loss. Spleen was palpable 19 cm
below the left costophrenic margin andthe liver was palpable 6cm belowtheright. She
wasinitially treated with proguanil, folic acid and trenxene (an analgesic). She was
referred to the haematology outpatient department and entered the LPD study on 20"
April 2005.
Investigation results
Bloodresults performed locally showed: haemoglobin 9.2g/dl, WCC 30.4x10°/1, platelets
151x10°/l, MCV 89.841, neutrophils 6.04x10°/1, lymphocytes 22.9x10°/1, LDH 266U/1 and
HIV test was negative. The blood film showed a marked lymphocytosis with mainly
Page 138
small to intermediate sized cells with a high nuclear:cytoplasmicratio andlittle evidence
of cytoplasmic granulation. There was also marked polychromasia with some nucleated
red blood cells. Bone marrow trephine reported at HMDSshowedincreasedcellularity
for age, normal haemopoietic elements were present as well as a striking T-cell
lymphocytosis. There was an atypical lymphoid infiltrate with a highly aberrant
immunophenotype. No definitive diagnosis was madeon the trephine, but additional flow
cytometric analysis performed on peripheral blood taken to HMDSin July 2005
demonstrated the following immunophenotype: CD3— CD16+ CD2+/— CD7+ CD5—
CD8— CD4— CD38+ TCR- CD56+ CD57— HLADR- CD52+ CD1a— CD34-. A
diagnosis ofNK-cell leukaemia was made. (Figure 5.14)
Treatment
Whilst the diagnosis wasbeingclarified the patient continued treatment with proguanilas
the differential diagnosis was HMS.Shedid not respond to this howeverand at 6 month
follow-up the spleen remained 19 cm. Follow-up bloods showed: haemoglobin 8.2¢/dl,
WCC21.6x10°/1, platelets 85x10°/1. She became more symptomatic ofher splenomegaly
and so wasgiven trial of oral cyclophosphamide. After 2 cycles she felt better, but the
spleen wasstill palpable at 19 cm and the haemoglobin andplatelets had fallen further:
haemoglobin 7.5 g/dl, WCC 10. 1x10°/land platelets 37x10°/1. As her counts hadfallen,
her spleen size had not reduced and the chemotherapy was expensive for a family on such
limited incomea period ofwatchful waiting was commenced. Nofurther follow-upis
available.
Page 139
Figure 5.14 —Case 5 NK cell leukaemia — Flow cytometry — gated on CD3 negative
CD16 positive cells
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Discussion
This case demonstrates that the model we developedassisted not only in straightforward
cases, but also in making less common, more complicated diagnoses. Chronic NK-cell
leukaemia makes up approximately 5% ofall large granular lymphocyte disorders and so
is a rare LPD (Lamy & Loughran, 2003). Treatment decisionsin this case were difficult,
as will be discussed, and knowing the diagnosis helped in making these decisions. As
with many indolent LPDs, the decision to commence treatment waslargely based on the
patient’s symptoms, although her blood counts had also started to fall. Such subjective
decisionsare particularly difficult to make when communicationis via an interpreter and
wherepatient involvementin treatment decisionsisless part of the culture thanit is in the
UK.
Treatment options for indolent NK cell leukaemia include cyclophosphamide,
methotrexate and ciclosporin (Alekshun & Sokol, 2007). We decidedto treat her with
oral cyclophosphamide asthis was readily available and frequently used in the
haematology outpatient clinic. Oral methotrexate was occasionally, but not reliably
available. Ciclosporin wasnotavailable locally and there were no facilities for checking
therapeutic levels.
Thepatient and her husband were farmersliving in a rural village and did not have much
money,but were able to pay for the chemotherapy.It is likely in such a situation that the
extended family helped to cover the cost of this. Following the 2 cycles of chemotherapy
her counts had deteriorated further, although she wasfeeling better. In a situation where it
is not possible to give supportive care with platelet transfusions it was very importantnot
to drop her counts any further with chemotherapy.
There may have beena significant placebo effect regarding the cyclophosphamideas her
spleen did not improve and her counts deteriorated. The patient looked and reported
feeling better following the 2 cycles of cyclophosphamide however. Again it was very
difficult to assess this via an interpreter.
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A treatment option that we considered wassplenic radiotherapy. This may be a useful
treatment modality in the future for symptomatic, indolent, splenic LPDs in a topical
setting as radiotherapy becomes more widely available. Radiotherapy is often quite
expensive however, butlessrisky in such a setting than splenectomy. A typical course of
splenic radiotherapy would cost approximately 1 million cedis (£60).
Summary
e Chemotherapy and radiotherapyare available in developing countries, such as
Ghana,soit is vital that facilities for the rapid and correct diagnosis of LPDsare
also available so that the correct treatment is given
e The possibility of dual pathology or one pathology mimicking another, especially
tuberculosis and lymphoma,needsto be borne in mind and physicians educated
accordingly
e Using this method ofremote diagnosis, it was possible to make complicated and
clinically unexpected diagnoses thus improving patient management
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Chapter 6 - Discussion
Introduction
This chapter summarises and describes the limitations of the project, highlights potential
pitfalls in the diagnosis of lymphomas,looks at importantissuesrelating to research in
developing countries and finally discusses future research potentials.
Project summary
The project achieved its main objective which was to develop andtest a modelfor the
diagnosisand classification of LPDs in Ghana, West Africa. Utilising modern laboratory
and communication methods, we wereable to set up a system to diagnose and categorise
LPDsin Ghana. Modern diagnostic techniques, not currently available locally, were used
in a clinically meaningful way and results were used to inform treatment decisions.
Preliminary epidemiological data regarding LPDsin West Africa was also collected with
a view to expandingonthis in future studies. The system was robust andis sustainable.
There weresignificant differences between the spectrum ofLPDs diagnosed in Ghana
and those diagnosed at HMDS.Inthe project there were significantly more cases of
SMZL, PTCL and T-ALL,butless cases ofDLBL than seen at HMDS. Amongst the
patients with SMZLthere wasa striking excess of female patients. We envisaged that the
excess numbers of cases of SMZL seen in Ghana compared to Yorkshire would be due to
chronic infection causing antigenic stimulation. Wedid not see an excess of cases with
mutated JGHVgenes,and in those cases that were mutated, the mutation load was
relatively low. Further work in this area is necessary.
Limitations of the project
The problems encountered whensetting up the project are discussed in Chapter 2. These
included the differences between the two centres, the numberofpatients lost to follow-
Page 143
up, communication problems, missing results as patients were unable to payforall the
relevantinvestigations, potential concerns regarding the quality of local test results and
poor documentation. Where possible ways around these problems were soughtin order to
minimise their impact on the project outcomes, however this was not alwayspossible for
exampleit was not possible to do all the usual staging investigations on patients and this
resulted in missing data. Further data is missing as a result of patients beinglost to
follow-up both before and after a definitive diagnosis was made.
150 patients were entered into the project over a 13 monthperiod. Althoughall the
patients entered werefelt to clinically have a LPD only 41% were diagnosed with a LPD.
This resulted in small numbersofpatients in each LPD sub-group making comparisons
difficult.
As a result it is not possible to draw major epidemiological conclusions howeverthis
project does provide the basis for further work investigating LPDs in WestAfrica.
Potential pitfalls in the diagnosis of lymphoma
Problemsregarding accurate lymphomadiagnosis are not limited to developing countries.
The clinical impact of expert pathological review on lymphoma managementin Wales
wasassessed between January 1998 and August 2000 (Lesteret al, 2003). Following
expert review by the All Wales Lymphoma Panel (AWLP), the pathological diagnosis,
made bylocaldistrict general hospital pathologists, was altered in 125 of 745 (17%)
specimens. Case notes were reviewed in 99 (79%) ofthese cases. In 46 of the 99 cases
the patients’ managementwaschanged asa result of expert pathological review. Overall,
management was changedin 8% ofcases referred to AWLP for expert central
pathological review.
Asdiscussed in Chapter1, five ILSG pathologists in Germany remotely reviewed 206
cases ofNHL diagnosed in Kuwait (Temmimet al, 2004). In 4 cases (2%) the diagnosis
madebythe local pathologists was altered when the case was reviewed andin a further 4
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cases the review material was not adequate. Although this study was doneaspart ofthe
‘Clinical characteristics and pathological classification ofNHL in the developing
countries’ project the original diagnoses were madein a national centre with facilities for
immunophenotyping.It is therefore nota true reflection ofthe facilities available when
most cases ofNHLare diagnosed in developing countries hence in the low discordance
rate.
Immunophenotyping is crucial in the modern diagnosis of LPDs. Our study demonstrates
that it is feasible to perform this remotely in a clinically meaningful manner. Performing
such tests remotely in an established laboratory such as HMDShas some advantages such
as the economyofscale, a high throughput allowsbatching oftests which reduces the
reagentcosts, and makesit easier to maintain a high quality service. Ideally a transfer of
technology should occurso that these tests becomeavailable locally to provide a more
flexible service, avoid the costs and potential problems associated with transportation and
allow localscientists and clinicians to learn new techniques. These techniquesare
expensive andthis is currently prohibitive for most patients in countries like Ghana.Itis
howevercrucial to ensure that the correct diagnosis is made before potentially harmful
therapies such as radiotherapy and chemotherapyare given.
Research in developing countries
In 1990 the Commission on Health Research for Development estimated that only about
5% ofthe world’s resources for health research were being applied to the health problems
of developing countries, where 93% of the world’s burden of ‘preventable mortality’
occurred (Health Research, Essential Link to Equity in Development, 1990). In 1998 the
Global Forum for Health Research was foundedto try to address this imbalance which
wasdescribed using the term ‘10/90 gap’. Non-communicable diseases now have a much
greater impactin developing countries makingit difficult to estimate what percentage of
the world’s resources for health research is currently spent in developing countries. There
remains a gross imbalance, however, and although the term ‘10/90 gap’ is no longer
accurate it continues to be used to describethis.
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Although morehealth research is desperately needed in developing countries, carrying
out suchresearch needsto be carefully planned to avoid exploitation ofparticipants and
other potential ethical issues. Emanuelet a/ (2004)outline a frameworkfor ethical
research in developing countries that involves 8 principles with 31 associated
benchmarks. (Appendix 9) These principles and benchmarks encompassthe key elements
in the developmentofa collaborative diagnostic and therapeutic service described by
Eden (2002) and discussed in Chapter1.
Collaborative partnership,the first of the 8 principles, is crucial to ethical health research
in developing countries. As discussed in Chapter 1, collaborations between developing
and more developedpartnershipsare an excellent wayoftransferring diagnostic skills
and techniquesas wellas facilitating research and improving the diagnosis and treatment
ofcertain illnesses. When collaborative researchis set up,it is importantthat local
collaborators lead the decision making processso that the most appropriate research takes
place and there is a transfer of appropriate skills and knowledge.
A long term,sustainable approachto research projects is necessary and short term ‘fixes’
must be avoided (Lawn & Lawn, 2002). This is vital in order to avoid diverting trained
healthcare staff from clinical work into short-term projects and adding to the “brain drain’
that already exists in healthcare in many developing countries. Transfer of relevant health
technology in an appropriate manneris necessary to build local scientific capacity to
monitor and control disease; for example the Sustainable Sciences Institute in San
Francisco aimsto help infectious disease biomedicalscientists in developing countries
accesstraining, funding, information, collaborators, equipment and supplies (Harris &
Tanner, 2000). The institute emphasises long term follow-up oftechnical, financial and
material support via 4 programmes:on-site training, small grant, networking and
consulting and material aid.
Ensuring informed consentofparticipants can be difficult in any researchproject, but
language andcultural barriers can makethis even harder to achieve. Hill et a/ (2008)
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looked at the outcomeofinformed consentfor a placebo-controlled vitamin A
supplementation study among Ghanaian women aged 15-45 years. They surveyed 1971
trial subjects and found that although subjects knew they were taking part in research,
most thought they were receiving active and beneficial medication. Variables associated
with knowledge were education and district of residence, but fieldworkers’ characteristics
werenotassociated with subjects’ knowledge.
Quality assurance is another issue commonto research projects throughout the world, but
is a particular concern in developing countries, where such systems maybe non-existent
or poorly implemented. Scott et al (2007) set up a simple and sustainable quality
assurance program forclinical chemistry services in Eritrea. Over a 10 year period they
increased the numberoftests available locally and provided training and assistance with
quality control. They encountered many difficulties during this process, such as the
withdrawal of spare parts and reagents by a US based manufacturerand a lack of e-mail
or fax communication with the district hospitals in Eritrea. When quality controlfailures
occurred they were investigated — at onesite recurrent failures over a 6 monthperiod
were found to be due to poor-quality water for cleaning glassware and reuse ofdisposable
cuvettes and reagent boats. If such measuresare notin place in laboratories then this has
serious implications for the interpretation of results generated by that laboratory.
Future research
Asdiscussed in Chapter1, prospectively collected data utilising the WHOclassification
of LPDs wasnotpreviously available in sub-Saharan Africa. We were only able to get a
‘snapshot’ of information regarding LPDsin Ghana as mostofpopulation doesnot have
accessto health care, howeverit will being interesting to observe whether there are any
changes in the patient demographicsor the diagnoses made in the next few years as more
patients are able to access health care in Ghanaasa result of the national insurance
system. For example, with more equitable access to health care younger patients, who
previously struggled to pay for hospital visits, investigations and treatment as they often
did not haveaccess to the ‘extended family’ system, may present earlier and more
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frequently resulting in, for example, earlier presentation of patient with HL and perhaps
more patients presenting at a stage where diagnosis and treatmentis more successful
rather than presenting with end stage disease, so frail that treatmentis futile. Ongoing
data collection will also provide valuable epidemiological information regarding LPDsin
Ghana which mayinfluence future treatment of LPDs both in Ghanaandpotentially
elsewhere.
Ongoing improvementsin technology such as e-mail and telepathology, along with faster
and morereliable transportation of samples, as well as improvements in techniques for
stabilizing specimens, will combine to makereal-time diagnostic collaborations more
feasible and clinically relevant.
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Chapter 7 — Conclusion
There is evidence that the spectrum of LPDs in Ghana, and other West African countries,
is likely to be different to that found elsewhere. Infection mayplay role in pathogenesis
and thisis likely to influence treatment options. With the increasing availability of
chemotherapy and radiotherapy in Ghana, and other developing countries, there is an
urgent need to improve the diagnosis of LPDs, and other malignancies, to ensure that
appropriate treatmentis given. Real-time collaborative diagnosis alongside research, with
a view to transfer of diagnostic skills and technology, would address these problemsin a
practical and sustainable manner.
A collaborative model wasset up to comprehensively diagnose LPDs in Ghana. Local
clinicians and technicians were closely involved in the design and running of the project
with a view to the model being continued whenthe initial MD project finished. Full
diagnostic work up was performed on samples sent to the UK and the results were
available to clinicians in Ghana in a clinically relevant time span. Transfer of skills and
technology is envisaged over the coming years to improve the diagnostic facilities
available locally.
It was possible to remotely diagnose and classify patients presenting with a suspected
LPDin clinically relevant time scale. Theuseof state of the art diagnostic techniques
improved diagnosis and the managementof46/150 (31%) patients, even in a setting
where there were limited therapeutic options. 41% ofpatients (61/150) with a suspected
LPD had a proven LPD, 13% (20/150) had other diagnoses and in 46% (69/150)there
remained somediagnostic uncertainty.
This study has demonstratedthatit is possible to perform complex immunophenotypic,
cytogenetic and molecular analysis as part of the diagnostic work up ofpatients with
suspect LPDs in West Africa. This small cohort ofpatients has provided an insight into
the spectrum of LPDs seen in Ghana. Further study is clearly worthwhile and,utilising
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the model we have developed,it should be possible to make a definitive assessment of
the epidemiology ofLPDsin Africa and gain insight into their biology.
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Appendix 1: Laboratory techniques in the diagnosis of LPDs
Histology
Biopsy samples need to be fixed and processedpriorto staining. If it is anticipated there
will be minimal delay between a biopsy sample being taken and it arriving at the
laboratory, it is sent fresh so that flow cytometry can be performed, allowing rapid
immunophenotypingresults. The biopsy is then fixed in 10% formalin.Ifit is not
possible to get the biopsy sampleto the laboratory quickly it is sent in 10% formalin.
Formalin is an effective fixative, but needs to be allowed to penetrate the biopsy
specimentherefore for larger biopsies the sample is sliced before fixing in formalin.
Samples are fixed for 24-48 hours before being processed in a stepwise manner which
allows replacement ofwater with graded alcohols whichare then replaced by chloroform
or xylene. This allows permeation by paraffin wax, forming a tissue block. As boneis
harder than paraffin wax, bone marrow trephine samples needto either be decalcified
before being paraffin embedded or embeddedin resin, whichis harder than paraffin. As
trephine morphologyis better preserved with resin embeddingthis is the method used at
HMDS.
Immunophenotyping
Flow cytometry
Samples
Peripheral blood and BM aspirate samples can be kept in EDTA for up to 24-48 hours
before processing. CSF and serousfluid do not require transport media unless they are
very cellular. A small piece of fresh biopsy sample can be shakenin isotonic saline to
liberate cells or a piece of tissue can be injected with cell culture medium and chopped
into small piecesto release cells for flow cytometry.
Sample preparation
Prior to staining with antibody, the white cells need to be separated from the redcells.
This can be done by either density gradient centrifugation or whole blood lysis. The
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advantage of whole bloodlysis is that it minimises the loss of white cell fractions and
thus permits subsequent quantification of lymphocytes subsets. Whole bloodlysis is the
method we used to prepare the PB and BM samples for freezing prior to molecular
analysis. This is the method described in steps 6-12 of Appendix 2. Following step 12 the
white cell count of the sample is measured. 5 x 10° cells are required and this is
calculated from the following formula: required volume (ul) = 500/WCC (10/1). The
appropriate amount of lysed sample is then conjugated with the extended B-panel of
fluorochrome conjugated antibodies:
CD3/CD3/CD19 CD20/CDS/CD19
CD10/CD38/CD19 Kappa/Lambda/CD19
FMC7/CD22/CD19 CD11a/CD23/CD19
IgM/IgD/CD19 IgG/CD79b/CD19
CD103/CD25/CD19 CD11c/CD62L/CD19
CD38/CD52/CD19
The fluorochromes used are fluorescein isothiocyanate (FITC), phycoerythrin (PE) and
Cy5. These differ in their emission spectrum so it is possible to analyse cells labelled
with three different antibodies at once against their size (forward scatter) and granularity
(side scatter).
Analysis
First a scattergram is produced of forward scatter versus side scatter. Then the population
of cells of interest is identified and drawn around (gated). The fluorescent data for the
cells that are within this area, or gate, can then be assessed on a histogram — this
represents the surface antibody expressionofthe cells. (Figure A1.1)
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Figure Al.1. Extended B-panel flow cytometry analysis document
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Immunocytochemistry
Immunoperoxidase and alkaline phosphatase anti-alkaline phosphatase are the 2
commonly used immunocytochemistry techniques (Matuteset al, 2001). The former is
simplerandis particularly useful for the study of lymphoid cells, whereasthe latter
permits good preservation of cell morphology. Immunoperoxidase can be performed with
directly labelled antibodies or via an indirect technique involving several layers
(described below). Unstained blood and marrowslides can be stored at minus 20°C until
needed.
Cytocentrifuge slides are allowedto dry for at least 6-8 hours(if fresh) or thawed(if
frozen) and the area to be studied marked. Theslidesare fixed in acetone, allowed to dry
and the area marked with a silicone ring. Theslides are then incubated with thefirst layer
of monoclonal antibody, washed and immediately incubated with the second layer of
monoclonal antibody. The slides are washed twice, incubated with the third layer of
antibody andlabelled with peroxidase. The slides are again washed twice and then
incubated with a diaminobenzidinesolution, rinsed and counterstainedpriorto a final
wash.Theslides are then allowed to dry prior to microscopy.
Immunohistochemistry
Fresh slides ofparaffin embedded tissue are made andtreated to allow antibody
penetration. As above, both direct and indirect methods ofantibody staining are feasible,
although the indirect method is more commonly used asit is more sensitive. In the
indirect method an unlabeled primary antibodyreacts with tissue antigen and then a
secondary antibody, labeled with a fluorescent dye or an enzyme,is added andthis reacts
with the first unlabeled antibody. A biotinylated secondary antibody is commonly
coupled with streptavidin-horseradish peroxidase and then reacted with diaminobenzidine
to produce a brownstain wherever primary and secondary antibodies are attached.
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Molecular techniques
Conventional Cytogenetics
For conventional cytogenetics a fresh sample of involved blood, marrowortissue, in a
preservative free heparin medium, mustget to the laboratory within 24 hours ofbeing
taken. 1x10°/I cells are cultured and then colchicine is added whicharrests cell division at
mitosis. The cells are put into a hypotonic solution and then fixed and spread onto slides
prior to banding andanalysis.
FISH
FISH canbecarried out on thin sections if only a small amountoftissue is available.
Alternatively, if more tissue is available, thick sections can be cut and nuclei extracted.
Slides are prepared and then fixed. Thin sections then require enzyme digestion to allow
the probe access to the target DNA.Theslides are then dehydrated sequentially in
progressively stronger concentrations of ethanol. The slides are then incubated with
formamide hybridisation buffer prior to probe application. They are then allowed to
hybridise and subsequently washed. Thisstage is light sensitive and timing of the washes
is critical. The slides are then counterstained and read with an imaging microscope.
PCR
PCRallows amplification of specific DNA sequences. Short DNA primer sequences,
complementary to the ends of the sequence of interest, are used. These are mixed with the
sample DNA along with nucleotides and a thermostable DNA polymerase. A
thermocycler is used to heat and cool the mixture through many programmedcycles.
Cycles consist of a denaturation stage where the two strands ofDNA comeapart at a very
high temperature (~93°C), the mixture is then cooled slightly (50-60°C) to allow the
primersto bind and then reheated (~73°C) to allow strand extension. This results in four
copies from the original two. This process can be repeated many times. The end product
is then separated out by electrophoresis on an ethidium bromide containing gel and read
underultraviolet light.
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Appendix 2: Processing samples for LPD project
10.
Per patient need: 4 BMAslides, 4 PB slides, 4mls PB in EDTA, 2mls PB in
plain/serum tube (once sample taken stand tubein rack if possible), 2mls BMA in
EDTA,4 pieces parafilm, 3 12ml tubes with caps, 4 eppendorfs with lids, 80mls
phosphate buffered solution (PBS), 40mls ammonium chloride (NH,C1), 6 pastettes,
trephine in formalin pot with completed HMDSform.
(11 PBS = 8.5g NaCl + 0.382g diNaHPO, + 0.462g KdiHPO, + 11 distilled water; 11
NH4Cl 0.86% = 8.6g NH4Cl1 + 11 distilled water)
Also need: centrifuge for 12ml tubes, permanent marker, waterbath at 37°C.
Wrapslides tightly in parafilm (stretch first) to ensure no air bubbles are trapped. Put
2 slides back to back perpiece ofparafilm. If wearing glovestry to avoid getting
powderonslides or parafilm. Label outside ofparafilm with patient’s name number
and ‘PB’/’BM’.
Pastette serum into eppendorfwith white/orangelid and label both tube andlid (with
patient name, ‘serum’ and numberas per David’slist).
Label 12ml tubes (patient number(as above) plus ‘PCR’/’BM’/’PB’) and set up
racks.
Using pastette put 2mls PB in ‘PB’ and ‘PCR’ tube. With clean pastette put 2mls
BMAin ‘BM’ tube. (Generally use all the sample.)
Add 10mls NH,Clto ‘PB’ and ‘BM’tubes. Put in waterbath at 37°C for 5 minutes.
Add 10mls PBS to ‘PCR’ tube. Mix well. Cap tube. Centrifuge all tubes at 2000rpm
for 4minutes. Remove cap. Decant supernatant. Flick ‘PB’ and ‘BM’tubes to break
up pellet. Take care with ‘PCR’ tube not to pour off sample.
Add 10mls NH,Clto ‘PB’ and ‘BM’tubes. Put in waterbath at 37°C for 5 minutes.
Add 10mls PBS to ‘PCR’ tube. Mix well. Cap tube. Centrifuge at 2000rpm for
4minutes. Remove cap. Decant supernatant (Care with ‘PCR’tube). Flick ‘PB’ and
‘BM’tubesto break up pellet.
Using clean pastette transfer sample from ‘PCR’ tube to eppendorfwith yellow lid
and label both eppendorftube andlid (with patient name, number and ‘PCR’).
Add 10mls PBSto the ‘PB’ and ‘BM’tubes. Mix. Recap tube. Centrifuge at 2000rpm
for 4minutes. Remove cap. Decant supernatant. Flick tubes.
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11. Add 10mls PBS. Mix. Recap tube. Centrifuge at 2000rpm for 4minutes. Removecap.
Decant supernatant. Flick tubes.
12. Add 10mls PBS. Mix. Recap tube. Centrifuge at 2000rpm for 4minutes. Removecap.
Decant supernatant.
13. Using clean pastettes transfer samples from 12mltubes to eppendorfs with red (PB)
and green (BM)lids and label both eppendorftube andlid (with patient name,
numberand ‘PB’/’BM’respectively).
14. Put all samples in -20°C freezer.
NB- PBSshould bestoredin the fridge and discarded after 4 weeks.
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Appendix 3: The WHOclassification of Lymphoid Neoplasms(Jaffe et al, 2001)
B-CELL NEOPLASMS
Precursor B-cell neoplasm
Precursor B lymphoblastic leukaemia/lymphoma
Mature B-cell neoplasm
Chronic lymphocytic leukaemia/small lymphocytic lymphoma
B-cell prolymphocytic leukaemia
Lymphoplasmacytic lymphoma
Splenic marginal zone lymphoma
Hairy cell leukaemia
Plasma cell myeloma
Solitary plasmacytoma ofbone
Extraosseous plasmacytoma
Primary amyloidosis
Heavy chain disease
Extranodal marginal zone B-cell lymphoma of Mucosa-Associated Lymphoid Tissue
Nodal marginal zone B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
Primary effusion lymphoma
Burkitt lymphoma/leukaemia
B-cell proliferations of uncertain malignant potential
Lymphomatoid granulomatosis
Post-transplant lymphoproliferative disorder, polymorphic
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T-CELL AND NK-CELL NEOPLASMS
Precursor T-cell neoplasms
Precursor T lymphoblastic leukaemia/lymphoma
Blastic NK cell lymphoma
Mature T-cell and NK-cell neoplasms
T-cell prolymphocytic leukaemia
T-cell large granular lymphocytic leukaemia
Aggressive NK cell leukaemia
Adult T-cell leukaemia/lymphoma
Extranodal NK/T cell lymphoma,nasal type
Enteropathy-type T-cell lymphoma
Hepatosplenic T-cell lymphoma
Subcutaneouspanniculitis-like T-cell lymphoma
Mycosis fungoides
Sezary syndrome
Primary cutaneousanaplastic large cell lymphoma
Peripheral T-cell lymphoma, unspecified
Angioimmunoblastic T-cell lymphoma
Anaplastic large cell lymphoma
T-cell proliferation of uncertain malignant potential
Lymphomatoid papulosis
HODGKIN LYMPHOMA
Nodular lymphocyte predominant Hodgkin lymphoma
Classical Hodgkin lymphoma:
Nodularsclerosis classical Hodgkin lymphoma
Lymphocyte-rich classical Hodgkin lymphoma
Mixedcellularity classical Hodgkin lymphoma
Lymphocyte-depleted classical Hodgkin lymphoma
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Appendix 4: KATH consent form Name:
Hospital Number:
Consent form for patients being investigated for possible
lymphoproliferative disorders (LPDs)
Hello. My nameis Dr Liz Stephens and I work at Komfo Anokye
Teaching Hospital. I would like to talk to you about a study we are
doing to find out what LPDs people wholive in Ghanaget.
LPD is a disease that can cause lumps to appear onor in your
body and can affect blood, inside bones, glands and other areas of
the body. You have beenreferred to this clinic because your doctors
think you may have a LPD.
In order to find out if you have a LPD youwill need to have
some tests including a bone marrowtest and blood tests. You may
also need some x-rays or scans and possibly a piece of the lump may
need to be removed for tests. Some of the procedures are
uncomfortable (e.g. a blood test) and someare morepainful(e.g. a
bone marrowtest). Local anaesthetic (where you are awake, but the
pain is numbed) is used for the bone marrow test and most of the
lymph node biopsies, a general anaesthetic (where you are asleep) is
used for some of the lymph nodebiopsies.
If you take part in the study extra tests will be done on samples
taken. Someof these tests will be done in Ghana, some will be done
in Britain. You will not have to undergo any extra investigations as
part of the study.
There is no extra cost for being part of the study, but youwill
get extra results if you take part. These results will help your doctors
decide which treatmentis best for you. You will be told any extra
results at yourclinic visits.
If you do not wantto take part in this study you are free to
refuse andit will not affect how you are looked after by your doctors.
You are also free to withdraw from the study at any time.
Signed/thuMbprint............ccceeceseeseceseeeseeeeeeees e
(parent or guardian for children under 16 years)
Signature/thumbprint of child if under 16 Year...
Witnessed DY...........cccseeeeeeeeeeseeeees POSICION......0:ccccccccceeeeeesesseetsttteeeeeeees
(For participants who do not speak English this form will be translated into their local language)
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Appendix 5: KBTH consent form
INFORMED CONSENT TO PARTICIPATE IN RESEARCH
Principle Investigator:
Dr Elizabeth Stephens
Department ofMedicine
KATHPOBox1934
Kumasi
Co-Investigators:
Dr Imelda Bates
Liverpool School of Tropical Medicine
PembrokePlace
Liverpool L3 SOA
Dr George Bedu-Addo
School ofMedical Sciences
E-mail lizstephens@doctors.org.uk
Telephone 0243454800
Dr Roger Owen
HMDS,Leeds GeneralInfirmary
Great George Street
Leeds
Dr Bartholomew Akanmori
Noguchi MemorialInstitute
KNUST, Kumasi Accra
Dr Ivy Ekem
Department ofHaematology
University of Ghana Medical School E-mail ivyekem@ug.edu.gh
Accra Telephone 673036 Ext 5363
Title of project: Lymphoproliferative disorders (LPDs) in Ghana
Youare being asked to volunteerasa participant in a research study. This form is
designed to provide you with information aboutthis study and to answer any of your
questions. After going through this form you mayrefuseto participate in the study. This
will not affect your managementin any way.
PURPOSE OF STUDY:This study has been designed by Ghanaian and British doctors
and will be carried out by them. The aim ofthe study is to discover more about
lymphoproliferative disorders in Ghana, in particular, which lymphoproliferative
disorders occur in Ghana and whetherthey are different to the lymphoproliferative
disorders that are seen in other countries.
PROCEDURES:Ifyou decideto participate in the study, you will have your clinical
history taken (how thedisease started and progressed) and will have a full physical
examination. These details will be recorded on a questionnaire. Your doctor will decide
which investigations you need to diagnose your LPD.Ifyou have any bloodtests, x-rays
or scans,the results of these will be noted on the questionnaire. If your doctor decides
you need a bone marrowtest and/or lymph nodebiopsy,part of this sample will undergo
extra investigations. An extra ten millilitres (about two teaspoonfuls) ofblood will be
taken for extra tests that look at exposure to malaria and presence of LPD cells or extra
proteins in your blood.
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BENEFITS:This study will tell us more about whether you have a LPD and if so what
type. This will help guide your doctor when deciding what treatment to give you. The
study will also tell us more about what types ofLPD occur in Ghana. This mayhelp usto
diagnoseandtreat patients with LPD better in the future.
RISKS:Theonly extra procedure that may be performedaspart of this study may be an
extra blood test. Where possible we will try to take all the necessary bloodtests for the
study when youare having your routine LPD bloodtests taken. Rarely, you might
experience minorbruisingat the site ofblood taking as with any bloodtest.
CONFIDENTIALITY:All information obtained on you during the course of this study
will be kept confidential. Should the results of this study be published, you will be
referred to only by number. Should the samples taken from you be needed for any other
investigation, the investigator understands that you will be informed and your written
consentobtainedfirst.
SUBJECT RIGHTS:Any questions you have involving the research and your rights
may be addressedto:
Dr Ivy Ekem
Department of Haematology
University of Ghana Medical School
Tel 673036 Ext 5363
Your participation in this study is voluntary and youare free to withdraw withoutpenalty
at any time. The treatment ofyour condition will not be affected. You will be given a
copy of this form to keep. If you have any problemsrelating to the researchers, contact
the Executive Secretary, University of Ghana Medical School, PO Box 4236, Accra.
Signed/thumbprint. icc. cccsuesscs ss csnpisiaas ss saws ss anwaamiawe s a wearin sows cesDatei. ss ssevs
(parent or guardian for children under 16 years)
Signature/thumbprint of child if under 16 ‘Yeats cccsccsss ss cscnaswes s ctosannvna svexemumee s 4 weomeees
WIINESSE DYsess es cavccesees senewswes esPOSIION......... 0. cece ce ee eee e ee ee enone Date..........
(Forparticipants who do not speak English this form will be translated into their local language)
TAVESUIQALOD.. « « cscnncawss cecmmrxenss cammemnens 1 eramereae t cemmmmenes 10 pesmmnE CerrTomens meDate.........
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Appendix 6: Consumables required perpatient
The following consumables were required per patient entered:
8 slides for the project, an additional 3 slides per KATHpatient
2 EDTAtubes and 1 serum tube
10% formalin in an eppendorf(and formalin in potif also for lymph node biopsy)
4 pieces of parafilm
3 12mltubes with caps
4 eppendorfs with lids
80mls PBS
40mls NH,Cl
6 pastettes
Onelitre ofPBS was made by mixing 8.5g NaCl and 0.382g diNaHPO,and 0.462g
KdiHPO,in llitre of distilled water. This wasstored in a refrigerator for up to four
weeks. Onelitre of 0.86% Ammonium Chloride was made by mixing 8.6g ofNH,Clin
onelitre of distilled water. This was stored at room temperature indefinitely.
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Appendix 7: Project Pro Forma
Pro forma for patients investigated for LPD
At presentation
Name: Sex:
Date ofbirth/Age: Employment:
Date of presentation to teaching hospital: Hospital:
Source ofpatient referral to haematologyclinic: Clinician:
Presenting symptoms:
Sweats yes/no wt loss severe/mod/mild/no fevers yes/no
Performance status: no symptoms/symptoms, but ambulatory/Bedridden<half day/
bedridden>half day/chronically bedridden
Examination findingsat presentation:
General:
Liver(cm): Spleen(cm): Nodes:
Medication History:
Whenlast took herbal medications:
Frequency of malaria symptoms(peryr):
Other previous Infections:
Past medical history:
Tests booked: Bloods requested:
Scans requested:
?lymph node biopsy booked yes/no Date:
Date blood and marrowsession:
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Whenavailable/1* follow-up
FBC: Hb(g/dl) WCC(x107/1) Pits(x107/1) MCV(fl)
Diff WCC%: Neut(%) Lymph(%) MID (%)
Diff WCC count: Neut(x10°/1) Lymph(x10/1) MID(x107/1)
Blood film findings:
Biochem results: Ur/BUN(mmol/1) Creatinine(umol/l) LDH(U/I)
Albumin(g/1) Bilirubin(umol/1) ALT(U/]) AST(U/I)
Alk phos(U/I) Ca(umol/l) ESR(mnj+hr) CRP
HIV status known? yes/no Ifknown result pos/neg
IfFNA performed: Site:
Date:
Result:
If biopsy taken: Site biopsied:
Date biopsied:
Results of biopsy:
Posted to HMDS -— date: By whom:
If scans/x-rays performed: Type scan/x-ray:
Date of scan/x-ray:
Results of scan/x-ray:
Provisional diagnosis:
Treatment initiated:
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To befilled in at blood and marrow session
Marital status: Married/Living with sexual partner/Single/Separated/Divorced/Widowed
Live: Urban/Peri-Urban/Rural
How manypeopleare currently living in your household?
How manydependents do you have?
How manychildren (aged 0-5) live with you in the same house?
Whatis the highest level of formal education that you have had?
No formal education/Primary-incomplete/Primary-complete/JSS-incomplete
JSS-complete/SSS-incomplete/SSS-complete/University/Postgraduate/Adult education
Whatis your current occupation?
Managerial/professional/administrative Skilled manual worker(driver, brick layer)
Manualworker(house servant, waiter) Ownbusiness- type ofbusiness
Subsistence farmer Trader Unemployed House wife
Student Retired Other- specify
Main roofing material of the house you nowlive in?
Grass/thatched/tin Corrugated tin roofwith unfinished ceiling
Tile with unfinished ceiling Corrugated tin roofwith finished ceiling
Tile with finished ceiling Other- specify
Doesyour house have anyofthe following:
Electricity yes/no TV yes/no Kitchen stove yes/no Refrigerator yes/no
How did you cometo the hospital?
Walking/bicycle/bus/shared taxi/private taxi/tro-tro/private car/motorbike/other — specify
Who accompaniedyouto the hospital?
Partner/spouse Child under l6yrs Child over 16yrs Sibling
Otherrelative — specify Other — specify No one
Trephine posted to HMDS— date: By whom:
Aspirate report:
Flow results:
HMDSresults:
Ann Arborstage:
Numberofextranodalsites:
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6 month follow-up
Treatment so far:
Current symptoms:
Current examination:
FBC: Hb WCC Pits
Diff WCC(%): Neut Lymph
Bloodfilm findings:
Other relevant investigation results:
Repeat blood and marrow session relevant? yes/no
12 month follow-up
Treatmentso far:
Current symptoms:
Current examination:
FBC: Hb WCC Pits
Diff WCC(%): Neut Lymph
Bloodfilm findings:
Otherrelevant investigation results:
Repeat blood and marrowsession relevant? yes/no
MCV
Mono
If so date booked:
MCV
Mono
If so date booked:
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18 month follow-up
Treatmentso far:
Current symptoms:
Current examination:
FBC: Hb WCC Pits
Diff WCC(%): Neut Lymph
Bloodfilm findings:
Other relevant investigation results:
Repeat blood and marrowsession relevant? yes/no
24 month follow-up
Treatmentso far:
Current symptoms:
Current examination:
FBC: Hb WCC Plts
Diff WCC(%): Neut Lymph
Bloodfilm findings:
Otherrelevant investigation results:
Repeat blood and marrowsession relevant? yes/no
MCV
Mono
If so date booked:
MCV
Mono
If so date booked
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Appendix 8: Supplementary socioeconomic data
Co-habitees and dependents
 
       
   
 
     
All SMZL Non- SND Other p
patients SMZL diagnoses
n=18 LPDs n=29 n=60
n=150 n=43
Numberofother people 6.5 10 6 7 7 0.202
living in house median (0-50) (3-17) (0-20) (1-20) (1-50) KW
(range)
Numberofdependents 0 a 1 0 0 0.247
median (range) (0-30) (0-10) (0-30) (0-15) (0-10) KW
Marital status
B® Widowed
@ Divorced
O Separated
D Single
B® Living with sexual partner
® Married     All patients SMZL Non-SMZL SNDLPDs
 
 
Other
diagnoses
Transport to hospital
 SA
A
 
All patients SMZL Non-SMZLLPDs SND Otherdiagnoses
 
 
@ Not documented
@ Ambulance
B@ Lorry
@ Private car
@ Trotro
O Private taxi
O Shared taxi
@ Bus
B® Walked    
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Employment
 
B Retired
@ Students
DB Housewives
@ Unemployed
B Traders
@ Farmers
O Own business
O Manual work
B Skilled manual work 
 
 ® Managerial/professional/
All patients SMZL Non-SMZL SND Other administration
LPDs diagnoses     
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Appendix 9: Ethical principles and benchmarksfor multinational research
 
(Emanuelet al, 2004)
Principles Benchmarks
Collaborative Develop partnerships with researchers, makers of health policies, and the
partnership community.
Involve partners in sharing responsibilities for determining the
importanceof health problem, assessing the value ofresearch, planning,
conducting, and overseeing research, and integrating research into the
health-care system.
Respect the community’s values, culture, traditions, and social practices.
Develop the capacity for researchers, makers ofhealth policies, and the
community to becomefull and equalpartners in the research enterprise.
Ensurethat recruited participants and communities receive benefits from
the conduct andresults of research.
Share fairly financial and other rewardsofthe research.
 
Social value Specify the beneficiaries of the research—who.
Assess the importanceofthe health problems being investigated and the
prospective value ofthe research for each of the beneficiaries—what.
Enhancethe value ofthe research for each ofthe beneficiaries through
dissemination ofknowledge, product development, long-term research
collaboration, and/or health system improvements.
Prevent supplanting the extant health system infrastructure and services. Scientificvalidity  Ensure that the scientific design ofthe research realizes social value forthe primary beneficiaries of the research.Ensure that the scientific design realizes the scientific objectives whileguaranteeing research participants the health-care interventions to whichthey are entitled.Ensure that the research studyis feasible within the social, political, andcultural context or with sustainable improvementsin the local health-careand physical infrastructure.
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Ethical principles and benchmarksfor multinational research continued
 
Principles Benchmarks
Fair selection Select the study population to ensurescientific validity of the research.
of study Select the study population to minimizethe risks of the research and
population enhanceother principles, especially collaborative partnership and social
value.
Identify and protect vulnerable populations.
Favourable Assess the potential risks and benefits of the research to the study
risk-benefit population in the contextofits health risks.
 
 
ratio Assessthe risk-benefit ratio by comparing thenetrisks of the research
project with the potential benefits derived from collaborative partnership,
social value, and respect for study populations.
Independent Ensure public accountability through reviews mandated by laws and
review regulations.
Ensure public accountability through transparency and reviews by other
international and nongovernmentalbodies, as appropriate.
Ensure independence and competence ofthe reviews.
Informed Involve the community in establishing recruitment procedures and
consent incentives. Disclose information in culturally and linguistically appropriate formats.Implement supplementary community and familial consent procedureswhereculturally appropriate.Obtain consentin culturally and linguistically appropriate formats.Ensure the freedom to refuse or withdraw.
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Ethical principles and benchmarksfor multinational research continued
 
Principles Benchmarks
 
 
Respect for recruited participants
and study communities
 
Develop and implement proceduresto
protect the confidentiality of recruited and
enrolled participants.
Ensure that participants know they can
withdraw without penalty.
Provide enrolled participants with
informationthat arises in the course of the
research study.
Monitor and develop interventions for
medical conditions, including research-
related injuries, for enrolled participants at
least as good as existing local norms.
Inform participants and the study
community ofthe results of the research.
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